

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp243

Request ID: cder_mpl1r_wp243_nsdv_v01

Request Description: In this report, we characterized dispensing and administration patterns of 25 New Molecular Entities (NMEs) approved from July 1, 2017 to December 31, 2017, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module, version 11.0.0

Data Source: We distributed this request to 14 Sentinel Data Partners on May 4, 2023. The study period included data from January 1, 2017 to most recent available data. Please see Appendix A for a list of dates of available data for each Data Partner (DP).

Study Design: We identified individuals initiating any of the 25 NME drugs. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with NME. The analyses characterized dispensing patterns by examining cumulative exposure episode durations, first exposure episode durations, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall, and stratified by age and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were NMEs approved between July 1, 2017 and December 31, 2017, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products, and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the query period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, and 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 31 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 24 chronic conditions and seven lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW)¹ algorithms and included: acute myocardial infarction, Alzheimer's disease and related conditions, atrial fibrillation, diabetes mellitus, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, and osteoporosis. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes used to define baseline characteristics in this request, and Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Overview for Request: cder_mpl1r_wp243

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

¹Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse.
<https://www.ccwdata.org/web/guest/condition-categories>

Table of Contents

Glossary (CIDA)	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
Table 1a	Aggregated Characteristics of Abemaciclib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1b	Aggregated Characteristics of Acalabrutinib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1c	Aggregated Characteristics of Angiotensin II in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1d	Aggregated Characteristics of Benralizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1e	Aggregated Characteristics of Benznidazole in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1f	Aggregated Characteristics of Copanlisib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1g	Aggregated Characteristics of Emicizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1h	Aggregated Characteristics of Enasidenib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1i	Aggregated Characteristics of Ertugliflozin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1j	Aggregated Characteristics of Ertugliflozin and Sitagliptin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1k	Aggregated Characteristics of Ertugliflozin and Metformin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1l	Aggregated Characteristics of Glecaprevir and Pibrentasvir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1m	Aggregated Characteristics of Guselkumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1n	Aggregated Characteristics of Inotuzumab Ozogamicin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1o	Aggregated Characteristics of Latanoprostene Bunod Ophthalmic Solution in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1p	Aggregated Characteristics of Letemovir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1q	Aggregated Characteristics of Macimorelin Acetate in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1r	Aggregated Characteristics of Meropenem and Vaborbactam in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1s	Aggregated Characteristics of Neratinib Maleate in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1t	Aggregated Characteristics of Netarsudil in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1u	Aggregated Characteristics of Ozenoxacin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1v	Aggregated Characteristics of Secnidazole in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1w	Aggregated Characteristics of Semaglutide in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
Table 1x	Aggregated Characteristics of Sofosbuvir Velpatasvir and Voxilaprevir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Table of Contents

Table 1y Aggregated Characteristics of Vestronidase Alfa-Vjbc in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Table 2a Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Table 2b Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Table 2c Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Table 2d Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Table 2e Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Table 2f Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Table 3a Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Table 3b Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Table 3c Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Table 3d Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Table 3e Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Table 3f Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Table 4a Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Table 4b Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Table 4c Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Table 4d Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Table 4e Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Table 4f Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Table 5a Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Table 5b Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Table 5c Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Table 5d Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Table 5e Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Table of Contents

<u>Table 5f</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group
<u>Table 6a</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Table 6b</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Table 6c</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex
<u>Table 6d</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex
<u>Table 6e</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group
<u>Table 6f</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group
<u>Table 7a</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Table 7b</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex
<u>Table 7c</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group
<u>Table 8a</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Table 8b</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex
<u>Table 8c</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group
<u>Table 9</u>	Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Table 10</u>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Figure 1a</u>	Patient Entry into Study by Month for Abemaciclib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Figure 1b</u>	Patient Entry into Study by Month for Acalabrutinib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Figure 1c</u>	Patient Entry into Study by Month for Angiotensin II in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Figure 1d</u>	Patient Entry into Study by Month for Benralizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Figure 1e</u>	Patient Entry into Study by Month for Benznidazole in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Figure 1f</u>	Patient Entry into Study by Month for Copanlisib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Figure 1g</u>	Patient Entry into Study by Month for Emicizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Figure 1h</u>	Patient Entry into Study by Month for Enasidenib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022
<u>Figure 1i</u>	Patient Entry into Study by Month for Ertugliflozin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Table of Contents

Figure 1j Patient Entry into Study by Month for Ertugliflozin and Sitagliptin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1k Patient Entry into Study by Month for Ertugliflozin and Metformin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1l Patient Entry into Study by Month for Glecaprevir and Pibrentasvir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1m Patient Entry into Study by Month for Guselkumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1n Patient Entry into Study by Month for Inotuzumab Ozogamicin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1o Patient Entry into Study by Month for Latanoprostene Bunod Ophthalmic Solution in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1p Patient Entry into Study by Month for Letemovir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1q Patient Entry into Study by Month for Macimorelin Acetate in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1r Patient Entry into Study by Month for Meropenem and Vaborbactam in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1s Patient Entry into Study by Month for Neratinib Maleate in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1t Patient Entry into Study by Month for Netarsudil in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1u Patient Entry into Study by Month for Ozenoxacin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1v Patient Entry into Study by Month for Secnidazole in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1w Patient Entry into Study by Month for Semaglutide in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1x Patient Entry into Study by Month for Sofosbuvir Velpatasvir and Voxilaprevir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Figure 1y Patient Entry into Study by Month for Vestronidase Alfa-Vjvk in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Appendix A Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 4, 2023)

Appendix B List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Appendix C List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Used to Define Exposures in this Request

Appendix D List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Appendix E List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Appendix F Specifications Defining Parameters for this Request

Appendix G Specifications Defining Parameters for Baseline Characteristics in this Request

Appendix H Design Diagram of Cohort Entry Requirements and Index Exposure

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded.

Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of Abemaciclib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Abemaciclib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	12,091	N/A ²
Demographic Characteristics		
Age (years)	65.8	10.6
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	4,417	36.5%
≥ 65 years	7,181	59.4%
Sex		
Female	11,902	98.4%
Male	189	1.6%
Race ¹		
American Indian or Alaska Native	42	0.3%
Asian	220	1.8%
Black or African American	983	8.1%
Native Hawaiian or Other Pacific Islander	20	0.2%
Unknown	4,034	33.4%
White	6,792	56.2%
Hispanic origin		
Yes	278	2.3%
No	7,495	62.0%
Unknown	4,318	35.7%
Year		
2017	329	2.7%
2018	2,218	18.3%
2019	2,231	18.5%
2020	2,061	17.0%
2021	2,390	19.8%
2022	2,862	23.7%
Health Characteristics		
Acute Myocardial Infarction	69	0.6%
Alzheimer's Disease and related conditions	316	2.6%
Atrial Fibrillation	737	6.1%
Diabetes Mellitus	2,207	18.3%

Table 1a. Aggregated Characteristics of Abemaciclib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Abemaciclib	
	Number/Mean	Percent/ Standard Deviation
Heart Failure	1,109	9.2%
Hyperlipidemia	3,451	28.5%
Hypertension	5,148	42.6%
Depression	2,691	22.3%
Ischemic Heart Disease	1,501	12.4%
Rheumatoid Arthritis/Osteoarthritis	1,920	15.9%
Stroke/Transient Ischemic Attack	329	2.7%
Breast Cancer	11,956	98.9%
Colorectal Cancer	146	1.2%
Prostate Cancer	19	0.2%
Lung Cancer	337	2.8%
Endometrial Cancer	112	0.9%
Acquired Hypothyroidism	1,738	14.4%
Anemia	4,168	34.5%
Asthma	616	5.1%
Benign Prostatic Hyperplasia	27	0.2%
Chronic Kidney Disease	1,705	14.1%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	932	7.7%
Glaucoma	322	2.7%
Osteoporosis	1,016	8.4%
Obesity: diagnosed or identified by weight management procedures	2,401	19.9%
Obesity: identified by weight management-related prescriptions	74	0.6%
Overweight	1,137	9.4%
Smoking: diagnosed or identified by smoking cessation procedures	2,883	23.8%
Smoking: identified by smoking-related prescriptions	54	0.4%
Alcohol Abuse or Dependence	138	1.1%
Drug Abuse or Dependence	347	2.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	300	2.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25.7	15.4
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.6	9.4

Table 1a. Aggregated Characteristics of Abemaciclib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Abemaciclib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	20.7	15.9
Mean number of generics dispensed	9.0	5.2
Mean number of unique drug classes dispensed	8.4	4.6

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented.

²N/A: Not Applicable

Table 1b. Aggregated Characteristics of Acalabrutinib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Acalabrutinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	11,134	N/A ²
Demographic Characteristics		
Age (years)	75.0	8.4
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	19	0.2%
41-64 years	1,164	10.5%
≥ 65 years	9,951	89.4%
Sex		
Female	4,162	37.4%
Male	6,972	62.6%
Race ¹		
American Indian or Alaska Native	16	0.1%
Asian	77	0.7%
Black or African American	614	5.5%
Native Hawaiian or Other Pacific Islander	12	0.1%
Unknown	1,806	16.2%
White	8,609	77.3%
Hispanic origin		
Yes	80	0.7%
No	8,843	79.4%
Unknown	2,211	19.9%
Year		
2017	35	0.3%
2018	497	4.5%
2019	854	7.7%
2020	2,719	24.4%
2021	4,089	36.7%
2022	2,940	26.4%
Health Characteristics		
Acute Myocardial Infarction	138	1.2%
Alzheimer's Disease and related conditions	510	4.6%
Atrial Fibrillation	2,152	19.3%
Diabetes Mellitus	2,493	22.4%

Table 1b. Aggregated Characteristics of Acalabrutinib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Acalabrutinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	1,827	16.4%
Hyperlipidemia	4,696	42.2%
Hypertension	6,087	54.7%
Depression	1,759	15.8%
Ischemic Heart Disease	3,146	28.3%
Rheumatoid Arthritis/Osteoarthritis	1,777	16.0%
Stroke/Transient Ischemic Attack	322	2.9%
Breast Cancer	403	3.6%
Colorectal Cancer	178	1.6%
Prostate Cancer	699	6.3%
Lung Cancer	213	1.9%
Endometrial Cancer	35	0.3%
Acquired Hypothyroidism	1,744	15.7%
Anemia	5,814	52.2%
Asthma	469	4.2%
Benign Prostatic Hyperplasia	1,427	12.8%
Chronic Kidney Disease	2,860	25.7%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	1,393	12.5%
Glaucoma	495	4.4%
Osteoporosis	484	4.3%
Obesity: diagnosed or identified by weight management procedures	1,869	16.8%
Obesity: identified by weight management-related prescriptions	40	0.4%
Overweight	1,250	11.2%
Smoking: diagnosed or identified by smoking cessation procedures	3,288	29.5%
Smoking: identified by smoking-related prescriptions	25	0.2%
Alcohol Abuse or Dependence	195	1.8%
Drug Abuse or Dependence	229	2.1%
History of Cardiac Arrest	20	0.2%
History of Coronary Angioplasty or Bypass	963	8.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.4	13.2
Mean number of emergency room encounters	0.4	1.0
Mean number of inpatient hospital encounters	0.4	0.9
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.6	9.7

Table 1b. Aggregated Characteristics of Acalabrutinib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Acalabrutinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	18.2	14.1
Mean number of generics dispensed	8.6	5.1
Mean number of unique drug classes dispensed	8.1	4.7

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

²N/A: Not Applicable

Table 1c. Aggregated Characteristics of Angiotensin II in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Angiotensin II		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	28	N/A ³
Demographic Characteristics		
Age (years)	55.1	14.2
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	13	46.4%
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	0	0.0%
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	17	60.7%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	0	0.0%
Unknown	*****	*****
Year		
2017	0	0.0%
2018	*****	*****
2019	*****	*****
2020	*****	*****
2021	*****	*****
2022	14	50.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****

Table 1c. Aggregated Characteristics of Angiotensin II in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Angiotensin II	
	Number/Mean	Percent/ Standard Deviation
Heart Failure	*****	*****
Hyperlipidemia	11	39.3%
Hypertension	11	39.3%
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/Transient Ischemic Attack	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
Chronic Obstructive Pulmonary Disease and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.3	17.6
Mean number of emergency room encounters	1.1	2.4
Mean number of inpatient hospital encounters	0.6	1.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	2.5	3.8

Table 1c. Aggregated Characteristics of Angiotensin II in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Angiotensin II		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	15.0	16.1
Mean number of generics dispensed	7.2	7.0
Mean number of unique drug classes dispensed	6.6	6.2

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

²NaN: Not a Number

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

³N/A: Not Applicable

Table 1d. Aggregated Characteristics of Benralizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Benralizumab		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	24,071	N/A ²
Demographic Characteristics		
Age (years)	62.3	12.4
Age		
0-17 years	370	1.5%
18-24 years	327	1.4%
25-40 years	1,699	7.1%
41-64 years	8,409	34.9%
≥ 65 years	13,266	55.1%
Sex		
Female	15,605	64.8%
Male	8,466	35.2%
Race ¹		
American Indian or Alaska Native	71	0.3%
Asian	408	1.7%
Black or African American	1,985	8.2%
Native Hawaiian or Other Pacific Islander	33	0.1%
Unknown	8,174	34.0%
White	13,400	55.7%
Hispanic origin		
Yes	450	1.9%
No	14,592	60.6%
Unknown	9,029	37.5%
Year		
2017	43	0.2%
2018	2,240	9.3%
2019	7,696	32.0%
2020	5,230	21.7%
2021	5,110	21.2%
2022	3,752	15.6%
Health Characteristics		
Acute Myocardial Infarction	101	0.4%
Alzheimer's Disease and related conditions	367	1.5%
Atrial Fibrillation	1,595	6.6%
Diabetes Mellitus	5,165	21.5%

Table 1d. Aggregated Characteristics of Benralizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Benralizumab		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	2,492	10.4%
Hyperlipidemia	7,975	33.1%
Hypertension	10,908	45.3%
Depression	5,359	22.3%
Ischemic Heart Disease	4,343	18.0%
Rheumatoid Arthritis/Osteoarthritis	4,716	19.6%
Stroke/Transient Ischemic Attack	359	1.5%
Breast Cancer	497	2.1%
Colorectal Cancer	107	0.4%
Prostate Cancer	405	1.7%
Lung Cancer	174	0.7%
Endometrial Cancer	42	0.2%
Acquired Hypothyroidism	3,097	12.9%
Anemia	3,961	16.5%
Asthma	21,209	88.1%
Benign Prostatic Hyperplasia	869	3.6%
Chronic Kidney Disease	2,400	10.0%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	8,777	36.5%
Glaucoma	789	3.3%
Osteoporosis	1,371	5.7%
Obesity: diagnosed or identified by weight management procedures	7,833	32.5%
Obesity: identified by weight management-related prescriptions	289	1.2%
Overweight	2,345	9.7%
Smoking: diagnosed or identified by smoking cessation procedures	5,931	24.6%
Smoking: identified by smoking-related prescriptions	191	0.8%
Alcohol Abuse or Dependence	303	1.3%
Drug Abuse or Dependence	778	3.2%
History of Cardiac Arrest	32	0.1%
History of Coronary Angioplasty or Bypass	981	4.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.7	12.5
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.3	7.8

Table 1d. Aggregated Characteristics of Benralizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Benralizumab		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	29.6	61.5
Mean number of generics dispensed	12.2	7.2
Mean number of unique drug classes dispensed	11.3	6.0

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

²N/A: Not Applicable

Table 1e. Aggregated Characteristics of Benznidazole in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Benznidazole		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	51	N/A ²
Demographic Characteristics		
Age (years)	51.2	14.3
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	35	68.6%
≥ 65 years	*****	*****
Sex		
Female	27	52.9%
Male	24	47.1%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	39	76.5%
White	*****	*****
Hispanic origin		
Yes	16	31.4%
No	12	23.5%
Unknown	23	45.1%
Year		
2017	*****	*****
2018	19	37.3%
2019	16	31.4%
2020	*****	*****
2021	*****	*****
2022	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	*****	*****

Table 1e. Aggregated Characteristics of Benznidazole in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Benznidazole		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	*****	*****
Hyperlipidemia	*****	*****
Hypertension	20	39.2%
Depression	*****	*****
Ischemic Heart Disease	11	21.6%
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/Transient Ischemic Attack	*****	*****
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	0	0.0%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
Chronic Obstructive Pulmonary Disease and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	11	21.6%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.0	16.6
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	6.9	11.7

Table 1e. Aggregated Characteristics of Benznidazole in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Benznidazole		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	13.5	11.8
Mean number of generics dispensed	6.6	4.8
Mean number of unique drug classes dispensed	6.1	4.1

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1f. Aggregated Characteristics of Copanlisib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Copanlisib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	304	N/A ²
Demographic Characteristics		
Age (years)	70.1	10.2
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	227	74.7%
Sex		
Female	144	47.4%
Male	160	52.6%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	68	22.4%
White	224	73.7%
Hispanic origin		
Yes	*****	*****
No	223	73.4%
Unknown	*****	*****
Year		
2017	*****	*****
2018	*****	*****
2019	160	52.6%
2020	55	18.1%
2021	48	15.8%
2022	25	8.2%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	33	10.9%
Diabetes Mellitus	55	18.1%

Table 1f. Aggregated Characteristics of Copanlisib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Copanlisib	
	Number/Mean	Percent/ Standard Deviation
Heart Failure	37	12.2%
Hyperlipidemia	104	34.2%
Hypertension	144	47.4%
Depression	74	24.3%
Ischemic Heart Disease	60	19.7%
Rheumatoid Arthritis/Osteoarthritis	47	15.5%
Stroke/Transient Ischemic Attack	*****	*****
Breast Cancer	19	6.3%
Colorectal Cancer	*****	*****
Prostate Cancer	13	4.3%
Lung Cancer	13	4.3%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	35	11.5%
Anemia	171	56.3%
Asthma	12	3.9%
Benign Prostatic Hyperplasia	27	8.9%
Chronic Kidney Disease	68	22.4%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	36	11.8%
Glaucoma	*****	*****
Osteoporosis	15	4.9%
Obesity: diagnosed or identified by weight management procedures	53	17.4%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	27	8.9%
Smoking: diagnosed or identified by smoking cessation procedures	91	29.9%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	13	4.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28.3	15.7
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.6	1.2
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	8.5	12.9

Table 1f. Aggregated Characteristics of Copanlisib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Copanlisib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	20.8	15.1
Mean number of generics dispensed	9.7	5.6
Mean number of unique drug classes dispensed	9.0	5.0

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1g. Aggregated Characteristics of Emicizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Emicizumab		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	2,033	N/A ²
Demographic Characteristics		
Age (years)	34.7	19.2
Age		
0-17 years	643	31.6%
18-24 years	190	9.3%
25-40 years	442	21.7%
41-64 years	456	22.4%
≥ 65 years	302	14.9%
Sex		
Female	286	14.1%
Male	1,747	85.9%
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	32	1.6%
Black or African American	144	7.1%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,197	58.9%
White	646	31.8%
Hispanic origin		
Yes	97	4.8%
No	701	34.5%
Unknown	1,235	60.7%
Year		
2017	*****	*****
2018	*****	*****
2019	497	24.4%
2020	333	16.4%
2021	455	22.4%
2022	419	20.6%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	24	1.2%
Atrial Fibrillation	37	1.8%
Diabetes Mellitus	159	7.8%

Table 1g. Aggregated Characteristics of Emicizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Emicizumab	
	Number/Mean	Percent/ Standard Deviation
Heart Failure	58	2.9%
Hyperlipidemia	246	12.1%
Hypertension	366	18.0%
Depression	215	10.6%
Ischemic Heart Disease	131	6.4%
Rheumatoid Arthritis/Osteoarthritis	182	9.0%
Stroke/Transient Ischemic Attack	35	1.7%
Breast Cancer	19	0.9%
Colorectal Cancer	11	0.5%
Prostate Cancer	11	0.5%
Lung Cancer	14	0.7%
Endometrial Cancer	11	0.5%
Acquired Hypothyroidism	74	3.6%
Anemia	319	15.7%
Asthma	63	3.1%
Benign Prostatic Hyperplasia	58	2.9%
Chronic Kidney Disease	113	5.6%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	70	3.4%
Glaucoma	21	1.0%
Osteoporosis	38	1.9%
Obesity: diagnosed or identified by weight management procedures	226	11.1%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	92	4.5%
Smoking: diagnosed or identified by smoking cessation procedures	247	12.1%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	29	1.4%
Drug Abuse or Dependence	71	3.5%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	30	1.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.0	12.4
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	7.0	14.8

Table 1g. Aggregated Characteristics of Emicizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Emicizumab		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	12.3	14.2
Mean number of generics dispensed	4.2	4.1
Mean number of unique drug classes dispensed	3.8	3.6

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1h. Aggregated Characteristics of Enasidenib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Enasidenib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	1,480	N/A ²
Demographic Characteristics		
Age (years)	72.9	8.9
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	195	13.2%
≥ 65 years	1,264	85.4%
Sex		
Female	629	42.5%
Male	851	57.5%
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	113	7.6%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	272	18.4%
White	1,059	71.6%
Hispanic origin		
Yes	28	1.9%
No	1,153	77.9%
Unknown	299	20.2%
Year		
2017	146	9.9%
2018	283	19.1%
2019	254	17.2%
2020	312	21.1%
2021	277	18.7%
2022	208	14.1%
Health Characteristics		
Acute Myocardial Infarction	30	2.0%
Alzheimer's Disease and related conditions	85	5.7%
Atrial Fibrillation	278	18.8%
Diabetes Mellitus	358	24.2%

Table 1h. Aggregated Characteristics of Enasidenib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Enasidenib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	294	19.9%
Hyperlipidemia	661	44.7%
Hypertension	976	65.9%
Depression	344	23.2%
Ischemic Heart Disease	438	29.6%
Rheumatoid Arthritis/Osteoarthritis	320	21.6%
Stroke/Transient Ischemic Attack	102	6.9%
Breast Cancer	59	4.0%
Colorectal Cancer	27	1.8%
Prostate Cancer	105	7.1%
Lung Cancer	34	2.3%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	299	20.2%
Anemia	1,383	93.4%
Asthma	94	6.4%
Benign Prostatic Hyperplasia	211	14.3%
Chronic Kidney Disease	516	34.9%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	233	15.7%
Glaucoma	60	4.1%
Osteoporosis	87	5.9%
Obesity: diagnosed or identified by weight management procedures	264	17.8%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	193	13.0%
Smoking: diagnosed or identified by smoking cessation procedures	599	40.5%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	46	3.1%
Drug Abuse or Dependence	40	2.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	155	10.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	39.1	22.8
Mean number of emergency room encounters	0.8	1.5
Mean number of inpatient hospital encounters	1.3	1.4
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	16.9	18.4

Table 1h. Aggregated Characteristics of Enasidenib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Enasidenib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	24.4	16.2
Mean number of generics dispensed	11.4	5.8
Mean number of unique drug classes dispensed	10.6	5.1

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1i. Aggregated Characteristics of Ertugliflozin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Ertugliflozin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	18,637	N/A ²
Demographic Characteristics		
Age (years)	56.5	9.8
Age		
0-17 years	13	0.1%
18-24 years	101	0.5%
25-40 years	1,564	8.4%
41-64 years	12,974	69.6%
≥ 65 years	3,985	21.4%
Sex		
Female	9,224	49.5%
Male	9,413	50.5%
Race ¹		
American Indian or Alaska Native	76	0.4%
Asian	1,851	9.9%
Black or African American	1,546	8.3%
Native Hawaiian or Other Pacific Islander	77	0.4%
Unknown	8,009	43.0%
White	7,078	38.0%
Hispanic origin		
Yes	2,201	11.8%
No	10,241	54.9%
Unknown	6,195	33.2%
Year		
2017	0	0.0%
2018	10,558	56.7%
2019	2,526	13.6%
2020	2,651	14.2%
2021	1,728	9.3%
2022	1,174	6.3%
Health Characteristics		
Acute Myocardial Infarction	79	0.4%
Alzheimer's Disease and related conditions	305	1.6%
Atrial Fibrillation	510	2.7%
Diabetes Mellitus	15,509	83.2%

Table 1i. Aggregated Characteristics of Ertugliflozin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Ertugliflozin	
	Number/Mean	Percent/ Standard Deviation
Heart Failure	884	4.7%
Hyperlipidemia	7,197	38.6%
Hypertension	8,361	44.9%
Depression	2,761	14.8%
Ischemic Heart Disease	2,486	13.3%
Rheumatoid Arthritis/Osteoarthritis	1,930	10.4%
Stroke/Transient Ischemic Attack	323	1.7%
Breast Cancer	173	0.9%
Colorectal Cancer	61	0.3%
Prostate Cancer	119	0.6%
Lung Cancer	35	0.2%
Endometrial Cancer	29	0.2%
Acquired Hypothyroidism	1,413	7.6%
Anemia	2,041	11.0%
Asthma	592	3.2%
Benign Prostatic Hyperplasia	484	2.6%
Chronic Kidney Disease	1,522	8.2%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	772	4.1%
Glaucoma	512	2.7%
Osteoporosis	134	0.7%
Obesity: diagnosed or identified by weight management procedures	5,119	27.5%
Obesity: identified by weight management-related prescriptions	1,141	6.1%
Overweight	1,187	6.4%
Smoking: diagnosed or identified by smoking cessation procedures	2,124	11.4%
Smoking: identified by smoking-related prescriptions	466	2.5%
Alcohol Abuse or Dependence	258	1.4%
Drug Abuse or Dependence	443	2.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	626	3.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.1	10.9
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.3	15.8

Table 1i. Aggregated Characteristics of Ertugliflozin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Ertugliflozin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	34.5	23.9
Mean number of generics dispensed	10.8	5.8
Mean number of unique drug classes dispensed	9.2	5.1

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1j. Aggregated Characteristics of Ertugliflozin and Sitagliptin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Ertugliflozin and Sitagliptin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	836	N/A ²
Demographic Characteristics		
Age (years)	58.4	10.5
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	515	61.6%
≥ 65 years	251	30.0%
Sex		
Female	405	48.4%
Male	431	51.6%
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	41	4.9%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	504	60.3%
White	273	32.7%
Hispanic origin		
Yes	21	2.5%
No	273	32.7%
Unknown	542	64.8%
Year		
2017	0	0.0%
2018	67	8.0%
2019	235	28.1%
2020	246	29.4%
2021	194	23.2%
2022	94	11.2%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	11	1.3%
Atrial Fibrillation	31	3.7%
Diabetes Mellitus	698	83.5%

Table 1j. Aggregated Characteristics of Ertugliflozin and Sitagliptin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Ertugliflozin and Sitagliptin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	54	6.5%
Hyperlipidemia	401	48.0%
Hypertension	458	54.8%
Depression	135	16.1%
Ischemic Heart Disease	101	12.1%
Rheumatoid Arthritis/Osteoarthritis	88	10.5%
Stroke/Transient Ischemic Attack	18	2.2%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	81	9.7%
Anemia	97	11.6%
Asthma	26	3.1%
Benign Prostatic Hyperplasia	22	2.6%
Chronic Kidney Disease	88	10.5%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	48	5.7%
Glaucoma	19	2.3%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	296	35.4%
Obesity: identified by weight management-related prescriptions	28	3.3%
Overweight	76	9.1%
Smoking: diagnosed or identified by smoking cessation procedures	108	12.9%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	23	2.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.5	7.8
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.3	4.6

Table 1j. Aggregated Characteristics of Ertugliflozin and Sitagliptin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Ertugliflozin and Sitagliptin	
	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	22.6	17.3
Mean number of generics dispensed	9.1	5.3
Mean number of unique drug classes dispensed	7.9	4.6

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1k. Aggregated Characteristics of Ertugliflozin and Metformin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Ertugliflozin and Metformin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	1,348	N/A ²
Demographic Characteristics		
Age (years)	55.1	9.6
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	959	71.1%
≥ 65 years	236	17.5%
Sex		
Female	573	42.5%
Male	775	57.5%
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	94	7.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	763	56.6%
White	391	29.0%
Hispanic origin		
Yes	148	11.0%
No	546	40.5%
Unknown	654	48.5%
Year		
2017	0	0.0%
2018	640	47.5%
2019	222	16.5%
2020	215	15.9%
2021	146	10.8%
2022	125	9.3%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	22	1.6%
Diabetes Mellitus	1,048	77.7%

Table 1k. Aggregated Characteristics of Ertugliflozin and Metformin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Ertugliflozin and Metformin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	45	3.3%
Hyperlipidemia	523	38.8%
Hypertension	572	42.4%
Depression	168	12.5%
Ischemic Heart Disease	145	10.8%
Rheumatoid Arthritis/Osteoarthritis	130	9.6%
Stroke/Transient Ischemic Attack	*****	*****
Breast Cancer	11	0.8%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	90	6.7%
Anemia	134	9.9%
Asthma	22	1.6%
Benign Prostatic Hyperplasia	28	2.1%
Chronic Kidney Disease	68	5.0%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	41	3.0%
Glaucoma	31	2.3%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	366	27.2%
Obesity: identified by weight management-related prescriptions	99	7.3%
Overweight	87	6.5%
Smoking: diagnosed or identified by smoking cessation procedures	120	8.9%
Smoking: identified by smoking-related prescriptions	26	1.9%
Alcohol Abuse or Dependence	14	1.0%
Drug Abuse or Dependence	29	2.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	28	2.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.6	8.6
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.3	9.7

Table 1k. Aggregated Characteristics of Ertugliflozin and Metformin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Ertugliflozin and Metformin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	28.3	20.7
Mean number of generics dispensed	9.5	5.6
Mean number of unique drug classes dispensed	8.2	4.9

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 11. Aggregated Characteristics of Glecaprevir and Pibrentasvir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Glecaprevir and Pibrentasvir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	74,786	N/A ²
Demographic Characteristics		
Age (years)	53.3	11.9
Age		
0-17 years	23	0.0%
18-24 years	1,211	1.6%
25-40 years	15,058	20.1%
41-64 years	44,253	59.2%
≥ 65 years	14,241	19.0%
Sex		
Female	30,524	40.8%
Male	44,262	59.2%
Race ¹		
American Indian or Alaska Native	1,072	1.4%
Asian	1,138	1.5%
Black or African American	13,304	17.8%
Native Hawaiian or Other Pacific Islander	84	0.1%
Unknown	18,980	25.4%
White	40,208	53.8%
Hispanic origin		
Yes	6,201	8.3%
No	54,514	72.9%
Unknown	14,071	18.8%
Year		
2017	7,404	9.9%
2018	42,363	56.6%
2019	11,811	15.8%
2020	6,128	8.2%
2021	4,425	5.9%
2022	2,655	3.6%
Health Characteristics		
Acute Myocardial Infarction	379	0.5%
Alzheimer's Disease and related conditions	1,346	1.8%
Atrial Fibrillation	2,203	2.9%
Diabetes Mellitus	12,372	16.5%

Table 11. Aggregated Characteristics of Glecaprevir and Pibrentasvir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Glecaprevir and Pibrentasvir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	5,065	6.8%
Hyperlipidemia	9,496	12.7%
Hypertension	25,648	34.3%
Depression	21,532	28.8%
Ischemic Heart Disease	7,334	9.8%
Rheumatoid Arthritis/Osteoarthritis	8,548	11.4%
Stroke/Transient Ischemic Attack	1,297	1.7%
Breast Cancer	529	0.7%
Colorectal Cancer	423	0.6%
Prostate Cancer	643	0.9%
Lung Cancer	380	0.5%
Endometrial Cancer	59	0.1%
Acquired Hypothyroidism	3,384	4.5%
Anemia	12,326	16.5%
Asthma	2,745	3.7%
Benign Prostatic Hyperplasia	1,919	2.6%
Chronic Kidney Disease	9,478	12.7%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	7,881	10.5%
Glaucoma	1,100	1.5%
Osteoporosis	914	1.2%
Obesity: diagnosed or identified by weight management procedures	10,645	14.2%
Obesity: identified by weight management-related prescriptions	269	0.4%
Overweight	5,754	7.7%
Smoking: diagnosed or identified by smoking cessation procedures	27,513	36.8%
Smoking: identified by smoking-related prescriptions	5,984	8.0%
Alcohol Abuse or Dependence	10,015	13.4%
Drug Abuse or Dependence	23,182	31.0%
History of Cardiac Arrest	100	0.1%
History of Coronary Angioplasty or Bypass	1,753	2.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.2	29.3
Mean number of emergency room encounters	0.7	1.6
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	12.0	25.7

Table 1I. Aggregated Characteristics of Glecaprevir and Pibrentasvir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Glecaprevir and Pibrentasvir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	22.2	48.9
Mean number of generics dispensed	7.9	6.2
Mean number of unique drug classes dispensed	7.3	5.3

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

²N/A: Not Applicable

Table 1m. Aggregated Characteristics of Guselkumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Guselkumab		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	25,685	N/A ²
Demographic Characteristics		
Age (years)	50.8	12.8
Age		
0-17 years	37	0.1%
18-24 years	934	3.6%
25-40 years	5,796	22.6%
41-64 years	14,568	56.7%
≥ 65 years	4,350	16.9%
Sex		
Female	12,958	50.4%
Male	12,727	49.6%
Race ¹		
American Indian or Alaska Native	62	0.2%
Asian	356	1.4%
Black or African American	527	2.1%
Native Hawaiian or Other Pacific Islander	25	0.1%
Unknown	17,741	69.1%
White	6,974	27.2%
Hispanic origin		
Yes	438	1.7%
No	5,981	23.3%
Unknown	19,266	75.0%
Year		
2017	868	3.4%
2018	3,914	15.2%
2019	3,710	14.4%
2020	4,268	16.6%
2021	6,923	27.0%
2022	6,002	23.4%
Health Characteristics		
Acute Myocardial Infarction	60	0.2%
Alzheimer's Disease and related conditions	163	0.6%
Atrial Fibrillation	580	2.3%
Diabetes Mellitus	4,068	15.8%

Table 1m. Aggregated Characteristics of Guselkumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Guselkumab	
	Number/Mean	Percent/ Standard Deviation
Heart Failure	826	3.2%
Hyperlipidemia	4,650	18.1%
Hypertension	6,219	24.2%
Depression	4,367	17.0%
Ischemic Heart Disease	1,942	7.6%
Rheumatoid Arthritis/Osteoarthritis	6,971	27.1%
Stroke/Transient Ischemic Attack	155	0.6%
Breast Cancer	230	0.9%
Colorectal Cancer	58	0.2%
Prostate Cancer	119	0.5%
Lung Cancer	53	0.2%
Endometrial Cancer	25	0.1%
Acquired Hypothyroidism	1,641	6.4%
Anemia	2,214	8.6%
Asthma	765	3.0%
Benign Prostatic Hyperplasia	391	1.5%
Chronic Kidney Disease	1,252	4.9%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	957	3.7%
Glaucoma	323	1.3%
Osteoporosis	373	1.5%
Obesity: diagnosed or identified by weight management procedures	5,957	23.2%
Obesity: identified by weight management-related prescriptions	372	1.4%
Overweight	1,502	5.8%
Smoking: diagnosed or identified by smoking cessation procedures	3,477	13.5%
Smoking: identified by smoking-related prescriptions	309	1.2%
Alcohol Abuse or Dependence	512	2.0%
Drug Abuse or Dependence	681	2.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	511	2.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.9	10.0
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.6	6.4

Table 1m. Aggregated Characteristics of Guselkumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Guselkumab		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	18.4	17.9
Mean number of generics dispensed	7.4	5.4
Mean number of unique drug classes dispensed	6.8	4.9

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1n. Aggregated Characteristics of Inotuzumab Ozogamicin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Inotuzumab Ozogamicin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	592	N/A ²
Demographic Characteristics		
Age (years)	60.4	17.1
Age		
0-17 years	21	3.5%
18-24 years	26	4.4%
25-40 years	68	11.5%
41-64 years	127	21.5%
≥ 65 years	350	59.1%
Sex		
Female	282	47.6%
Male	310	52.4%
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	38	6.4%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	179	30.2%
White	355	60.0%
Hispanic origin		
Yes	30	5.1%
No	376	63.5%
Unknown	186	31.4%
Year		
2017	*****	*****
2018	*****	*****
2019	142	24.0%
2020	163	27.5%
2021	141	23.8%
2022	127	21.5%
Health Characteristics		
Acute Myocardial Infarction	14	2.4%
Alzheimer's Disease and related conditions	38	6.4%
Atrial Fibrillation	78	13.2%
Diabetes Mellitus	181	30.6%

Table 1n. Aggregated Characteristics of Inotuzumab Ozogamicin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Inotuzumab Ozogamicin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	114	19.3%
Hyperlipidemia	273	46.1%
Hypertension	383	64.7%
Depression	191	32.3%
Ischemic Heart Disease	162	27.4%
Rheumatoid Arthritis/Osteoarthritis	104	17.6%
Stroke/Transient Ischemic Attack	47	7.9%
Breast Cancer	30	5.1%
Colorectal Cancer	*****	*****
Prostate Cancer	28	4.7%
Lung Cancer	12	2.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	92	15.5%
Anemia	533	90.0%
Asthma	53	9.0%
Benign Prostatic Hyperplasia	64	10.8%
Chronic Kidney Disease	236	39.9%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	68	11.5%
Glaucoma	14	2.4%
Osteoporosis	31	5.2%
Obesity: diagnosed or identified by weight management procedures	178	30.1%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	81	13.7%
Smoking: diagnosed or identified by smoking cessation procedures	210	35.5%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	21	3.5%
Drug Abuse or Dependence	38	6.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	56	9.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	29.7	17.1
Mean number of emergency room encounters	1.1	1.6
Mean number of inpatient hospital encounters	2.5	2.3
Mean number of non-acute institutional encounters	0.1	0.5
Mean number of other ambulatory encounters	23.6	22.9

Table 1n. Aggregated Characteristics of Inotuzumab Ozogamicin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Inotuzumab Ozogamicin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	29.9	19.4
Mean number of generics dispensed	14.3	6.7
Mean number of unique drug classes dispensed	13.2	5.8

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 10. Aggregated Characteristics of Latanoprostene Bunod Ophthalmic Solution in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Latanoprostene Bunod Ophthalmic Solution		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	54,803	N/A ²
Demographic Characteristics		
Age (years)	74.9	10.1
Age		
0-17 years	43	0.1%
18-24 years	63	0.1%
25-40 years	471	0.9%
41-64 years	6,604	12.1%
≥ 65 years	47,622	86.9%
Sex		
Female	32,003	58.4%
Male	22,800	41.6%
Race ¹		
American Indian or Alaska Native	94	0.2%
Asian	3,073	5.6%
Black or African American	6,607	12.1%
Native Hawaiian or Other Pacific Islander	104	0.2%
Unknown	12,004	21.9%
White	32,921	60.1%
Hispanic origin		
Yes	1,305	2.4%
No	40,275	73.5%
Unknown	13,223	24.1%
Year		
2017	43	0.1%
2018	8,086	14.8%
2019	10,281	18.8%
2020	9,494	17.3%
2021	14,559	26.6%
2022	12,340	22.5%
Health Characteristics		
Acute Myocardial Infarction	182	0.3%
Alzheimer's Disease and related conditions	2,554	4.7%
Atrial Fibrillation	5,008	9.1%
Diabetes Mellitus	13,768	25.1%

Table 10. Aggregated Characteristics of Latanoprostene Bunod Ophthalmic Solution in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Latanoprostene Bunod Ophthalmic Solution		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	4,651	8.5%
Hyperlipidemia	21,236	38.7%
Hypertension	26,855	49.0%
Depression	6,670	12.2%
Ischemic Heart Disease	10,039	18.3%
Rheumatoid Arthritis/Osteoarthritis	8,877	16.2%
Stroke/Transient Ischemic Attack	1,388	2.5%
Breast Cancer	1,457	2.7%
Colorectal Cancer	422	0.8%
Prostate Cancer	1,699	3.1%
Lung Cancer	331	0.6%
Endometrial Cancer	133	0.2%
Acquired Hypothyroidism	6,145	11.2%
Anemia	9,786	17.9%
Asthma	2,007	3.7%
Benign Prostatic Hyperplasia	3,080	5.6%
Chronic Kidney Disease	7,212	13.2%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	3,484	6.4%
Glaucoma	42,173	77.0%
Osteoporosis	3,179	5.8%
Obesity: diagnosed or identified by weight management procedures	7,831	14.3%
Obesity: identified by weight management-related prescriptions	377	0.7%
Overweight	4,880	8.9%
Smoking: diagnosed or identified by smoking cessation procedures	6,356	11.6%
Smoking: identified by smoking-related prescriptions	119	0.2%
Alcohol Abuse or Dependence	501	0.9%
Drug Abuse or Dependence	723	1.3%
History of Cardiac Arrest	34	0.1%
History of Coronary Angioplasty or Bypass	2,406	4.4%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.0	12.5
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.1	7.4

Table 1o. Aggregated Characteristics of Latanoprostene Bunod Ophthalmic Solution in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Latanoprostene Bunod Ophthalmic Solution		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	20.2	17.8
Mean number of generics dispensed	8.5	5.1
Mean number of unique drug classes dispensed	8.0	4.6

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

²N/A: Not Applicable

Table 1p. Aggregated Characteristics of Letemovir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Letemovir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	4,466	N/A ²
Demographic Characteristics		
Age (years)	56.4	13.9
Age		
0-17 years	54	1.2%
18-24 years	175	3.9%
25-40 years	624	14.0%
41-64 years	1,787	40.0%
≥ 65 years	1,826	40.9%
Sex		
Female	1,997	44.7%
Male	2,469	55.3%
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	133	3.0%
Black or African American	327	7.3%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	2,002	44.8%
White	1,993	44.6%
Hispanic origin		
Yes	232	5.2%
No	2,212	49.5%
Unknown	2,022	45.3%
Year		
2017	12	0.3%
2018	706	15.8%
2019	740	16.6%
2020	959	21.5%
2021	1,161	26.0%
2022	888	19.9%
Health Characteristics		
Acute Myocardial Infarction	67	1.5%
Alzheimer's Disease and related conditions	210	4.7%
Atrial Fibrillation	564	12.6%
Diabetes Mellitus	1,245	27.9%

Table 1p. Aggregated Characteristics of Letermovir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Letermovir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	813	18.2%
Hyperlipidemia	1,738	38.9%
Hypertension	2,730	61.1%
Depression	1,317	29.5%
Ischemic Heart Disease	1,141	25.5%
Rheumatoid Arthritis/Osteoarthritis	612	13.7%
Stroke/Transient Ischemic Attack	247	5.5%
Breast Cancer	154	3.4%
Colorectal Cancer	58	1.3%
Prostate Cancer	111	2.5%
Lung Cancer	45	1.0%
Endometrial Cancer	17	0.4%
Acquired Hypothyroidism	691	15.5%
Anemia	4,165	93.3%
Asthma	351	7.9%
Benign Prostatic Hyperplasia	416	9.3%
Chronic Kidney Disease	2,048	45.9%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	598	13.4%
Glaucoma	82	1.8%
Osteoporosis	280	6.3%
Obesity: diagnosed or identified by weight management procedures	967	21.7%
Obesity: identified by weight management-related prescriptions	19	0.4%
Overweight	541	12.1%
Smoking: diagnosed or identified by smoking cessation procedures	1,757	39.3%
Smoking: identified by smoking-related prescriptions	39	0.9%
Alcohol Abuse or Dependence	149	3.3%
Drug Abuse or Dependence	272	6.1%
History of Cardiac Arrest	19	0.4%
History of Coronary Angioplasty or Bypass	302	6.8%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	41.5	20.2
Mean number of emergency room encounters	0.9	2.5
Mean number of inpatient hospital encounters	2.4	1.9
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	28.4	24.8

Table 1p. Aggregated Characteristics of Letemovir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Letemovir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	31.6	18.4
Mean number of generics dispensed	14.9	6.7
Mean number of unique drug classes dispensed	13.7	5.8

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1q. Aggregated Characteristics of Macimorelin Acetate in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Macimorelin Acetate		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	46	N/A ³
Demographic Characteristics		
Age (years)	44.9	12.5
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	26	56.5%
≥ 65 years	*****	*****
Sex		
Female	24	52.2%
Male	22	47.8%
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	0	0.0%
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2017	0	0.0%
2018	*****	*****
2019	*****	*****
2020	*****	*****
2021	14	30.4%
2022	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****

Table 1q. Aggregated Characteristics of Macimorelin Acetate in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Macimorelin Acetate		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	12	26.1%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/Transient Ischemic Attack	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
Chronic Obstructive Pulmonary Disease and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	20.2	18.4
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	4.6	6.5

Table 1q. Aggregated Characteristics of Macimorelin Acetate in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Macimorelin Acetate		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	19.6	14.2
Mean number of generics dispensed	8.6	5.5
Mean number of unique drug classes dispensed	8.0	4.8

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

²NaN: Not a Number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .*

³N/A: Not Applicable

Table 1r. Aggregated Characteristics of Meropenem and Vaborbactam in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Meropenem and Vaborbactam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	4,045	N/A ²
Demographic Characteristics		
Age (years)	70.2	13.3
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	127	3.1%
41-64 years	1,018	25.2%
≥ 65 years	2,886	71.3%
Sex		
Female	2,141	52.9%
Male	1,904	47.1%
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	55	1.4%
Black or African American	410	10.1%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	733	18.1%
White	2,836	70.1%
Hispanic origin		
Yes	95	2.3%
No	3,197	79.0%
Unknown	753	18.6%
Year		
2017	0	0.0%
2018	31	0.8%
2019	199	4.9%
2020	1,338	33.1%
2021	1,614	39.9%
2022	863	21.3%
Health Characteristics		
Acute Myocardial Infarction	278	6.9%
Alzheimer's Disease and related conditions	978	24.2%
Atrial Fibrillation	1,117	27.6%
Diabetes Mellitus	2,056	50.8%

Table 1r. Aggregated Characteristics of Meropenem and Vaborbactam in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Meropenem and Vaborbactam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	1,608	39.8%
Hyperlipidemia	2,298	56.8%
Hypertension	3,201	79.1%
Depression	1,599	39.5%
Ischemic Heart Disease	1,867	46.2%
Rheumatoid Arthritis/Osteoarthritis	1,242	30.7%
Stroke/Transient Ischemic Attack	523	12.9%
Breast Cancer	146	3.6%
Colorectal Cancer	110	2.7%
Prostate Cancer	128	3.2%
Lung Cancer	157	3.9%
Endometrial Cancer	34	0.8%
Acquired Hypothyroidism	955	23.6%
Anemia	2,415	59.7%
Asthma	321	7.9%
Benign Prostatic Hyperplasia	532	13.2%
Chronic Kidney Disease	2,182	53.9%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	1,495	37.0%
Glaucoma	117	2.9%
Osteoporosis	295	7.3%
Obesity: diagnosed or identified by weight management procedures	1,349	33.3%
Obesity: identified by weight management-related prescriptions	21	0.5%
Overweight	484	12.0%
Smoking: diagnosed or identified by smoking cessation procedures	1,595	39.4%
Smoking: identified by smoking-related prescriptions	25	0.6%
Alcohol Abuse or Dependence	192	4.7%
Drug Abuse or Dependence	356	8.8%
History of Cardiac Arrest	61	1.5%
History of Coronary Angioplasty or Bypass	589	14.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.1	24.2
Mean number of emergency room encounters	1.3	2.4
Mean number of inpatient hospital encounters	1.4	1.7
Mean number of non-acute institutional encounters	0.5	1.0
Mean number of other ambulatory encounters	27.5	33.1

Table 1r. Aggregated Characteristics of Meropenem and Vaborbactam in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Meropenem and Vaborbactam	
	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	36.6	30.8
Mean number of generics dispensed	13.0	7.0
Mean number of unique drug classes dispensed	11.9	6.2

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1s. Aggregated Characteristics of Neratinib Maleate in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Neratinib Maleate		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	2,965	N/A ²
Demographic Characteristics		
Age (years)	56.7	10.4
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	1,681	56.7%
≥ 65 years	903	30.5%
Sex		
Female	2,941	99.2%
Male	24	0.8%
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	266	9.0%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,532	51.7%
White	1,068	36.0%
Hispanic origin		
Yes	169	5.7%
No	1,296	43.7%
Unknown	1,500	50.6%
Year		
2017	386	13.0%
2018	915	30.9%
2019	666	22.5%
2020	449	15.1%
2021	301	10.2%
2022	248	8.4%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	26	0.9%
Atrial Fibrillation	78	2.6%
Diabetes Mellitus	385	13.0%

Table 1s. Aggregated Characteristics of Neratinib Maleate in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Neratinib Maleate		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	335	11.3%
Hyperlipidemia	560	18.9%
Hypertension	883	29.8%
Depression	592	20.0%
Ischemic Heart Disease	206	6.9%
Rheumatoid Arthritis/Osteoarthritis	276	9.3%
Stroke/Transient Ischemic Attack	50	1.7%
Breast Cancer	2,928	98.8%
Colorectal Cancer	27	0.9%
Prostate Cancer	*****	*****
Lung Cancer	48	1.6%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	309	10.4%
Anemia	909	30.7%
Asthma	123	4.1%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	197	6.6%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	101	3.4%
Glaucoma	57	1.9%
Osteoporosis	153	5.2%
Obesity: diagnosed or identified by weight management procedures	505	17.0%
Obesity: identified by weight management-related prescriptions	19	0.6%
Overweight	265	8.9%
Smoking: diagnosed or identified by smoking cessation procedures	503	17.0%
Smoking: identified by smoking-related prescriptions	25	0.8%
Alcohol Abuse or Dependence	35	1.2%
Drug Abuse or Dependence	79	2.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	35	1.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	24.6	14.3
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	5.4	9.8

Table 1s. Aggregated Characteristics of Neratinib Maleate in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Neratinib Maleate		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	19.5	15.2
Mean number of generics dispensed	8.1	5.0
Mean number of unique drug classes dispensed	7.6	4.5

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1t. Aggregated Characteristics of Netarsudil in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Netarsudil		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	151,751	N/A ²
Demographic Characteristics		
Age (years)	75.8	10.4
Age		
0-17 years	171	0.1%
18-24 years	183	0.1%
25-40 years	1,302	0.9%
41-64 years	16,824	11.1%
≥ 65 years	133,271	87.8%
Sex		
Female	86,133	56.8%
Male	65,618	43.2%
Race ¹		
American Indian or Alaska Native	333	0.2%
Asian	5,918	3.9%
Black or African American	23,119	15.2%
Native Hawaiian or Other Pacific Islander	316	0.2%
Unknown	30,391	20.0%
White	91,674	60.4%
Hispanic origin		
Yes	3,583	2.4%
No	114,008	75.1%
Unknown	34,160	22.5%
Year		
2017	0	0.0%
2018	18,022	11.9%
2019	36,456	24.0%
2020	34,312	22.6%
2021	37,048	24.4%
2022	25,913	17.1%
Health Characteristics		
Acute Myocardial Infarction	660	0.4%
Alzheimer's Disease and related conditions	8,739	5.8%
Atrial Fibrillation	14,602	9.6%
Diabetes Mellitus	41,145	27.1%

Table 1t. Aggregated Characteristics of Netarsudil in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Netarsudil	
	Number/Mean	Percent/ Standard Deviation
Heart Failure	14,806	9.8%
Hyperlipidemia	57,761	38.1%
Hypertension	77,290	50.9%
Depression	19,016	12.5%
Ischemic Heart Disease	28,639	18.9%
Rheumatoid Arthritis/Osteoarthritis	23,744	15.6%
Stroke/Transient Ischemic Attack	4,482	3.0%
Breast Cancer	3,893	2.6%
Colorectal Cancer	1,108	0.7%
Prostate Cancer	4,620	3.0%
Lung Cancer	1,037	0.7%
Endometrial Cancer	371	0.2%
Acquired Hypothyroidism	17,249	11.4%
Anemia	28,410	18.7%
Asthma	5,638	3.7%
Benign Prostatic Hyperplasia	8,384	5.5%
Chronic Kidney Disease	22,619	14.9%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	10,856	7.2%
Glaucoma	122,920	81.0%
Osteoporosis	8,245	5.4%
Obesity: diagnosed or identified by weight management procedures	22,288	14.7%
Obesity: identified by weight management-related prescriptions	1,047	0.7%
Overweight	13,569	8.9%
Smoking: diagnosed or identified by smoking cessation procedures	19,350	12.8%
Smoking: identified by smoking-related prescriptions	248	0.2%
Alcohol Abuse or Dependence	1,540	1.0%
Drug Abuse or Dependence	2,162	1.4%
History of Cardiac Arrest	120	0.1%
History of Coronary Angioplasty or Bypass	7,115	4.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.4	13.2
Mean number of emergency room encounters	0.2	0.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.6	8.9

Table 1t. Aggregated Characteristics of Netarsudil in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Netarsudil		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	22.1	98.6
Mean number of generics dispensed	9.0	5.3
Mean number of unique drug classes dispensed	8.6	4.6

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

²N/A: Not Applicable

Table 1u. Aggregated Characteristics of Ozenoxacin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Ozenoxacin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	1,641	N/A ²
Demographic Characteristics		
Age (years)	38.0	19.0
Age		
0-17 years	372	22.7%
18-24 years	156	9.5%
25-40 years	345	21.0%
41-64 years	632	38.5%
≥ 65 years	136	8.3%
Sex		
Female	982	59.8%
Male	659	40.2%
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	17	1.0%
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	1,370	83.5%
White	243	14.8%
Hispanic origin		
Yes	14	0.9%
No	85	5.2%
Unknown	1,542	94.0%
Year		
2017	0	0.0%
2018	87	5.3%
2019	665	40.5%
2020	396	24.1%
2021	242	14.7%
2022	251	15.3%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	23	1.4%
Diabetes Mellitus	85	5.2%

Table 1u. Aggregated Characteristics of Ozenoxacin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Ozenoxacin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	24	1.5%
Hyperlipidemia	164	10.0%
Hypertension	166	10.1%
Depression	191	11.6%
Ischemic Heart Disease	48	2.9%
Rheumatoid Arthritis/Osteoarthritis	99	6.0%
Stroke/Transient Ischemic Attack	*****	*****
Breast Cancer	20	1.2%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	84	5.1%
Anemia	113	6.9%
Asthma	37	2.3%
Benign Prostatic Hyperplasia	26	1.6%
Chronic Kidney Disease	40	2.4%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	20	1.2%
Glaucoma	12	0.7%
Osteoporosis	15	0.9%
Obesity: diagnosed or identified by weight management procedures	165	10.1%
Obesity: identified by weight management-related prescriptions	12	0.7%
Overweight	88	5.4%
Smoking: diagnosed or identified by smoking cessation procedures	74	4.5%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	11	0.7%
Drug Abuse or Dependence	25	1.5%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	14	0.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.3	9.7
Mean number of emergency room encounters	0.2	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.0
Mean number of other ambulatory encounters	1.8	5.1

Table 1u. Aggregated Characteristics of Ozenoxacin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Ozenoxacin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	11.5	13.1
Mean number of generics dispensed	5.6	5.1
Mean number of unique drug classes dispensed	5.2	4.6

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1v. Aggregated Characteristics of Secnidazole in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Secnidazole		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	9,558	N/A ²
Demographic Characteristics		
Age (years)	36.0	11.1
Age		
0-17 years	121	1.3%
18-24 years	1,808	18.9%
25-40 years	4,706	49.2%
41-64 years	2,632	27.5%
≥ 65 years	291	3.0%
Sex		
Female	9,535	99.8%
Male	23	0.2%
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	42	0.4%
Black or African American	813	8.5%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	7,683	80.4%
White	1,009	10.6%
Hispanic origin		
Yes	125	1.3%
No	1,581	16.5%
Unknown	7,852	82.2%
Year		
2017	0	0.0%
2018	2,251	23.6%
2019	3,449	36.1%
2020	2,309	24.2%
2021	1,016	10.6%
2022	533	5.6%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	20	0.2%
Atrial Fibrillation	22	0.2%
Diabetes Mellitus	274	2.9%

Table 1v. Aggregated Characteristics of Secnidazole in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Secnidazole	
	Number/Mean	Percent/ Standard Deviation
Heart Failure	50	0.5%
Hyperlipidemia	439	4.6%
Hypertension	653	6.8%
Depression	1,513	15.8%
Ischemic Heart Disease	106	1.1%
Rheumatoid Arthritis/Osteoarthritis	355	3.7%
Stroke/Transient Ischemic Attack	24	0.3%
Breast Cancer	60	0.6%
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	371	3.9%
Anemia	717	7.5%
Asthma	256	2.7%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	89	0.9%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	58	0.6%
Glaucoma	53	0.6%
Osteoporosis	34	0.4%
Obesity: diagnosed or identified by weight management procedures	1,238	13.0%
Obesity: identified by weight management-related prescriptions	76	0.8%
Overweight	646	6.8%
Smoking: diagnosed or identified by smoking cessation procedures	635	6.6%
Smoking: identified by smoking-related prescriptions	66	0.7%
Alcohol Abuse or Dependence	96	1.0%
Drug Abuse or Dependence	163	1.7%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	11	0.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.1	8.5
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.0	0.3
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.2	5.3

Table 1v. Aggregated Characteristics of Secnidazole in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Secnidazole		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	10.5	11.9
Mean number of generics dispensed	5.3	4.4
Mean number of unique drug classes dispensed	5.1	4.0

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1w. Aggregated Characteristics of Semaglutide in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Semaglutide	
	Number/Mean	Percent/ Standard Deviation
Number of unique patients	982,602	N/A ²
Demographic Characteristics		
Age (years)	60.6	11.0
Age		
0-17 years	459	0.0%
18-24 years	5,849	0.6%
25-40 years	76,894	7.8%
41-64 years	458,381	46.6%
≥ 65 years	441,019	44.9%
Sex		
Female	562,761	57.3%
Male	419,841	42.7%
Race ¹		
American Indian or Alaska Native	6,643	0.7%
Asian	13,561	1.4%
Black or African American	76,901	7.8%
Native Hawaiian or Other Pacific Islander	1,535	0.2%
Unknown	433,302	44.1%
White	450,660	45.9%
Hispanic origin		
Yes	24,802	2.5%
No	476,423	48.5%
Unknown	481,377	49.0%
Year		
2017	0	0.0%
2018	33,697	3.4%
2019	123,677	12.6%
2020	178,605	18.2%
2021	301,810	30.7%
2022	344,813	35.1%
Health Characteristics		
Acute Myocardial Infarction	5,450	0.6%
Alzheimer's Disease and related conditions	15,375	1.6%
Atrial Fibrillation	53,140	5.4%
Diabetes Mellitus	705,188	71.8%

Table 1w. Aggregated Characteristics of Semaglutide in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Semaglutide	
	Number/Mean	Percent/ Standard Deviation
Heart Failure	87,748	8.9%
Hyperlipidemia	478,073	48.7%
Hypertension	553,320	56.3%
Depression	208,533	21.2%
Ischemic Heart Disease	182,021	18.5%
Rheumatoid Arthritis/Osteoarthritis	156,813	16.0%
Stroke/Transient Ischemic Attack	17,848	1.8%
Breast Cancer	16,544	1.7%
Colorectal Cancer	4,638	0.5%
Prostate Cancer	12,535	1.3%
Lung Cancer	2,809	0.3%
Endometrial Cancer	2,510	0.3%
Acquired Hypothyroidism	129,856	13.2%
Anemia	153,083	15.6%
Asthma	45,553	4.6%
Benign Prostatic Hyperplasia	32,977	3.4%
Chronic Kidney Disease	159,949	16.3%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	59,788	6.1%
Glaucoma	28,510	2.9%
Osteoporosis	16,374	1.7%
Obesity: diagnosed or identified by weight management procedures	493,599	50.2%
Obesity: identified by weight management-related prescriptions	86,760	8.8%
Overweight	75,117	7.6%
Smoking: diagnosed or identified by smoking cessation procedures	151,674	15.4%
Smoking: identified by smoking-related prescriptions	7,552	0.8%
Alcohol Abuse or Dependence	12,061	1.2%
Drug Abuse or Dependence	24,338	2.5%
History of Cardiac Arrest	832	0.1%
History of Coronary Angioplasty or Bypass	53,615	5.5%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	11.2	11.5
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.0	6.4

Table 1w. Aggregated Characteristics of Semaglutide in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Semaglutide		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	23.4	41.4
Mean number of generics dispensed	9.5	5.3
Mean number of unique drug classes dispensed	8.5	4.7

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

²N/A: Not Applicable

Table 1x. Aggregated Characteristics of Sofosbuvir Velpatasvir Voxilaprevir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Sofosbuvir Velpatasvir Voxilaprevir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	5,567	N/A ²
Demographic Characteristics		
Age (years)	60.0	9.3
Age		
0-17 years	0	0.0%
18-24 years	21	0.4%
25-40 years	307	5.5%
41-64 years	3,365	60.4%
≥ 65 years	1,874	33.7%
Sex		
Female	1,456	26.2%
Male	4,111	73.8%
Race ¹		
American Indian or Alaska Native	*****	*****
Asian	105	1.9%
Black or African American	1,352	24.3%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,391	25.0%
White	2,657	47.7%
Hispanic origin		
Yes	332	6.0%
No	3,973	71.4%
Unknown	1,262	22.7%
Year		
2017	1,379	24.8%
2018	2,176	39.1%
2019	775	13.9%
2020	569	10.2%
2021	417	7.5%
2022	251	4.5%
Health Characteristics		
Acute Myocardial Infarction	16	0.3%
Alzheimer's Disease and related conditions	101	1.8%
Atrial Fibrillation	171	3.1%
Diabetes Mellitus	1,327	23.8%

Table 1x. Aggregated Characteristics of Sofosbuvir Velpatasvir Voxilaprevir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Sofosbuvir Velpatasvir Voxilaprevir		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	347	6.2%
Hyperlipidemia	865	15.5%
Hypertension	2,348	42.2%
Depression	1,355	24.3%
Ischemic Heart Disease	614	11.0%
Rheumatoid Arthritis/Osteoarthritis	853	15.3%
Stroke/Transient Ischemic Attack	105	1.9%
Breast Cancer	26	0.5%
Colorectal Cancer	43	0.8%
Prostate Cancer	75	1.3%
Lung Cancer	26	0.5%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	291	5.2%
Anemia	925	16.6%
Asthma	210	3.8%
Benign Prostatic Hyperplasia	219	3.9%
Chronic Kidney Disease	595	10.7%
Chronic Obstructive Pulmonary Disease and Bronchiectasis	594	10.7%
Glaucoma	119	2.1%
Osteoporosis	58	1.0%
Obesity: diagnosed or identified by weight management procedures	994	17.9%
Obesity: identified by weight management-related prescriptions	30	0.5%
Overweight	458	8.2%
Smoking: diagnosed or identified by smoking cessation procedures	2,013	36.2%
Smoking: identified by smoking-related prescriptions	253	4.5%
Alcohol Abuse or Dependence	788	14.2%
Drug Abuse or Dependence	1,057	19.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	144	2.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.0	19.2
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	0.3
Mean number of other ambulatory encounters	8.1	18.9

Table 1x. Aggregated Characteristics of Sofosbuvir Velpatasvir Voxilaprevir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Patient Characteristics	Sofosbuvir Velpatasvir Voxilaprevir	
	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	23.7	21.3
Mean number of generics dispensed	8.2	5.7
Mean number of unique drug classes dispensed	7.5	5.1

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .

²N/A: Not Applicable

Table 1y. Aggregated Characteristics of Vestronidase Alfa Vjvk in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Vestronidase Alfa Vjvk		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Number of unique patients	*****	N/A ²
Demographic Characteristics		
Age (years)	14.0	7.7
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2017	*****	*****
2018	*****	*****
2019	*****	*****
2020	0	0.0%
2021	0	0.0%
2022	0	0.0%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%

Table 1y. Aggregated Characteristics of Vestronidase Alfa Vjvk in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Vestronidase Alfa Vjvk		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Heart Failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertension	0	0.0%
Depression	0	0.0%
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/Transient Ischemic Attack	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	0	0.0%
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
Chronic Obstructive Pulmonary Disease and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	0	0.0%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.5	6.0
Mean number of emergency room encounters	0.1	0.3
Mean number of inpatient hospital encounters	0.6	1.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	37.8	49.4

Table 1y. Aggregated Characteristics of Vestronidase Alfa Vjbk in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Vestronidase Alfa Vjbk		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation
Mean number of filled prescriptions	23.3	56.1
Mean number of generics dispensed	4.2	2.0
Mean number of unique drug classes dispensed	4.1	2.0

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

²NaN: Not a Number

*****Data are not presented in these cells due to a small sample size or to ensure a small cell cannot be recalculated through the cells presented .*

³N/A: Not Applicable

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>Abemaciclib</i>	88,477	87,789	99.2%	592	0.7%	96	0.1%	0	0.0%
<i>Acalabrutinib</i>	106,098	105,836	99.8%	168	0.2%	*****	*****	*****	*****
<i>Angiotensin II</i>	37	37	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Benralizumab</i>	212,262	177,768	83.7%	34,398	16.2%	*****	*****	*****	*****
<i>Benznidazole</i>	83	70	84.3%	13	15.7%	0	0.0%	0	0.0%
<i>Copanlisib</i>	4,369	4,369	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Emicizumab</i>	29,101	28,132	96.7%	926	3.2%	*****	*****	*****	*****
<i>Enasidenib</i>	8,178	8,111	99.2%	35	0.4%	32	0.4%	0	0.0%
<i>Ertugliflozin</i>	88,042	74,454	84.6%	1,191	1.4%	12,222	13.9%	175	0.2%
<i>Ertugliflozin and Sitagliptin</i>	6,077	5,073	83.5%	*****	*****	918	15.1%	*****	*****
<i>Ertugliflozin and Metformin</i>	7,274	6,076	83.5%	*****	*****	1,063	14.6%	*****	*****
<i>Glecaprevir and Pibrentasvir</i>	171,723	170,574	99.3%	711	0.4%	192	0.1%	246	0.1%
<i>Guselkumab</i>	178,530	70,129	39.3%	107,581	60.3%	672	0.4%	148	0.1%
<i>Inotuzumab Ozogamicin</i>	3,206	3,206	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Latanoprostene Bunod Ophthalmic Solution</i>	319,017	186,947	58.6%	82,345	25.8%	46,991	14.7%	2,734	0.9%
<i>Letermovir</i>	19,780	19,308	97.6%	*****	*****	330	1.7%	*****	*****
<i>Macimorelin Acetate</i>	48	48	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Meropenem and Vaborbactam</i>	6,579	6,579	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Neratinib Maleate</i>	17,605	17,537	99.6%	*****	*****	*****	*****	0	0.0%
<i>Netarsudil</i>	1,012,744	695,249	68.7%	151,609	15.0%	160,222	15.8%	5,664	0.6%
<i>Ozenoxacin</i>	2,167	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Secnidazole</i>	13,586	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Semaglutide</i>	6,246,642	4,650,002	74.4%	469,593	7.5%	1,119,016	17.9%	8,031	0.1%

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>Sofosbuvir Velpatasvir Voxilaprevir</i>	16,883	16,822	99.6%	25	0.1%	23	0.1%	13	0.1%
<i>Vestronidase Alfa Vjbk</i>	98	****	****	****	****	****	****	0	0.0%

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Abemaciclib</i>	88,477	1	28	28	28	84	26.6	5.7
<i>Acalabrutinib</i>	106,098	1	30	30	30	120	29.1	4.7
<i>Angiotensin II</i>	37	1	1	1	1	1	1.0	0.0
<i>Benralizumab</i>	212,262	1	1	1	28	216	12.4	20.4
<i>Benznidazole</i>	83	1	30	30	30	60	30.2	14.0
<i>Copanlisib</i>	4,369	1	1	1	1	28	1.1	1.7
<i>Emicizumab</i>	29,101	1	1	1	28	387	9.6	14.7
<i>Enasidenib</i>	8,178	1	30	30	30	90	29.3	5.8
<i>Ertugliflozin</i>	88,042	1	30	30	30	264	36.8	22.6
<i>Ertugliflozin and Sitagliptin</i>	6,077	1	30	30	30	180	38.5	22.1
<i>Ertugliflozin and Metformin</i>	7,274	1	30	30	30	194	37.6	22.4
<i>Glecaprevir and Pibrentasvir</i>	171,723	1	28	28	28	280	26.5	9.2
<i>Guselkumab</i>	178,530	1	30	45	56	807	41.5	16.2
<i>Inotuzumab Ozogamicin</i>	3,206	1	1	1	1	30	1.1	1.4
<i>Latanoprostene Bunod Ophthalmic Solution</i>	319,017	1	25	30	50	365	39.7	22.8
<i>Letermovir</i>	19,780	1	28	28	28	114	28.2	8.7
<i>Macimorelin Acetate</i>	48	1	1	1	1	30	4.6	9.6
<i>Meropenem and Vaborbactam</i>	6,579	1	1	1	1	23	1.4	1.4
<i>Neratinib Maleate</i>	17,605	1	30	30	30	90	28.8	4.7
<i>Netarsudil</i>	1,012,744	1	25	28	45	500	37.6	23.5
<i>Ozenoxacin</i>	2,167	2	30	30	30	90	26.8	8.0
<i>Secnidazole</i>	13,586	1	1	1	1	90	2.6	6.4
<i>Semaglutide</i>	6,246,642	1	28	28	35	422	39.5	23.0
<i>Sofosbuvir Velpatasvir Voxilaprevir</i>	16,883	1	28	28	28	280	27.1	7.2
<i>Vestronidase Alfa Vjbk</i>	98	1	14	28	28	76	22.1	13.3

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Abemaciclib	88,477	87,789	100.0%	592	100.0%	96	100.0%	0	NaN
Female	87,085	86,411	98.4%	578	97.6%	96	100.0%	0	NaN
Male	1,392	1,378	1.6%	14	2.4%	0	0.0%	0	NaN
Acalabrutinib	106,098	105,836	100.0%	168	100.0%	*****	*****	*****	*****
Female	38,513	38,415	36.3%	70	41.7%	*****	*****	*****	*****
Male	67,585	67,421	63.7%	98	58.3%	*****	*****	*****	*****
Angiotensin II	37	37	100.0%	0	NaN	0	NaN	0	NaN
Female	11	11	29.7%	0	NaN	0	NaN	0	NaN
Male	26	26	70.3%	0	NaN	0	NaN	0	NaN
Benralizumab	212,262	177,768	100.0%	34,398	100.0%	*****	*****	*****	*****
Female	136,977	113,782	64.0%	23,127	67.2%	*****	*****	*****	*****
Male	75,285	63,986	36.0%	11,271	32.8%	*****	*****	*****	*****
Benznidazole	83	70	100.0%	13	100.0%	0	NaN	0	NaN
Female	44	*****	*****	*****	*****	0	NaN	0	NaN
Male	39	*****	*****	*****	*****	0	NaN	0	NaN
Copanlisib	4,369	4,369	100.0%	0	NaN	0	NaN	0	NaN
Female	2,064	2,064	47.2%	0	NaN	0	NaN	0	NaN
Male	2,305	2,305	52.8%	0	NaN	0	NaN	0	NaN
Emicizumab	29,101	28,132	100.0%	926	100.0%	*****	*****	*****	*****
Female	674	648	2.3%	26	2.8%	*****	*****	*****	*****
Male	28,427	27,484	97.7%	900	97.2%	*****	*****	*****	*****
Enasidenib	8,178	8,111	100.0%	35	100.0%	32	100.0%	0	NaN
Female	3,533	3,506	43.2%	*****	*****	*****	*****	0	NaN
Male	4,645	4,605	56.8%	*****	*****	*****	*****	0	NaN
Ertugliflozin	88,042	74,454	100.0%	1,191	100.0%	12,222	100.0%	175	100.0%
Female	40,749	34,991	47.0%	531	44.6%	5,131	42.0%	96	54.9%
Male	47,293	39,463	53.0%	660	55.4%	7,091	58.0%	79	45.1%
Ertugliflozin and Sitagliptin	6,077	5,073	100.0%	*****	*****	918	100.0%	*****	*****
Female	2,720	2,321	45.8%	*****	*****	362	39.4%	*****	*****
Male	3,357	2,752	54.2%	*****	*****	556	60.6%	*****	*****
Ertugliflozin and Metformin	7,274	6,076	100.0%	*****	*****	1,063	100.0%	*****	*****

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Number of Dispensings by Days Supplied								
	1-30 Days		31-60 Days		61-90 Days		91+ Days		
	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	
Female	2,748	2,299	37.8%	*****	*****	393	37.0%	*****	*****
Male	4,526	3,777	62.2%	*****	*****	670	63.0%	*****	*****
Glecaprevir and Pibrentasvir	171,723	170,574	100.0%	711	100.0%	192	100.0%	246	100.0%
Female	68,349	67,866	39.8%	318	44.7%	63	32.8%	102	41.5%
Male	103,374	102,708	60.2%	393	55.3%	129	67.2%	144	58.5%
Guselkumab	178,530	70,129	100.0%	107,581	100.0%	672	100.0%	148	100.0%
Female	85,771	33,135	47.2%	52,211	48.5%	362	53.9%	63	42.6%
Male	92,759	36,994	52.8%	55,370	51.5%	310	46.1%	85	57.4%
Ozogamicin	3,206	3,206	100.0%	0	NaN	0	NaN	0	NaN
Female	1,594	1,594	49.7%	0	NaN	0	NaN	0	NaN
Male	1,612	1,612	50.3%	0	NaN	0	NaN	0	NaN
Latanoprostene Bunod Ophthalmic Solution	319,017	186,947	100.0%	82,345	100.0%	46,991	100.0%	2,734	100.0%
Female	189,895	112,612	60.2%	49,245	59.8%	26,479	56.3%	1,559	57.0%
Male	129,122	74,335	39.8%	33,100	40.2%	20,512	43.7%	1,175	43.0%
Letermovir	19,780	19,308	100.0%	*****	*****	330	100.0%	*****	*****
Female	8,576	8,366	43.3%	*****	*****	150	45.5%	*****	*****
Male	11,204	10,942	56.7%	*****	*****	180	54.5%	*****	*****
Acetate	48	48	100.0%	0	NaN	0	NaN	0	NaN
Female	24	24	50.0%	0	NaN	0	NaN	0	NaN
Male	24	24	50.0%	0	NaN	0	NaN	0	NaN
Meropenem and Vaborbactam	6,579	6,579	100.0%	0	NaN	0	NaN	0	NaN
Female	3,535	3,535	53.7%	0	NaN	0	NaN	0	NaN
Male	3,044	3,044	46.3%	0	NaN	0	NaN	0	NaN
Maleate	17,605	17,537	100.0%	*****	*****	*****	*****	0	NaN
Female	17,475	17,408	99.3%	*****	*****	*****	*****	0	NaN
Male	130	129	0.7%	*****	*****	*****	*****	0	NaN
Netarsudil	1,012,744	695,249	100.0%	151,609	100.0%	160,222	100.0%	5,664	100.0%
Female	587,675	408,450	58.7%	85,990	56.7%	90,064	56.2%	3,171	56.0%

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Male	425,069	286,799	41.3%	65,619	43.3%	70,158	43.8%	2,493	44.0%
Ozenoxacin	2,167	*****	*****	*****	*****	*****	*****	0	NaN
Female	1,309	*****	*****	*****	*****	*****	*****	0	NaN
Male	858	*****	*****	*****	*****	*****	*****	0	NaN
Secnidazole	13,586	*****	*****	0	NaN	*****	*****	0	NaN
Female	13,559	*****	*****	0	NaN	*****	*****	0	NaN
Male	27	*****	*****	0	NaN	*****	*****	0	NaN
Semaglutide	6,246,642	4,650,002	100.0%	469,593	100.0%	1,119,016	100.0%	8,031	100.0%
Female	3,466,988	2,612,898	56.2%	269,686	57.4%	580,343	51.9%	4,061	50.6%
Male	2,779,654	2,037,104	43.8%	199,907	42.6%	538,673	48.1%	3,970	49.4%
Sofosbuvir Velpatasvir Voxilaprevir	16,883	16,822	100.0%	25	100.0%	23	100.0%	13	100.0%
Female	4,264	4,249	25.3%	*****	*****	*****	*****	*****	*****
Male	12,619	12,573	74.7%	*****	*****	*****	*****	*****	*****
Vestronidase Alfa Vjbk	98	*****	*****	*****	*****	*****	*****	0	NaN
Female	80	*****	*****	*****	*****	*****	*****	0	NaN
Male	18	*****	*****	*****	*****	*****	*****	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

¹ NaN: Not a Number

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	88,477	1	28	28	28	84	26.6	5.7
Female	87,085	1	28	28	28	84	26.6	5.7
Male	1,392	1	28	28	28	56	27.0	5.3
Acalabrutinib	106,098	1	30	30	30	120	29.1	4.7
Female	38,513	1	30	30	30	90	29.1	4.8
Male	67,585	1	30	30	30	120	29.2	4.6
Angiotensin II	37	1	1	1	1	1	1.0	0.0
Female	11	1	1	1	1	1	1.0	0.0
Male	26	1	1	1	1	1	1.0	0.0
Benralizumab	212,262	1	1	1	28	216	12.4	20.4
Female	136,977	1	1	1	28	216	12.9	20.7
Male	75,285	1	1	1	1	146	11.6	19.9
Benznidazole	83	1	30	30	30	60	30.2	14.0
Female	44	1	30	30	30	60	27.1	9.7
Male	39	7	27	30	60	60	33.8	17.1
Copanlisib	4,369	1	1	1	1	28	1.1	1.7
Female	2,064	1	1	1	1	28	1.0	0.9
Male	2,305	1	1	1	1	28	1.2	2.1
Emicizumab	29,101	1	1	1	28	387	9.6	14.7
Female	674	1	1	1	1	56	8.1	14.0
Male	28,427	1	1	1	28	387	9.6	14.7
Enasidenib	8,178	1	30	30	30	90	29.3	5.8
Female	3,533	1	30	30	30	90	29.1	5.3
Male	4,645	1	30	30	30	90	29.4	6.2
Ertugliflozin	88,042	1	30	30	30	264	36.8	22.6
Female	40,749	1	30	30	30	264	36.0	22.0
Male	47,293	1	30	30	30	217	37.6	23.1
Ertugliflozin and Sitagliptin	6,077	1	30	30	30	180	38.5	22.1
Female	2,720	1	30	30	30	120	37.2	21.0
Male	3,357	1	30	30	30	180	39.6	22.9
Metformin	7,274	1	30	30	30	194	37.6	22.4
Female	2,748	1	30	30	30	194	37.6	22.6
Male	4,526	1	30	30	30	120	37.6	22.3

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Glecaprevir and Pibrentasvir	171,723	1	28	28	28	280	26.5	9.2
Female	68,349	1	28	28	28	280	26.6	9.2
Male	103,374	1	28	28	28	280	26.4	9.2
Guselkumab	178,530	1	30	45	56	807	41.5	16.2
Female	85,771	1	30	56	56	807	41.8	16.5
Male	92,759	1	30	34	56	168	41.2	15.9
Ozogamicin	3,206	1	1	1	1	30	1.1	1.4
Female	1,594	1	1	1	1	28	1.1	1.5
Male	1,612	1	1	1	1	30	1.1	1.4
Latanoprostene Bunod Ophthalmic Solution	319,017	1	25	30	50	365	39.7	22.8
Female	189,895	1	25	30	50	365	39.2	22.4
Male	129,122	1	25	30	50	325	40.5	23.3
Letermovir	19,780	1	28	28	28	114	28.2	8.7
Female	8,576	1	28	28	28	114	28.3	8.8
Male	11,204	1	28	28	28	112	28.1	8.6
Acetate	48	1	1	1	1	30	4.6	9.6
Female	24	1	1	1	1	30	7.0	11.9
Male	24	1	1	1	1	30	2.2	5.9
Meropenem and Vaborbactam	6,579	1	1	1	1	23	1.4	1.4
Female	3,535	1	1	1	1	14	1.4	1.4
Male	3,044	1	1	1	1	23	1.4	1.3
Neratinib Maleate	17,605	1	30	30	30	90	28.8	4.7
Female	17,475	1	30	30	30	90	28.8	4.7
Male	130	15	30	30	30	31	28.9	3.6
Netarsudil	1,012,744	1	25	28	45	500	37.6	23.5
Female	587,675	1	25	25	45	375	37.2	23.3
Male	425,069	1	25	30	45	500	38.2	23.9
Ozenoxacin	2,167	2	30	30	30	90	26.8	8.0
Female	1,309	2	30	30	30	90	26.5	8.4
Male	858	2	30	30	30	60	27.1	7.5
Secnidazole	13,586	1	1	1	1	90	2.6	6.4
Female	13,559	1	1	1	1	90	2.6	6.4

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	27	1	1	1	1	30	3.1	7.7
Semaglutide	6,246,642	1	28	28	35	422	39.5	23.0
Female	3,466,988	1	28	28	30	422	38.9	22.5
Male	2,779,654	1	28	28	42	360	40.4	23.6
Sofosbuvir Velpatasvir Voxilaprevir	16,883	1	28	28	28	280	27.1	7.2
Female	4,264	1	28	28	28	280	27.2	7.7
Male	12,619	1	28	28	28	280	27.1	7.0
Vestronidase Alfa Vjbk	98	1	14	28	28	76	22.1	13.3
Female	80	1	10	28	28	76	21.8	14.2
Male	18	5	28	28	28	28	23.8	8.4

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Dispensings by Days Supplied								
	1-30 Days			31-60 Days		61-90 Days		91+ Days	
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Abemaciclib	88,477	87,789	100.0%	592	100.0%	96	100.0%	0	NaN
0-17 years	20	20	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	15	15	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	3,812	3,775	4.3%	*****	*****	*****	*****	0	NaN
41-64 years	34,882	34,662	39.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	49,748	49,317	56.2%	373	63.0%	58	60.4%	0	NaN
Acalabrutinib	106,098	105,836	100.0%	168	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	159	159	0.2%	0	0.0%	0	0.0%	0	0.0%
41-64 years	10,964	10,953	10.3%	*****	*****	*****	*****	0	0.0%
≥ 65 years	94,975	94,724	89.5%	*****	*****	*****	*****	*****	*****
Angiotensin II	37	37	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	18	18	48.6%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
Benralizumab	212,262	177,768	100.0%	34,398	100.0%	*****	*****	*****	*****
0-17 years	2,255	1,769	1.0%	*****	*****	*****	*****	0	0.0%
18-24 years	1,997	1,560	0.9%	*****	*****	*****	*****	0	0.0%
25-40 years	11,560	8,667	4.9%	*****	*****	*****	*****	*****	*****
41-64 years	65,748	48,404	27.2%	17,302	50.3%	*****	*****	*****	*****
≥ 65 years	130,702	117,368	66.0%	13,292	38.6%	*****	*****	*****	*****
Benznidazole	83	70	100.0%	13	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	60	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
Copanlisib	4,369	4,369	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	566	566	13.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	3,782	3,782	86.6%	0	NaN	0	NaN	0	NaN
Emicizumab	29,101	28,132	100.0%	926	100.0%	*****	*****	*****	*****
0-17 years	9,115	8,865	31.5%	233	25.2%	*****	*****	*****	*****
18-24 years	2,317	2,145	7.6%	*****	*****	*****	*****	*****	*****
25-40 years	7,335	7,059	25.1%	260	28.1%	*****	*****	*****	*****
41-64 years	7,039	6,790	24.1%	*****	*****	*****	*****	0	0.0%
≥ 65 years	3,295	3,273	11.6%	22	2.4%	0	0.0%	0	0.0%
Enasidenib	8,178	8,111	100.0%	35	100.0%	32	100.0%	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	13	13	0.2%	0	0.0%	0	0.0%	0	NaN
25-40 years	59	59	0.7%	0	0.0%	0	0.0%	0	NaN
41-64 years	961	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	7,145	*****	*****	*****	*****	*****	*****	0	NaN
Ertugliflozin	88,042	74,454	100.0%	1,191	100.0%	12,222	100.0%	175	100.0%
0-17 years	30	30	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	318	289	0.4%	*****	*****	*****	*****	0	0.0%
25-40 years	6,395	5,849	7.9%	*****	*****	*****	*****	*****	*****
41-64 years	58,453	52,369	70.3%	646	54.2%	5,292	43.3%	146	83.4%
≥ 65 years	22,846	15,917	21.4%	*****	*****	6,445	52.7%	*****	*****
Ertugliflozin and Sitagliptin	6,077	5,073	100.0%	*****	*****	918	100.0%	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	15	15	0.3%	0	0.0%	0	0.0%	0	0.0%
25-40 years	559	*****	*****	*****	*****	14	1.5%	0	0.0%
41-64 years	3,956	3,393	66.9%	*****	*****	511	55.7%	*****	*****
≥ 65 years	1,547	*****	*****	32	40.5%	393	42.8%	*****	*****
Ertugliflozin and Metformin	7,274	6,076	100.0%	*****	*****	1,063	100.0%	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	12	*****	*****	0	0.0%	*****	*****	0	0.0%
25-40 years	714	*****	*****	*****	*****	98	9.2%	*****	*****
41-64 years	5,039	4,482	73.8%	*****	*****	503	47.3%	*****	*****
≥ 65 years	1,509	979	16.1%	*****	*****	*****	*****	0	0.0%
Glecaprevir and Pibrentasvir	171,723	170,574	100.0%	711	100.0%	192	100.0%	246	100.0%
0-17 years	54	*****	*****	0	0.0%	*****	*****	0	0.0%
18-24 years	2,603	*****	*****	13	1.8%	*****	*****	*****	*****
25-40 years	32,286	32,046	18.8%	152	21.4%	*****	*****	*****	*****
41-64 years	104,876	104,162	61.1%	414	58.2%	105	54.7%	195	79.3%
≥ 65 years	31,904	31,728	18.6%	132	18.6%	*****	*****	*****	*****
Guselkumab	178,530	70,129	100.0%	107,581	100.0%	672	100.0%	148	100.0%
0-17 years	154	118	0.2%	*****	*****	0	0.0%	*****	*****
18-24 years	5,962	2,724	3.9%	*****	*****	*****	*****	23	15.5%
25-40 years	39,991	17,341	24.7%	22,510	20.9%	113	16.8%	27	18.2%
41-64 years	104,083	41,171	58.7%	62,491	58.1%	347	51.6%	74	50.0%
≥ 65 years	28,340	8,775	12.5%	19,338	18.0%	*****	*****	*****	*****
Inotuzumab Ozogamicin	3,206	3,206	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	55	55	1.7%	0	NaN	0	NaN	0	NaN
18-24 years	108	108	3.4%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Dispensings by Days Supplied								
	1-30 Days			31-60 Days		61-90 Days		91+ Days	
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	308	308	9.6%	0	NaN	0	NaN	0	NaN
41-64 years	670	670	20.9%	0	NaN	0	NaN	0	NaN
≥ 65 years	2,065	2,065	64.4%	0	NaN	0	NaN	0	NaN
Latanoprostene									
Bunod Ophthalmic Solution	319,017	186,947	100.0%	82,345	100.0%	46,991	100.0%	2,734	100.0%
0-17 years	171	126	0.1%	21	0.0%	*****	*****	*****	*****
18-24 years	286	213	0.1%	50	0.1%	23	0.0%	0	0.0%
25-40 years	2,444	1,661	0.9%	523	0.6%	*****	*****	*****	*****
41-64 years	36,746	25,197	13.5%	6,886	8.4%	*****	*****	*****	*****
≥ 65 years	279,370	159,750	85.5%	74,865	90.9%	42,144	89.7%	2,611	95.5%
Letermovir	19,780	19,308	100.0%	*****	*****	330	100.0%	*****	*****
0-17 years	232	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	655	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	2,805	2,729	14.1%	*****	*****	*****	*****	0	0.0%
41-64 years	7,985	7,818	40.5%	*****	*****	103	31.2%	*****	*****
≥ 65 years	8,103	7,897	40.9%	36	25.7%	170	51.5%	0	0.0%
Macimorelin Acetate	48	48	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	27	27	56.3%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
Meropenem and	6,579	6,579	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	450	450	6.8%	0	NaN	0	NaN	0	NaN
41-64 years	1,945	1,945	29.6%	0	NaN	0	NaN	0	NaN
≥ 65 years	4,168	4,168	63.4%	0	NaN	0	NaN	0	NaN
Neratinib Maleate	17,605	17,537	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	2,335	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	10,459	10,418	59.4%	*****	*****	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Netarsudil	1,012,744	695,249	100.0%	151,609	100.0%	160,222	100.0%	5,664	100.0%
0-17 years	791	627	0.1%	103	0.1%	*****	*****	*****	*****
18-24 years	804	634	0.1%	76	0.1%	94	0.1%	0	0.0%
25-40 years	7,739	5,798	0.8%	1,081	0.7%	*****	*****	*****	*****

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Dispensings by Days Supplied									
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	102,537	75,736	10.9%	12,022	7.9%	*****	*****	*****	*****
≥ 65 years	900,873	612,454	88.1%	138,327	91.2%	144,579	90.2%	5,513	97.3%
Ozenoxacin	2,167	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	463	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	207	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	458	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	839	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	200	*****	*****	*****	*****	*****	*****	0	NaN
Secnidazole	13,586	*****	*****	0	NaN	*****	*****	0	NaN
0-17 years	152	*****	*****	0	NaN	0	0.0%	0	NaN
18-24 years	2,480	*****	*****	0	NaN	0	0.0%	0	NaN
25-40 years	6,663	*****	*****	0	NaN	*****	*****	0	NaN
41-64 years	3,898	*****	*****	0	NaN	0	0.0%	0	NaN
≥ 65 years	393	*****	*****	0	NaN	0	0.0%	0	NaN
Semaglutide	6,246,642	4,650,002	100.0%	469,593	100.0%	1,119,016	100.0%	8,031	100.0%
0-17 years	2,309	1,963	0.0%	*****	*****	219	0.0%	*****	*****
18-24 years	28,165	23,148	0.5%	*****	*****	3,196	0.3%	*****	*****
25-40 years	434,376	353,358	7.6%	27,606	5.9%	52,963	4.7%	449	5.6%
41-64 years	3,066,749	2,353,082	50.6%	204,264	43.5%	505,807	45.2%	3,596	44.8%
≥ 65 years	2,715,043	1,918,451	41.3%	235,820	50.2%	556,831	49.8%	3,941	49.1%
Sofosbuvir									
Velpatasvir	16,883	16,822	100.0%	25	100.0%	23	100.0%	13	100.0%
Voxilaprevir									
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	59	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	895	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	10,380	10,336	61.4%	*****	*****	*****	*****	13	100.0%
≥ 65 years	5,549	5,536	32.9%	*****	*****	*****	*****	0	0.0%
Vestronidase									
Alfa Vjbk	98	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	62	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	15	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	21	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the

¹NaN: Not a Number

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	88,477	1	28	28	28	84	26.6	5.7
0-17 years	20	5	28	28	28	28	26.5	5.3
18-24 years	15	3	14	28	28	28	21.0	9.4
25-40 years	3,812	1	28	28	28	84	25.5	7.2
41-64 years	34,882	1	28	28	28	84	25.6	6.4
≥ 65 years	49,748	1	28	28	28	84	27.4	4.8
Acalabrutinib	106,098	1	30	30	30	120	29.1	4.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	159	8	30	30	30	30	29.0	4.0
41-64 years	10,964	1	30	30	30	90	28.9	4.8
≥ 65 years	94,975	1	30	30	30	120	29.2	4.7
Angiotensin II	37	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	18	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Benralizumab	212,262	1	1	1	28	216	12.4	20.4
0-17 years	2,255	1	1	1	30	90	19.9	21.6
18-24 years	1,997	1	1	1	30	84	18.7	22.2
25-40 years	11,560	1	1	1	31	112	19.8	22.8
41-64 years	65,748	1	1	1	40	112	19.6	23.2
≥ 65 years	130,702	1	1	1	1	216	7.9	17.1
Benznidazole	83	1	30	30	30	60	30.2	14.0
0-17 years	*****	1	7	7	30	30	15.0	13.9
18-24 years	*****	30	30	30	30	30	30.0	0.0
25-40 years	*****	6	11	30	30	31	23.0	11.3
41-64 years	60	7	30	30	30	60	32.2	13.1
≥ 65 years	*****	7	19	30	30	60	30.6	17.8
Copanlisib	4,369	1	1	1	1	28	1.1	1.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	28	28	28	28	22.0	11.6
41-64 years	566	1	1	1	1	21	1.0	0.8

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	3,782	1	1	1	1	28	1.0	0.6
Emicizumab	29,101	1	1	1	28	387	9.6	14.7
0-17 years	9,115	1	1	9	28	387	15.0	15.4
18-24 years	2,317	1	1	16	28	168	16.8	17.8
25-40 years	7,335	1	1	1	1	98	7.4	13.8
41-64 years	7,039	1	1	1	1	63	5.9	12.6
≥ 65 years	3,295	1	1	1	1	56	2.3	6.6
Enasidenib	8,178	1	30	30	30	90	29.3	5.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	13	30	30	30	30	30	30.0	0.0
25-40 years	59	1	30	30	30	30	27.3	6.3
41-64 years	961	1	30	30	30	90	29.0	5.4
≥ 65 years	7,145	1	30	30	30	90	29.4	5.9
Ertugliflozin	88,042	1	30	30	30	264	36.8	22.6
0-17 years	30	4	23	30	30	30	25.5	8.4
18-24 years	318	1	30	30	30	90	32.9	18.5
25-40 years	6,395	1	30	30	30	216	32.6	18.3
41-64 years	58,453	1	30	30	30	264	33.8	19.5
≥ 65 years	22,846	1	30	30	90	234	45.9	28.0
Ertugliflozin and Sitagliptin	6,077	1	30	30	30	180	38.5	22.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	15	30	30	30	30	30	30.0	0.0
25-40 years	559	2	30	30	30	90	31.0	10.1
41-64 years	3,956	1	30	30	30	125	37.2	20.8
≥ 65 years	1,547	1	30	30	75	180	44.7	26.8
Ertugliflozin and Metformin	7,274	1	30	30	30	194	37.6	22.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	15	30	30	50	90	42.0	25.8
25-40 years	714	1	30	30	30	194	37.2	23.4
41-64 years	5,039	1	30	30	30	186	34.5	19.2
≥ 65 years	1,509	1	30	30	90	90	48.2	28.0
Glecaprevir and Pibrentasvir	171,723	1	28	28	28	280	26.5	9.2
0-17 years	54	14	28	28	28	84	28.1	8.3
18-24 years	2,603	1	28	28	28	280	26.4	8.2
25-40 years	32,286	1	28	28	28	280	26.2	8.5

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	104,876	1	28	28	28	280	26.2	10.4
≥ 65 years	31,904	1	28	28	28	280	27.6	4.7
Guselkumab	178,530	1	30	45	56	807	41.5	16.2
0-17 years	154	1	28	30	30	112	30.3	16.2
18-24 years	5,962	1	30	31	56	168	39.9	15.6
25-40 years	39,991	1	30	31	56	393	40.2	15.1
41-64 years	104,083	1	30	34	56	280	41.5	15.3
≥ 65 years	28,340	1	28	56	56	807	43.6	20.2
Inotuzumab Ozogamicin	3,206	1	1	1	1	30	1.1	1.4
0-17 years	55	1	1	1	1	1	1.0	0.0
18-24 years	108	1	1	1	1	1	1.0	0.0
25-40 years	308	1	1	1	1	1	1.0	0.0
41-64 years	670	1	1	1	1	14	1.1	0.8
≥ 65 years	2,065	1	1	1	1	30	1.1	1.7
Latanoprostene Bunod Ophthalmic Solution	319,017	1	25	30	50	365	39.7	22.8
0-17 years	171	1	25	30	34	140	36.0	22.7
18-24 years	286	1	25	30	38	90	34.4	17.7
25-40 years	2,444	1	25	30	45	140	35.9	20.1
41-64 years	36,746	1	25	30	45	247	36.7	21.3
≥ 65 years	279,370	1	25	30	50	365	40.2	23.0
Letermovir	19,780	1	28	28	28	114	28.2	8.7
0-17 years	232	1	28	28	28	84	26.3	8.2
18-24 years	655	2	28	28	28	90	27.9	8.3
25-40 years	2,805	1	28	28	28	90	28.1	8.8
41-64 years	7,985	1	28	28	28	114	28.1	8.0
≥ 65 years	8,103	1	28	28	28	90	28.4	9.3
Macimorelin Acetate	48	1	1	1	1	30	4.6	9.6
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	16	30	30	15.5	20.5
25-40 years	*****	1	1	1	1	28	3.1	7.5
41-64 years	27	1	1	1	1	30	5.3	10.5
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Meropenem and Vaborbactam	6,579	1	1	1	1	23	1.4	1.4
0-17 years	*****	1	1	1	1	1	1.0	0.0

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	450	1	1	1	1	10	1.5	1.5
41-64 years	1,945	1	1	1	1	14	1.7	1.8
≥ 65 years	4,168	1	1	1	1	23	1.2	1.1
Neratinib Maleate	17,605	1	30	30	30	90	28.8	4.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	30	30	30	30	29.6	0.9
25-40 years	*****	1	30	30	30	90	28.0	5.8
41-64 years	10,459	1	30	30	30	90	28.6	5.0
≥ 65 years	4,806	1	30	30	30	60	29.5	3.1
Netarsudil	1,012,744	1	25	28	45	500	37.6	23.5
0-17 years	791	1	25	30	30	100	32.1	18.3
18-24 years	804	1	25	28	30	90	33.7	21.2
25-40 years	7,739	1	25	28	31	135	34.3	20.4
41-64 years	102,537	1	25	28	37	365	35.8	22.5
≥ 65 years	900,873	1	25	28	45	500	37.8	23.7
Ozenoxacin	2,167	2	30	30	30	90	26.8	8.0
0-17 years	463	2	30	30	30	31	26.4	7.8
18-24 years	207	5	30	30	30	30	26.3	8.1
25-40 years	458	2	30	30	30	60	26.8	7.8
41-64 years	839	2	30	30	30	90	26.6	8.2
≥ 65 years	200	5	30	30	30	90	28.5	8.4
Secnidazole	13,586	1	1	1	1	90	2.6	6.4
0-17 years	152	1	1	1	1	30	2.2	5.6
18-24 years	2,480	1	1	1	1	30	2.4	5.9
25-40 years	6,663	1	1	1	1	90	2.6	6.5
41-64 years	3,898	1	1	1	1	30	2.6	6.4
≥ 65 years	393	1	1	1	1	30	3.5	7.6
Semaglutide	6,246,642	1	28	28	35	422	39.5	23.0
0-17 years	2,309	1	28	28	30	140	33.8	18.4
18-24 years	28,165	1	28	28	30	180	35.3	19.8
25-40 years	434,376	1	28	28	30	308	35.7	20.2
41-64 years	3,066,749	1	28	28	30	395	38.4	22.4
≥ 65 years	2,715,043	1	28	28	56	422	41.4	24.0

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sofosbuvir Velpatasvir	16,883	1	28	28	28	280	27.1	7.2
Voxilaprevir								
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	59	1	28	28	28	28	26.9	4.8
25-40 years	895	1	28	28	28	84	26.6	5.2
41-64 years	10,380	1	28	28	28	280	26.8	8.6
≥ 65 years	5,549	1	28	28	28	84	27.7	3.6
Vestronidase Alfa Vjbk	98	1	14	28	28	76	22.1	13.3
0-17 years	62	1	5	28	28	28	19.5	11.7
18-24 years	15	5	28	28	28	76	30.0	17.1
25-40 years	21	1	28	28	28	56	24.2	13.0
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

¹ NaN: Not a Number

Table 3a. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Abemaciclib</i>	12,091	2,771	22.9%	2,875	23.8%	4,575	37.8%	1,381	11.4%	489	4.0%
<i>Acalabrutinib</i>	11,134	1,805	16.2%	1,955	17.6%	4,182	37.6%	2,335	21.0%	857	7.7%
<i>Angiotensin II</i>	28	28	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Benralizumab</i>	24,071	16,101	66.9%	1,718	7.1%	3,801	15.8%	1,769	7.3%	682	2.8%
<i>Benznidazole</i>	51	*****	*****	27	52.9%	*****	*****	0	0.0%	0	0.0%
<i>Copanlisib</i>	304	264	86.8%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Emicizumab</i>	2,033	1,157	56.9%	332	16.3%	293	14.4%	142	7.0%	109	5.4%
<i>Enasidenib</i>	1,480	376	25.4%	418	28.2%	534	36.1%	102	6.9%	50	3.4%
<i>Ertugliflozin</i>	18,637	4,324	23.2%	5,167	27.7%	6,751	36.2%	1,482	8.0%	913	4.9%
<i>Ertugliflozin and Sitagliptin</i>	836	146	17.5%	140	16.7%	321	38.4%	158	18.9%	71	8.5%
<i>Ertugliflozin and Metformin</i>	1,348	279	20.7%	331	24.6%	519	38.5%	137	10.2%	82	6.1%
<i>Glecaprevir and Pibrentasvir</i>	74,786	8,424	11.3%	62,906	84.1%	3,393	4.5%	*****	*****	*****	*****
<i>Guselkumab</i>	25,685	2,971	11.6%	4,502	17.5%	11,452	44.6%	4,424	17.2%	2,336	9.1%
<i>Inotuzumab Ozogamicin</i>	592	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Latanoprostene Bunod Ophthalmic Solution</i>	54,803	8,169	14.9%	13,817	25.2%	21,378	39.0%	8,270	15.1%	3,169	5.8%
<i>Letermovir</i>	4,466	915	20.5%	1,774	39.7%	1,532	34.3%	194	4.3%	51	1.1%
<i>Macimorelin Acetate</i>	46	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Meropenem and Vaborbactam</i>	4,045	4,016	99.3%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Neratinib Maleate</i>	2,965	748	25.2%	621	20.9%	1,332	44.9%	244	8.2%	20	0.7%
<i>Netarsudil</i>	151,751	20,936	13.8%	35,150	23.2%	59,580	39.3%	25,719	16.9%	10,366	6.8%
<i>Ozenoxacin</i>	1,641	1,386	84.5%	211	12.9%	*****	*****	*****	*****	0	0.0%
<i>Secnidazole</i>	9,558	9,368	98.0%	171	1.8%	19	0.2%	0	0.0%	0	0.0%
<i>Semaglutide</i>	982,602	145,486	14.8%	223,781	22.8%	383,666	39.0%	156,879	16.0%	72,790	7.4%

Table 3a. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Number of Patients by Cumulative Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
<i>Sofosbuvir</i>											
<i>Velpatasvir</i>	5,567	383	6.9%	4,837	86.9%	*****	*****	*****	*****	0	0.0%
<i>Voxilaprevir</i>											
<i>Vestronidase Alfa</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Vjbk</i>											

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3b. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Distribution of Cumulative Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Abemaciclib</i>	12,091	1	43	112	252	1,735	194.7	233.5
<i>Acalabrutinib</i>	11,134	1	60	180	405	1,823	277.4	272.0
<i>Angiotensin II</i>	28	1	1	1	1	4	1.3	0.9
<i>Benralizumab</i>	24,071	1	5	16	112	1,626	109.3	210.4
<i>Benznidazole</i>	51	1	30	60	60	176	49.2	31.6
<i>Copanlisib</i>	304	1	4	8	17	392	15.8	28.1
<i>Emicizumab</i>	2,033	1	4	24	112	1,575	136.7	263.8
<i>Enasidenib</i>	1,480	1	30	90	195	1,756	162.0	210.7
<i>Ertugliflozin</i>	18,637	1	36	90	171	1,609	174.0	230.9
<i>Ertugliflozin and Sitagliptin</i>	836	1	89	180	390	1,490	280.2	268.8
<i>Ertugliflozin and Metformin</i>	1,348	1	49	111	241	1,410	203.1	248.1
<i>Glecaprevir and Pibrentasvir</i>	74,786	1	56	56	56	1,134	60.9	28.3
<i>Guselkumab</i>	25,685	1	84	193	386	1,843	288.4	298.6
<i>Inotuzumab Ozogamicin</i>	592	1	2	4	8	193	6.0	9.5
<i>Latanoprostene Bunod Ophthalmic Solution</i>	54,803	1	52	137	318	1,739	231.3	251.5
<i>Letermovir</i>	4,466	1	56	84	140	1,670	124.9	148.8
<i>Macimorelin Acetate</i>	46	1	1	1	1	31	4.8	9.8
<i>Meropenem and Vaborbactam</i>	4,045	1	1	1	1	708	2.2	13.5
<i>Neratinib Maleate</i>	2,965	1	30	120	300	1,262	170.7	153.1
<i>Netarsudil</i>	151,751	1	60	150	355	1,637	250.1	258.8
<i>Ozenoxacin</i>	1,641	2	30	30	30	450	35.3	28.0
<i>Secnidazole</i>	9,558	1	1	1	2	317	3.7	11.2
<i>Semaglutide</i>	982,602	1	60	148	346	1,782	251.4	269.8
<i>Sofosbuvir Velpatasvir Voxilaprevir</i>	5,567	1	84	84	84	497	82.1	30.3
<i>Vestronidase Alfa Vjbk</i>	*****	4	61	173	216	775	216.9	243.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Abemaciclib	12,091	2,771	100.0%	2,875	100.0%	4,575	100.0%	1,381	100.0%	489	100.0%
Female	11,902	2,725	98.3%	2,827	98.3%	4,511	98.6%	*****	*****	*****	*****
Male	189	46	1.7%	48	1.7%	64	1.4%	*****	*****	*****	*****
Acalabrutinib	11,134	1,805	100.0%	1,955	100.0%	4,182	100.0%	2,335	100.0%	857	100.0%
Female	4,162	727	40.3%	739	37.8%	1,543	36.9%	847	36.3%	306	35.7%
Male	6,972	1,078	59.7%	1,216	62.2%	2,639	63.1%	1,488	63.7%	551	64.3%
Angiotensin II	28	28	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Benralizumab	24,071	16,101	100.0%	1,718	100.0%	3,801	100.0%	1,769	100.0%	682	100.0%
Female	15,605	10,293	63.9%	1,157	67.3%	2,510	66.0%	1,186	67.0%	459	67.3%
Male	8,466	5,808	36.1%	561	32.7%	1,291	34.0%	583	33.0%	223	32.7%
Benznidazole	51	*****	*****	27	100.0%	*****	*****	0	NaN	0	NaN
Female	27	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	24	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Copanlisib	304	264	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	144	123	46.6%	*****	*****	*****	*****	0	0.0%	0	NaN
Male	160	141	53.4%	*****	*****	*****	*****	*****	*****	0	NaN
Emicizumab	2,033	1,157	100.0%	332	100.0%	293	100.0%	142	100.0%	109	100.0%
Female	286	271	23.4%	*****	*****	*****	*****	*****	*****	*****	*****
Male	1,747	886	76.6%	*****	*****	*****	*****	*****	*****	*****	*****
Enasidenib	1,480	376	100.0%	418	100.0%	534	100.0%	102	100.0%	50	100.0%
Female	629	155	41.2%	175	41.9%	230	43.1%	44	43.1%	25	50.0%
Male	851	221	58.8%	243	58.1%	304	56.9%	58	56.9%	25	50.0%
Ertugliflozin	18,637	4,324	100.0%	5,167	100.0%	6,751	100.0%	1,482	100.0%	913	100.0%
Female	9,224	2,323	53.7%	2,642	51.1%	3,251	48.2%	626	42.2%	382	41.8%
Male	9,413	2,001	46.3%	2,525	48.9%	3,500	51.8%	856	57.8%	531	58.2%
Ertugliflozin and Sitagliptin	836	146	100.0%	140	100.0%	321	100.0%	158	100.0%	71	100.0%

Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	405	81	55.5%	67	47.9%	161	50.2%	69	43.7%	27	38.0%
Male	431	65	44.5%	73	52.1%	160	49.8%	89	56.3%	44	62.0%
Ertugliflozin and Metformin	1,348	279	100.0%	331	100.0%	519	100.0%	137	100.0%	82	100.0%
Female	573	139	49.8%	159	48.0%	195	37.6%	49	35.8%	31	37.8%
Male	775	140	50.2%	172	52.0%	324	62.4%	88	64.2%	51	62.2%
Glecaprevir and Pibrentasvir	74,786	8,424	100.0%	62,906	100.0%	3,393	100.0%	*****	*****	*****	*****
Female	30,524	3,554	42.2%	25,683	40.8%	1,261	37.2%	*****	*****	0	0.0%
Male	44,262	4,870	57.8%	37,223	59.2%	2,132	62.8%	*****	*****	*****	*****
Guselkumab	25,685	2,971	100.0%	4,502	100.0%	11,452	100.0%	4,424	100.0%	2,336	100.0%
Female	12,958	1,583	53.3%	2,392	53.1%	5,827	50.9%	2,062	46.6%	1,094	46.8%
Male	12,727	1,388	46.7%	2,110	46.9%	5,625	49.1%	2,362	53.4%	1,242	53.2%
Inotuzumab Ozogamicin	592	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	282	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
Male	310	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Latanoprostene Bunod Ophthalmic Solution	54,803	8,169	100.0%	13,817	100.0%	21,378	100.0%	8,270	100.0%	3,169	100.0%
Female	32,003	4,731	57.9%	8,088	58.5%	12,434	58.2%	4,848	58.6%	1,902	60.0%
Male	22,800	3,438	42.1%	5,729	41.5%	8,944	41.8%	3,422	41.4%	1,267	40.0%
Letemovir	4,466	915	100.0%	1,774	100.0%	1,532	100.0%	194	100.0%	51	100.0%
Female	1,997	421	46.0%	795	44.8%	682	44.5%	78	40.2%	21	41.2%
Male	2,469	494	54.0%	979	55.2%	850	55.5%	116	59.8%	30	58.8%
Macimorelin Acetate	46	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	24	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Male	22	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database

Number of Patients by Cumulative Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
Meropenem and Vaborbactam	4,045	4,016	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	2,141	2,130	53.0%	*****	*****	*****	*****	*****	*****	0	NaN
Male	1,904	1,886	47.0%	*****	*****	*****	*****	0	0.0%	0	NaN
Neratinib	2,965	748	100.0%	621	100.0%	1,332	100.0%	244	100.0%	20	100.0%
Female	2,941	*****	*****	*****	*****	*****	*****	*****	*****	20	100.0%
Male	24	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Netarsudil	151,751	20,936	100.0%	35,150	100.0%	59,580	100.0%	25,719	100.0%	10,366	100.0%
Female	86,133	11,973	57.2%	19,686	56.0%	33,635	56.5%	14,713	57.2%	6,126	59.1%
Male	65,618	8,963	42.8%	15,464	44.0%	25,945	43.5%	11,006	42.8%	4,240	40.9%
Ozenoxacin	1,641	1,386	100.0%	211	100.0%	*****	*****	*****	*****	0	NaN
Female	982	825	59.5%	131	62.1%	*****	*****	*****	*****	0	NaN
Male	659	561	40.5%	80	37.9%	*****	*****	*****	*****	0	NaN
Secnidazole	9,558	9,368	100.0%	171	100.0%	19	100.0%	0	NaN	0	NaN
Female	9,535	9,345	99.8%	171	100.0%	19	100.0%	0	NaN	0	NaN
Male	23	23	0.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
Semaglutide	982,602	145,486	100.0%	223,781	100.0%	383,666	100.0%	156,879	100.0%	72,790	100.0%
Female	562,761	86,525	59.5%	132,134	59.0%	221,747	57.8%	85,186	54.3%	37,169	51.1%
Male	419,841	58,961	40.5%	91,647	41.0%	161,919	42.2%	71,693	45.7%	35,621	48.9%
Sofosbuvir Velpatasvir Voxilaprevir	5,567	383	100.0%	4,837	100.0%	*****	*****	*****	*****	0	NaN
Female	1,456	122	31.9%	1,257	26.0%	*****	*****	*****	*****	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database

Number of Patients by Cumulative Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
Male	4,111	261	68.1%	3,580	74.0%	*****	*****	*****	*****	0	NaN
Vestronidase Alfa Vjbk	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	12,091	1	43	112	252	1,735	194.7	233.5
Female	11,902	1	44	112	252	1,735	194.6	233.3
Male	189	5	35	91	244	1,344	198.6	248.8
Acalabrutinib	11,134	1	60	180	405	1,823	277.4	272.0
Female	4,162	1	60	180	390	1,635	268.8	264.8
Male	6,972	1	60	188	415	1,823	282.6	276.1
Angiotensin II	28	1	1	1	1	4	1.3	0.9
Female	*****	1	1	1	1	4	1.4	1.1
Male	*****	1	1	1	1	4	1.3	0.8
Benralizumab	24,071	1	5	16	112	1,626	109.3	210.4
Female	15,605	1	5	16	112	1,626	112.7	215.0
Male	8,466	1	5	15	88	1,613	102.9	201.6
Benznidazole	51	1	30	60	60	176	49.2	31.6
Female	27	1	19	60	60	176	44.1	34.5
Male	24	7	30	60	60	120	54.9	27.5
Copanlisib	304	1	4	8	17	392	15.8	28.1
Female	144	1	3	8	18	105	14.8	18.2
Male	160	1	5	9	17	392	16.8	34.7
Emicizumab	2,033	1	4	24	112	1,575	136.7	263.8
Female	286	1	1	1	1	957	19.0	100.5
Male	1,747	1	9	30	161	1,575	156.0	276.9
Enasidenib	1,480	1	30	90	195	1,756	162.0	210.7
Female	629	5	32	90	180	1,327	163.7	208.3
Male	851	1	30	90	200	1,756	160.7	212.6
Ertugliflozin	18,637	1	36	90	171	1,609	174.0	230.9
Female	9,224	1	30	90	151	1,609	159.1	216.5
Male	9,413	1	46	98	184	1,544	188.7	243.3
Ertugliflozin and Sitagliptin	836	1	89	180	390	1,490	280.2	268.8
Female	405	5	60	180	360	1,190	249.9	239.1
Male	431	1	90	210	458	1,490	308.6	291.4
Ertugliflozin and Metformin	1,348	1	49	111	241	1,410	203.1	248.1
Female	573	1	36	90	180	1,410	180.4	239.7
Male	775	1	60	120	270	1,380	219.9	253.0
Glecaprevir and Pibrentasvir	74,786	1	56	56	56	1,134	60.9	28.3
Female	30,524	1	56	56	56	532	59.6	27.1
Male	44,262	1	56	56	75	1,134	61.8	29.2
Guselkumab	25,685	1	84	193	386	1,843	288.4	298.6
Female	12,958	1	82	178	364	1,811	276.4	293.4

Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	12,727	1	84	198	409	1,843	300.6	303.4
Inotuzumab Ozogamicin	592	1	2	4	8	193	6.0	9.5
Female	282	1	2	4	8	193	6.2	12.0
Male	310	1	2	4	7	59	5.7	6.4
Latanoprostene Bunod Ophthalmic Solution	54,803	1	52	137	318	1,739	231.3	251.5
Female	32,003	1	52	138	321	1,739	232.7	252.6
Male	22,800	1	51	136	313	1,724	229.4	250.0
Letermovir	4,466	1	56	84	140	1,670	124.9	148.8
Female	1,997	1	56	84	140	1,484	121.4	144.2
Male	2,469	1	56	84	140	1,670	127.7	152.4
Macimorelin Acetate	46	1	1	1	1	31	4.8	9.8
Female	24	1	1	1	1	30	7.0	11.9
Male	22	1	1	1	1	31	2.4	6.4
Meropenem and Vaborbactam	4,045	1	1	1	1	708	2.2	13.5
Female	2,141	1	1	1	1	708	2.3	17.2
Male	1,904	1	1	1	1	205	2.2	7.6
Neratinib Maleate	2,965	1	30	120	300	1,262	170.7	153.1
Female	2,941	1	30	120	300	1,262	170.8	153.2
Male	24	28	47	90	286	390	156.5	129.6
Netarsudil	151,751	1	60	150	355	1,637	250.1	258.8
Female	86,133	1	60	151	360	1,637	252.9	261.6
Male	65,618	1	60	150	350	1,598	246.5	255.2
Ozenoxacin	1,641	2	30	30	30	450	35.3	28.0
Female	982	2	30	30	30	427	35.4	28.1
Male	659	2	30	30	30	450	35.3	27.8
Secnidazole	9,558	1	1	1	2	317	3.7	11.2
Female	9,535	1	1	1	2	317	3.7	11.2
Male	23	1	1	1	2	30	3.7	8.3
Semaglutide	982,602	1	60	148	346	1,782	251.4	269.8
Female	562,761	1	58	140	329	1,730	239.4	260.0
Male	419,841	1	61	163	374	1,782	267.4	281.6
Sofosbuvir Velpatasvir Voxilaprevir	5,567	1	84	84	84	497	82.1	30.3
Female	1,456	1	84	84	84	378	79.6	27.1
Male	4,111	1	84	84	84	497	83.0	31.3

Table 3d. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Vestronidase Alfa Vjbk	*****	4	61	173	216	775	216.9	243.0
Female	*****	4	70	194	504	775	290.2	293.5
Male	*****	14	38	117	177	180	107.0	82.6

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Abemaciclib	12,091	2,771	100.0%	2,875	100.0%	4,575	100.0%	1,381	100.0%	489	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	110	3.8%	*****	*****	62	4.5%	14	2.9%
41-64 years	4,417	868	31.3%	1,023	35.6%	1,832	40.0%	508	36.8%	186	38.0%
≥ 65 years	7,181	1,813	65.4%	1,742	60.6%	2,526	55.2%	811	58.7%	289	59.1%
Acalabrutinib	11,134	1,805	100.0%	1,955	100.0%	4,182	100.0%	2,335	100.0%	857	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	19	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	1,164	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	9,951	1,631	90.4%	1,738	88.9%	3,705	88.6%	2,113	90.5%	764	89.1%
Angiotensin II	28	28	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	13	13	46.4%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Benralizumab	24,071	16,101	100.0%	1,718	100.0%	3,801	100.0%	1,769	100.0%	682	100.0%
0-17 years	370	187	1.2%	50	2.9%	92	2.4%	*****	*****	*****	*****
18-24 years	327	184	1.1%	36	2.1%	78	2.1%	*****	*****	*****	*****
25-40 years	1,699	872	5.4%	219	12.7%	398	10.5%	169	9.6%	41	6.0%

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	8,409	4,325	26.9%	847	49.3%	2,003	52.7%	914	51.7%	320	46.9%
≥ 65 years	13,266	10,533	65.4%	566	32.9%	1,230	32.4%	629	35.6%	308	45.2%
Benznidazole	51	*****	*****	27	100.0%	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	0	0.0%	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	35	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Copanlisib	304	264	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	*****	*****	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
≥ 65 years	227	190	72.0%	*****	*****	*****	*****	0	0.0%	0	NaN
Emicizumab	2,033	1,157	100.0%	332	100.0%	293	100.0%	142	100.0%	109	100.0%
0-17 years	643	250	21.6%	105	31.6%	164	56.0%	69	48.6%	55	50.5%
18-24 years	190	86	7.4%	22	6.6%	41	14.0%	26	18.3%	15	13.8%
25-40 years	442	250	21.6%	87	26.2%	58	19.8%	29	20.4%	18	16.5%
41-64 years	456	312	27.0%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	302	259	22.4%	*****	*****	*****	*****	*****	*****	*****	*****
Enasidenib	1,480	376	100.0%	418	100.0%	534	100.0%	102	100.0%	50	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Patients by Cumulative Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	195	*****	*****	*****	*****	*****	*****	13	12.7%	*****	*****
≥ 65 years	1,264	*****	*****	354	84.7%	447	83.7%	89	87.3%	*****	*****
Ertugliflozin	18,637	4,324	100.0%	5,167	100.0%	6,751	100.0%	1,482	100.0%	913	100.0%
0-17 years	13	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	101	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	1,564	439	10.2%	471	9.1%	535	7.9%	*****	*****	*****	*****
41-64 years	12,974	2,879	66.6%	3,860	74.7%	4,981	73.8%	797	53.8%	457	50.1%
≥ 65 years	3,985	966	22.3%	796	15.4%	1,206	17.9%	606	40.9%	411	45.0%
Ertugliflozin and Sitagliptin	836	146	100.0%	140	100.0%	321	100.0%	158	100.0%	71	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	15	10.3%	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	515	83	56.8%	81	57.9%	206	64.2%	102	64.6%	43	60.6%
≥ 65 years	251	48	32.9%	*****	*****	83	25.9%	*****	*****	*****	*****
Ertugliflozin and Metformin	1,348	279	100.0%	331	100.0%	519	100.0%	137	100.0%	82	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	44	13.3%	*****	*****	11	8.0%	*****	*****
41-64 years	959	196	70.3%	255	77.0%	378	72.8%	90	65.7%	40	48.8%
≥ 65 years	236	46	16.5%	*****	*****	90	17.3%	36	26.3%	*****	*****
Glecaprevir and Pibrentasvir	74,786	8,424	100.0%	62,906	100.0%	3,393	100.0%	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Patients by Cumulative Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
0-17 years	23	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	1,211	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	15,058	2,251	26.7%	12,170	19.3%	*****	*****	*****	*****	*****	*****
41-64 years	44,253	4,873	57.8%	37,099	59.0%	2,229	65.7%	*****	*****	*****	*****
≥ 65 years	14,241	1,068	12.7%	12,714	20.2%	*****	*****	*****	*****	0	0.0%
Guselkumab	25,685	2,971	100.0%	4,502	100.0%	11,452	100.0%	4,424	100.0%	2,336	100.0%
0-17 years	37	12	0.4%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	934	104	3.5%	*****	*****	*****	*****	*****	*****	50	2.1%
25-40 years	5,796	610	20.5%	1,104	24.5%	2,632	23.0%	984	22.2%	466	19.9%
41-64 years	14,568	1,369	46.1%	2,519	56.0%	6,721	58.7%	2,598	58.7%	1,361	58.3%
≥ 65 years	4,350	876	29.5%	694	15.4%	1,658	14.5%	663	15.0%	459	19.6%
Inotuzumab Ozogamicin	592	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	21	21	3.6%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	26	26	4.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	68	68	11.5%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	127	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	350	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Latanoprostene Bunod Ophthalmic Solution	54,803	8,169	100.0%	13,817	100.0%	21,378	100.0%	8,270	100.0%	3,169	100.0%
0-17 years	43	*****	*****	15	0.1%	15	0.1%	*****	*****	*****	*****
18-24 years	63	*****	*****	20	0.1%	19	0.1%	*****	*****	*****	*****
25-40 years	471	110	1.3%	130	0.9%	162	0.8%	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	6,604	1,149	14.1%	1,711	12.4%	2,613	12.2%	856	10.4%	275	8.7%
≥ 65 years	47,622	6,883	84.3%	11,941	86.4%	18,569	86.9%	7,362	89.0%	2,867	90.5%
Letemovir	4,466	915	100.0%	1,774	100.0%	1,532	100.0%	194	100.0%	51	100.0%
0-17 years	54	12	1.3%	18	1.0%	22	1.4%	*****	*****	0	0.0%
18-24 years	175	39	4.3%	79	4.5%	53	3.5%	*****	*****	*****	*****
25-40 years	624	137	15.0%	236	13.3%	216	14.1%	*****	*****	*****	*****
41-64 years	1,787	334	36.5%	699	39.4%	659	43.0%	*****	*****	*****	*****
≥ 65 years	1,826	393	43.0%	742	41.8%	582	38.0%	87	44.8%	22	43.1%
Macimorelin Acetate	46	45	100.0%	1	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Meropenem and Vaborbactam	4,045	4,016	100.0%	25	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	11	11	0.3%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	1,018	1,003	25.0%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Neratinib Maleate	2,965	748	100.0%	621	100.0%	1,332	100.0%	244	100.0%	20	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Patients by Cumulative Treatment Episode Duration												
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients		
18-24 years	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	79	10.6%	91	14.7%	170	12.8%	*****	*****	*****	*****	
41-64 years	1,681	386	51.6%	350	56.4%	775	58.2%	*****	*****	*****	*****	
≥ 65 years	903	280	37.4%	179	28.8%	387	29.1%	*****	*****	*****	*****	
Netarsudil	151,751	20,936	100.0%	35,150	100.0%	59,580	100.0%	25,719	100.0%	10,366	100.0%	
0-17 years	171	49	0.2%	47	0.1%	60	0.1%	*****	*****	*****	*****	
18-24 years	183	39	0.2%	64	0.2%	59	0.1%	*****	*****	*****	*****	
25-40 years	1,302	253	1.2%	356	1.0%	463	0.8%	*****	*****	*****	*****	
41-64 years	16,824	2,983	14.2%	4,212	12.0%	6,378	10.7%	2,380	9.3%	871	8.4%	
≥ 65 years	133,271	17,612	84.1%	30,471	86.7%	52,620	88.3%	23,137	90.0%	9,431	91.0%	
Ozenoxacin	1,641	1,386	100.0%	211	100.0%	*****	*****	*****	*****	0	NaN	
0-17 years	372	323	23.3%	*****	*****	*****	*****	0	0.0%	0	NaN	
18-24 years	156	131	9.5%	*****	*****	*****	*****	*****	*****	0	NaN	
25-40 years	345	293	21.1%	*****	*****	*****	*****	0	0.0%	0	NaN	
41-64 years	632	529	38.2%	84	39.8%	*****	*****	*****	*****	0	NaN	
≥ 65 years	136	110	7.9%	*****	*****	*****	*****	0	0.0%	0	NaN	
Secnidazole	9,558	9,368	100.0%	171	100.0%	19	100.0%	0	NaN	0	NaN	
0-17 years	121	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN	
18-24 years	1,808	1,773	18.9%	35	20.5%	0	0.0%	0	NaN	0	NaN	
25-40 years	4,706	4,607	49.2%	*****	*****	*****	*****	0	NaN	0	NaN	
41-64 years	2,632	2,584	27.6%	*****	*****	*****	*****	0	NaN	0	NaN	
≥ 65 years	291	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN	

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Patients by Cumulative Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Semaglutide	982,602	145,486	100.0%	223,781	100.0%	383,666	100.0%	156,879	100.0%	72,790	100.0%
0-17 years	459	91	0.1%	121	0.1%	192	0.1%	*****	*****	*****	*****
18-24 years	5,849	1,219	0.8%	1,612	0.7%	2,330	0.6%	*****	*****	*****	*****
25-40 years	76,894	13,742	9.4%	19,145	8.6%	31,485	8.2%	9,326	5.9%	3,196	4.4%
41-64 years	458,381	65,422	45.0%	99,649	44.5%	182,454	47.6%	76,067	48.5%	34,789	47.8%
≥ 65 years	441,019	65,012	44.7%	103,254	46.1%	167,205	43.6%	70,879	45.2%	34,669	47.6%
Sofosbuvir Velpatasvir Voxilaprevir	5,567	383	100.0%	4,837	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	307	*****	*****	252	5.2%	*****	*****	0	0.0%	0	NaN
41-64 years	3,365	251	65.5%	2,865	59.2%	*****	*****	*****	*****	0	NaN
≥ 65 years	1,874	95	24.8%	1,705	35.2%	74	21.6%	0	0.0%	0	NaN
Vestronidase Alfa Vjvk	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 3e. Categorical Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Patients by Cumulative Treatment Episode Duration										
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	12,091	1	43	112	252	1,735	194.7	233.5
0-17 years	*****	5	21	70	140	224	88.2	85.9
18-24 years	*****	14	21	65	137	172	78.8	72.9
25-40 years	*****	1	56	126	257	1,735	201.2	222.7
41-64 years	4,417	1	55	112	261	1,723	202.2	235.4
≥ 65 years	7,181	1	29	97	245	1,596	189.8	233.1
Acalabrutinib	11,134	1	60	180	405	1,823	277.4	272.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	19	30	90	175	300	1,076	242.4	240.8
41-64 years	1,164	1	60	180	390	1,823	271.8	273.7
≥ 65 years	9,951	1	60	180	407	1,660	278.2	271.8
Angiotensin II	28	1	1	1	1	4	1.3	0.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	13	1	1	1	1	4	1.4	1.0
≥ 65 years	*****	1	1	1	1	4	1.4	1.0
Benralizumab	24,071	1	5	16	112	1,626	109.3	210.4
0-17 years	370	1	6	30	163	1,121	120.9	180.6
18-24 years	327	1	3	28	155	1,400	113.8	194.2
25-40 years	1,699	1	4	28	183	1,514	134.3	207.8
41-64 years	8,409	1	5	28	217	1,626	152.7	235.3
≥ 65 years	13,266	1	5	13	24	1,593	78.1	188.8
Benznidazole	51	1	30	60	60	176	49.2	31.6
0-17 years	*****	1	4	7	34	60	18.8	27.6
18-24 years	*****	60	60	60	60	60	60.0	NaN
25-40 years	*****	6	6	30	102	102	46.0	50.0
41-64 years	35	7	30	60	60	176	55.1	30.9
≥ 65 years	*****	7	15	45	60	60	38.3	24.2
Copanlisib	304	1	4	8	17	392	15.8	28.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	3	3	3	3	3	3.0	NaN
25-40 years	*****	1	1	3	392	392	132.0	225.2
41-64 years	*****	1	2	5	9	50	8.0	8.8
≥ 65 years	227	1	5	9	18	105	16.9	19.6

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Emicizumab	2,033	1	4	24	112	1,575	136.7	263.8
0-17 years	643	1	16	55	307	1,575	212.0	301.8
18-24 years	190	1	10	59	301	1,276	204.4	293.5
25-40 years	442	1	6	25	75	1,490	122.2	253.7
41-64 years	456	1	1	12	40	1,551	90.3	234.2
≥ 65 years	302	1	1	2	19	1,396	25.2	114.3
Enasidenib	1,480	1	30	90	195	1,756	162.0	210.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	90	90	90	210	210	130.0	69.3
25-40 years	*****	12	45	61	150	210	89.5	61.2
41-64 years	195	5	40	90	180	990	143.2	153.6
≥ 65 years	1,264	1	30	90	204	1,756	166.0	219.5
Ertugliflozin	18,637	1	36	90	171	1,609	174.0	230.9
0-17 years	13	5	30	30	83	132	58.8	41.6
18-24 years	101	10	30	61	114	872	103.6	137.0
25-40 years	1,564	1	30	81	134	1,537	133.2	187.5
41-64 years	12,974	1	41	90	146	1,539	152.2	205.2
≥ 65 years	3,985	1	35	130	383	1,609	263.3	296.1
Ertugliflozin and Sitagliptin	836	1	89	180	390	1,490	280.2	268.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	90	90	180	180	180	150.0	52.0
25-40 years	*****	15	40	150	300	1,200	258.6	288.6
41-64 years	515	1	90	201	399	1,190	286.0	267.5
≥ 65 years	251	1	75	180	406	1,490	275.4	267.8
Ertugliflozin and Metformin	1,348	1	49	111	241	1,410	203.1	248.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	15	30	30	30	250	56.0	73.7
25-40 years	*****	1	46	90	187	1,168	184.4	248.8
41-64 years	959	1	47	102	209	1,380	181.3	224.7
≥ 65 years	236	2	60	180	479	1,410	308.4	308.1
Glecaprevir and Pibrentasvir	74,786	1	56	56	56	1,134	60.9	28.3
0-17 years	23	14	56	56	84	140	66.1	31.3
18-24 years	1,211	1	56	56	56	336	56.8	30.9
25-40 years	15,058	1	56	56	56	1,134	56.2	27.9
41-64 years	44,253	1	56	56	81	1,092	62.2	30.4

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	14,241	1	56	56	84	392	61.9	20.4
Guselkumab	25,685	1	84	193	386	1,843	288.4	298.6
0-17 years	37	1	28	103	192	532	125.9	129.4
18-24 years	934	1	84	176	354	1,688	254.7	246.4
25-40 years	5,796	1	84	186	366	1,811	277.1	280.8
41-64 years	14,568	1	88	196	393	1,843	296.7	299.2
≥ 65 years	4,350	1	56	168	382	1,767	283.9	328.2
Inotuzumab Ozogamicin	592	1	2	4	8	193	6.0	9.5
0-17 years	21	1	1	2	3	10	2.6	2.3
18-24 years	26	1	1	4	6	11	4.2	3.2
25-40 years	68	1	2	3	6	18	4.5	4.0
41-64 years	127	1	2	4	7	59	5.7	6.3
≥ 65 years	350	1	2	5	9	193	6.7	11.5
Latanoprostene Bunod Ophthalmic Solution	54,803	1	52	137	318	1,739	231.3	251.5
0-17 years	43	18	32	90	170	829	143.2	181.1
18-24 years	63	5	30	60	139	1,325	156.2	248.6
25-40 years	471	1	36	90	235	1,380	186.4	240.0
41-64 years	6,604	1	50	120	270	1,724	204.4	228.3
≥ 65 years	47,622	1	54	142	325	1,739	235.7	254.5
Letermovir	4,466	1	56	84	140	1,670	124.9	148.8
0-17 years	54	7	38	84	168	420	113.1	95.2
18-24 years	175	11	41	84	112	1,400	104.5	140.9
25-40 years	624	1	56	84	140	1,554	126.4	160.6
41-64 years	1,787	1	56	84	140	1,505	125.4	135.5
≥ 65 years	1,826	1	56	84	140	1,670	126.2	158.7
Macimorelin Acetate	46	1	1	1	1	31	4.8	9.8
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	16	30	30	15.5	20.5
25-40 years	*****	1	1	1	1	28	3.1	7.5
41-64 years	26	1	1	1	1	31	5.5	10.8
≥ 65 years	*****	1	1	1	2	2	1.3	0.5
Meropenem and Vaborbactam	4,045	1	1	1	1	708	2.2	13.5
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	3	1.2	0.6

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	127	1	1	1	2	205	5.2	19.5
41-64 years	1,018	1	1	1	1	708	3.2	23.4
≥ 65 years	2,886	1	1	1	1	315	1.8	6.8
Neratinib Maleate	2,965	1	30	120	300	1,262	170.7	153.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	29	30	45	60	37.0	15.4
25-40 years	*****	1	54	120	279	1,262	173.3	155.7
41-64 years	1,681	1	45	122	300	1,050	177.8	155.8
≥ 65 years	903	1	30	90	270	1,230	157.0	145.9
Netarsudil	151,751	1	60	150	355	1,637	250.1	258.8
0-17 years	171	3	30	80	202	932	148.3	177.1
18-24 years	183	1	40	75	168	900	147.2	170.4
25-40 years	1,302	1	47	104	274	1,321	202.7	231.4
41-64 years	16,824	1	50	120	297	1,581	217.1	240.3
≥ 65 years	133,271	1	61	158	360	1,637	255.0	261.1
Ozenoxacin	1,641	2	30	30	30	450	35.3	28.0
0-17 years	372	2	30	30	30	210	32.9	20.1
18-24 years	156	5	30	30	30	450	34.9	37.2
25-40 years	345	2	30	30	30	240	35.6	25.7
41-64 years	632	2	30	30	30	427	35.4	28.0
≥ 65 years	136	5	30	30	30	240	42.0	37.4
Secnidazole	9,558	1	1	1	2	317	3.7	11.2
0-17 years	121	1	1	1	1	60	2.8	7.4
18-24 years	1,808	1	1	1	2	90	3.3	8.0
25-40 years	4,706	1	1	1	2	317	3.7	11.7
41-64 years	2,632	1	1	1	2	243	3.9	11.2
≥ 65 years	291	1	1	1	1	246	4.7	18.1
Semaglutide	982,602	1	60	148	346	1,782	251.4	269.8
0-17 years	459	2	43	112	221	1,224	169.8	182.8
18-24 years	5,849	1	48	101	224	1,568	169.8	187.3
25-40 years	76,894	1	56	119	266	1,670	201.6	223.2
41-64 years	458,381	1	60	156	358	1,766	257.2	271.3
≥ 65 years	441,019	1	60	146	354	1,782	255.2	275.6
Sofosbuvir Velpatasvir Voxilaprevir	5,567	1	84	84	84	497	82.1	30.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	21	10	56	84	84	140	75.7	33.0

Table 3f. Continuous Summary of Patients' Cumulative Exposure Duration for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	307	3	84	84	84	252	77.6	30.5
41-64 years	3,365	1	84	84	84	497	82.6	33.6
≥ 65 years	1,874	2	84	84	84	364	82.1	23.1
Vestronidase Alfa Vjbk	*****	4	61	173	216	775	216.9	243.0
0-17 years	*****	14	70	172	180	775	242.2	305.9
18-24 years	*****	61	61	173	216	216	150.0	80.0
25-40 years	*****	4	4	254	504	504	254.0	353.6
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Abemaciclib</i>	32,958	19,068	57.9%	7,998	24.3%	5,134	15.6%	605	1.8%	153	0.5%
<i>Acalabrutinib</i>	35,219	17,594	50.0%	9,501	27.0%	6,941	19.7%	1,022	2.9%	161	0.5%
<i>Angiotensin II</i>	36	36	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Benralizumab</i>	181,796	163,638	90.0%	11,116	6.1%	6,133	3.4%	794	0.4%	115	0.1%
<i>Benznidazole</i>	64	43	67.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Copanlisib</i>	4,359	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.00%
<i>Emicizumab</i>	21,760	20,771	95.5%	436	2.0%	375	1.7%	109	0.5%	69	0.3%
<i>Enasidenib</i>	3,160	1,609	50.9%	930	29.4%	571	18.1%	39	1.2%	11	0.3%
<i>Ertugliflozin</i>	42,568	22,683	53.3%	12,369	29.1%	6,470	15.2%	793	1.9%	253	0.6%
<i>Ertugliflozin and Sitagliptin</i>	2,760	1,359	49.2%	840	30.4%	487	17.6%	63	2.3%	11	0.4%
<i>Ertugliflozin and Metformin</i>	3,698	2,118	57.3%	987	26.7%	505	13.7%	64	1.7%	24	0.6%
<i>Glecaprevir and Pibrentasvir</i>	98,261	46,972	47.8%	48,581	49.4%	2,647	2.7%	*****	*****	*****	*****
<i>Guselkumab</i>	95,624	35,629	37.3%	39,998	41.8%	17,390	18.2%	2,111	2.2%	496	0.5%
<i>Inotuzumab</i>	3,185	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Ozogamicin</i>											
<i>Latanoprostene</i>											
<i>Bunod</i>											
<i>Ophthalmic Solution</i>	225,692	117,940	52.3%	86,064	38.1%	19,276	8.5%	1,895	0.8%	517	0.2%
<i>Letermovir</i>	9,789	5,878	60.0%	2,687	27.4%	1,156	11.8%	56	0.6%	12	0.1%
<i>Macimorelin Acetate</i>	47	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Meropenem and</i>	4,580	4,556	99.5%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Neratinib</i>	7,350	4,477	60.9%	1,632	22.2%	1,121	15.3%	*****	*****	*****	*****
<i>Netarsudil</i>	662,039	380,905	57.5%	210,231	31.8%	62,312	9.4%	6,721	1.0%	1,870	0.3%
<i>Ozenoxacin</i>	1,945	1,807	92.9%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Secnidazole</i>	12,618	12,536	99.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Semaglutide</i>	2,884,431	1,412,148	49.0%	907,360	31.5%	461,181	16.0%	79,139	2.7%	24,603	0.9%
<i>Sofosbuvir</i>											
<i>Velpatasvir</i>	7,744	2,983	38.5%	4,491	58.0%	*****	*****	*****	*****	0	0.0%
<i>Voxilaprevir</i>											
<i>Vestronidase</i>											
<i>Alfa Vjbk</i>	54	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Abemaciclib</i>	32,958	1	28	28	70	1,735	71.4	106.5
<i>Acalabrutinib</i>	35,219	1	30	31	90	1,823	87.7	114.8
<i>Angiotensin II</i>	36	1	1	1	1	2	1.0	0.2
<i>Benralizumab</i>	181,796	1	1	1	1	1,414	14.5	53.1
<i>Benznidazole</i>	64	1	30	30	60	176	39.2	27.4
<i>Copanlisib</i>	4,359	1	1	1	1	84	1.1	2.4
<i>Emicizumab</i>	21,760	1	1	1	1	1,575	12.8	75.9
<i>Enasidenib</i>	3,160	1	30	30	90	1,619	75.9	101.6
<i>Ertugliflozin</i>	42,568	1	30	30	90	1,544	76.2	108.2
<i>Ertugliflozin and Sitagliptin</i>	2,760	1	30	42	90	1,124	84.9	104.1
<i>Ertugliflozin and Metformin</i>	3,698	1	30	30	90	1,380	74.0	108.9
<i>Glecaprevir and Pibrentasvir</i>	98,261	1	28	46	56	1,106	46.3	28.1
<i>Guselkumab</i>	95,624	1	30	56	60	1,843	77.5	113.3
<i>Inotuzumab Ozogamicin</i>	3,185	1	1	1	1	56	1.1	1.7
<i>Latanoprostene Bunod Ophthalmic Solution</i>	225,692	1	25	30	60	1,739	56.2	77.1
<i>Letermovir</i>	9,789	1	28	28	56	1,430	57.0	69.2
<i>Macimorelin Acetate</i>	47	1	1	1	1	31	4.7	9.7
<i>Meropenem and Vaborbactam</i>	4,580	1	1	1	1	668	2.0	10.7
<i>Neratinib Maleate</i>	7,350	1	30	30	60	937	68.9	85.6
<i>Netarsudil</i>	662,039	1	25	30	60	1,637	57.3	83.1
<i>Ozenoxacin</i>	1,945	2	30	30	30	450	29.8	16.0
<i>Secnidazole</i>	12,618	1	1	1	1	168	2.8	7.5
<i>Semaglutide</i>	2,884,431	1	28	37	84	1,782	85.6	126.4
<i>Sofosbuvir Velpatasvir Voxilaprevir</i>	7,744	1	28	56	84	497	59.0	34.1
<i>Vestronidase Alfa Vjbk</i>	54	1	1	28	56	180	40.2	47.3

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Abemaciclib	32,958	19,068	100.0%	7,998	100.0%	5,134	100.0%	605	100.0%	153	100.0%
Female	32,455	18,790	98.5%	7,869	98.4%	5,049	98.3%	*****	*****	*****	*****
Male	503	278	1.5%	129	1.6%	*****	*****	*****	*****	*****	*****
Acalabrutinib	35,219	17,594	100.0%	9,501	100.0%	6,941	100.0%	1,022	100.0%	161	100.0%
Female	13,181	6,689	38.0%	3,584	37.7%	2,499	36.0%	357	34.9%	52	32.3%
Male	22,038	10,905	62.0%	5,917	62.3%	4,442	64.0%	665	65.1%	109	67.7%
Angiotensin II	36	36	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	11	11	30.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	25	25	69.4%	0	NaN	0	NaN	0	NaN	0	NaN
Benralizumab	181,796	163,638	100.0%	11,116	100.0%	6,133	100.0%	794	100.0%	115	100.0%
Female	116,384	104,279	63.7%	7,409	66.7%	4,074	66.4%	540	68.0%	82	71.3%
Male	65,412	59,359	36.3%	3,707	33.3%	2,059	33.6%	254	32.0%	33	28.7%
Benznidazole	64	43	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	34	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	30	16	37.2%	*****	*****	*****	*****	0	NaN	0	NaN
Copanlisib	4,359	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	2,061	2,061	47.3%	0	0.0%	0	NaN	0	NaN	0	NaN
Male	2,298	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Emicizumab	21,760	20,771	100.0%	436	100.0%	375	100.0%	109	100.0%	69	100.0%
Female	544	527	2.5%	*****	*****	*****	*****	*****	*****	*****	*****
Male	21,216	20,244	97.5%	*****	*****	*****	*****	*****	*****	*****	*****
Enasidenib	3,160	1,609	100.0%	930	100.0%	571	100.0%	39	100.0%	11	100.0%
Female	1,393	719	44.7%	402	43.2%	249	43.6%	*****	*****	*****	*****
Male	1,767	890	55.3%	528	56.8%	322	56.4%	*****	*****	*****	*****
Ertugliflozin	42,568	22,683	100.0%	12,369	100.0%	6,470	100.0%	793	100.0%	253	100.0%
Female	20,237	11,138	49.1%	5,717	46.2%	2,943	45.5%	335	42.2%	104	41.1%
Male	22,331	11,545	50.9%	6,652	53.8%	3,527	54.5%	458	57.8%	149	58.9%
Ertugliflozin and Sitagliptin	2,760	1,359	100.0%	840	100.0%	487	100.0%	63	100.0%	11	100.0%
Female	1,212	635	46.7%	338	40.2%	205	42.1%	*****	*****	*****	*****
Male	1,548	724	53.3%	502	59.8%	282	57.9%	*****	*****	*****	*****

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Ertugliflozin and Metformin	3,698	2,118	100.0%	987	100.0%	505	100.0%	64	100.0%	24	100.0%
Female	1,423	827	39.0%	383	38.8%	178	35.2%	*****	*****	*****	*****
Male	2,275	1,291	61.0%	604	61.2%	327	64.8%	*****	*****	*****	*****
Glecaprevir and Pibrentasvir	98,261	46,972	100.0%	48,581	100.0%	2,647	100.0%	*****	*****	*****	*****
Female	40,005	19,408	41.3%	19,621	40.4%	951	35.9%	25	42.4%	0	0.0%
Male	58,256	27,564	58.7%	28,960	59.6%	1,696	64.1%	*****	*****	*****	*****
Guselkumab	95,624	35,629	100.0%	39,998	100.0%	17,390	100.0%	2,111	100.0%	496	100.0%
Female	45,690	17,175	48.2%	18,706	46.8%	8,550	49.2%	1,013	48.0%	246	49.6%
Male	49,934	18,454	51.8%	21,292	53.2%	8,840	50.8%	1,098	52.0%	250	50.4%
Inotuzumab Ozogamicin	3,185	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	1,578	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	1,607	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Latanoprostene Bunod Ophthalmic Solution	225,692	117,940	100.0%	86,064	100.0%	19,276	100.0%	1,895	100.0%	517	100.0%
Female	134,522	71,284	60.4%	50,568	58.8%	11,248	58.4%	1,123	59.3%	299	57.8%
Male	91,170	46,656	39.6%	35,496	41.2%	8,028	41.6%	772	40.7%	218	42.2%
Letermovir	9,789	5,878	100.0%	2,687	100.0%	1,156	100.0%	56	100.0%	12	100.0%
Female	4,355	2,668	45.4%	1,187	44.2%	471	40.7%	*****	*****	*****	*****
Male	5,434	3,210	54.6%	1,500	55.8%	685	59.3%	*****	*****	*****	*****
Macimorelin Acetate	47	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	24	24	52.2%	0	0.0%	0	NaN	0	NaN	0	NaN
Male	23	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Meropenem and Vaborbactam	4,580	4,556	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	2,429	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	2,151	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
Neratinib Maleate	7,350	4,477	100.0%	1,632	100.0%	*****	*****	*****	*****	*****	*****
Female	7,278	4,426	98.9%	1,617	99.1%	*****	*****	*****	*****	*****	*****
Male	72	51	1.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
Netarsudil	662,039	380,905	100.0%	210,231	100.0%	62,312	100.0%	6,721	100.0%	1,870	100.0%
Female	385,437	225,282	59.1%	119,891	57.0%	35,340	56.7%	3,836	57.1%	1,088	58.2%

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	276,602	155,623	40.9%	90,340	43.0%	26,972	43.3%	2,885	42.9%	782	41.8%
Ozenoxacin	1,945	1,807	100.0%	128	100.0%	*****	*****	*****	*****	0	NaN
Female	1,174	1,087	60.2%	*****	*****	*****	*****	0	0.0%	0	NaN
Male	771	720	39.8%	*****	*****	*****	*****	*****	*****	0	NaN
Secnidazole	12,618	12,536	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	12,592	12,510	99.8%	*****	*****	*****	*****	0	NaN	0	NaN
Male	26	26	0.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
Semaglutide	2,884,431	1,412,148	100.0%	907,360	100.0%	461,181	100.0%	79,139	100.0%	24,603	100.0%
Female	1,623,685	808,186	57.2%	506,277	55.8%	254,963	55.3%	41,957	53.0%	12,302	50.0%
Male	1,260,746	603,962	42.8%	401,083	44.2%	206,218	44.7%	37,182	47.0%	12,301	50.0%
Sofosbuvir Velpatasvir Voxilaprevir	7,744	2,983	100.0%	4,491	100.0%	*****	*****	*****	*****	0	NaN
Female	2,058	859	28.8%	1,145	25.5%	*****	*****	*****	*****	0	NaN
Male	5,686	2,124	71.2%	3,346	74.5%	*****	*****	*****	*****	0	NaN
Vestronidase Alfa Vjbk	54	36	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	32,958	1	28	28	70	1,735	71.4	106.5
Female	32,455	1	28	28	70	1,735	71.4	106.7
Male	503	5	28	28	84	759	74.6	98.9
Acalabrutinib	35,219	1	30	31	90	1,823	87.7	114.8
Female	13,181	1	30	30	90	1,615	84.9	109.9
Male	22,038	1	30	36	90	1,823	89.4	117.6
Angiotensin II	36	1	1	1	1	2	1.0	0.2
Female	11	1	1	1	1	1	1.0	0.0
Male	25	1	1	1	1	2	1.0	0.2
Benralizumab	181,796	1	1	1	1	1,414	14.5	53.1
Female	116,384	1	1	1	1	1,414	15.1	55.1
Male	65,412	1	1	1	1	1,243	13.3	49.5
Benznidazole	64	1	30	30	60	176	39.2	27.4
Female	34	1	30	30	30	176	35.1	29.8
Male	30	7	30	30	60	102	43.9	24.1
Copanlisib	4,359	1	1	1	1	84	1.1	2.4
Female	2,061	1	1	1	1	28	1.0	0.9
Male	2,298	1	1	1	1	84	1.2	3.2
Emicizumab	21,760	1	1	1	1	1,575	12.8	75.9
Female	544	1	1	1	1	957	10.0	69.8
Male	21,216	1	1	1	1	1,575	12.8	76.1
Enasidenib	3,160	1	30	30	90	1,619	75.9	101.6
Female	1,393	1	30	30	90	1,119	73.9	90.8
Male	1,767	1	30	30	90	1,619	77.4	109.5
Ertugliflozin	42,568	1	30	30	90	1,544	76.2	108.2
Female	20,237	1	30	30	90	1,398	72.5	103.0
Male	22,331	1	30	30	90	1,544	79.5	112.7
Ertugliflozin and Sitagliptin	2,760	1	30	42	90	1,124	84.9	104.1
Female	1,212	1	30	30	90	826	83.5	105.9
Male	1,548	1	30	60	90	1,124	85.9	102.6
Ertugliflozin and Metformin	3,698	1	30	30	90	1,380	74.0	108.9
Female	1,423	1	30	30	90	1,119	72.6	109.0
Male	2,275	1	30	30	90	1,380	74.9	108.8
Glecaprevir and Pibrentasvir	98,261	1	28	46	56	1,106	46.3	28.1
Female	40,005	1	28	42	56	532	45.4	26.7
Male	58,256	1	28	50	56	1,106	46.9	29.0
Guselkumab	95,624	1	30	56	60	1,843	77.5	113.3

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	45,690	1	30	56	62	1,646	78.4	114.3
Male	49,934	1	30	55	60	1,843	76.6	112.3
Inotuzumab Ozogamicin	3,185	1	1	1	1	56	1.1	1.7
Female	1,578	1	1	1	1	56	1.1	1.8
Male	1,607	1	1	1	1	38	1.1	1.6
Latanoprostene Bunod Ophthalmic Solution	225,692	1	25	30	60	1,739	56.2	77.1
Female	134,522	1	25	30	57	1,739	55.4	76.1
Male	91,170	1	25	30	60	1,724	57.4	78.6
Letermovir	9,789	1	28	28	56	1,430	57.0	69.2
Female	4,355	1	28	28	56	1,430	55.7	69.4
Male	5,434	1	28	28	56	1,405	58.0	69.1
Macimorelin Acetate	47	1	1	1	1	31	4.7	9.7
Female	24	1	1	1	1	30	7.0	11.9
Male	23	1	1	1	1	31	2.3	6.3
Meropenem and Vaborbactam	4,580	1	1	1	1	668	2.0	10.7
Female	2,429	1	1	1	1	668	2.0	14.2
Male	2,151	1	1	1	1	57	1.9	4.3
Neratinib Maleate	7,350	1	30	30	60	937	68.9	85.6
Female	7,278	1	30	30	60	937	69.0	85.8
Male	72	15	30	30	51	360	52.2	59.7
Netarsudil	662,039	1	25	30	60	1,637	57.3	83.1
Female	385,437	1	25	30	60	1,637	56.5	82.8
Male	276,602	1	25	30	66	1,598	58.5	83.5
Ozenoxacin	1,945	2	30	30	30	450	29.8	16.0
Female	1,174	2	30	30	30	180	29.6	13.6
Male	771	2	30	30	30	450	30.2	19.2
Secnidazole	12,618	1	1	1	1	168	2.8	7.5
Female	12,592	1	1	1	1	168	2.8	7.5
Male	26	1	1	1	1	30	3.3	7.9
Semaglutide	2,884,431	1	28	37	84	1,782	85.6	126.4
Female	1,623,685	1	28	31	84	1,705	83.0	121.7
Male	1,260,746	1	28	42	86	1,782	89.0	132.2
Sofosbuvir Velpatasvir Voxilaprevir	7,744	1	28	56	84	497	59.0	34.1
Female	2,058	1	28	56	84	378	56.3	31.3

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	5,686	1	28	56	84	497	60.0	35.0
Vestronidase Alfa Vjbk	54	1	1	28	56	180	40.2	47.3
Female	*****	1	1	28	56	168	36.3	44.0
Male	*****	14	28	45	117	180	71.3	64.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Abemaciclib	32,958	19,068	100.0%	7,998	100.0%	5,134	100.0%	605	100.0%	153	100.0%
0-17 years	15	****	****	****	****	0	0.0%	0	0.0%	0	0.0%
18-24 years	11	****	****	****	****	0	0.0%	0	0.0%	0	0.0%
25-40 years	1,355	792	4.2%	****	****	205	4.0%	****	****	****	****
41-64 years	12,219	7,107	37.3%	2,874	35.9%	1,919	37.4%	245	40.5%	74	48.4%
≥ 65 years	19,358	11,149	58.5%	4,794	59.9%	3,010	58.6%	****	****	****	****
Acalabrutinib	35,219	17,594	100.0%	9,501	100.0%	6,941	100.0%	1,022	100.0%	161	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	52	24	0.1%	15	0.2%	****	****	****	****	0	0.0%
41-64 years	3,674	1,851	10.5%	1,008	10.6%	****	****	****	****	19	11.8%
≥ 65 years	31,493	15,719	89.3%	8,478	89.2%	6,231	89.8%	923	90.3%	142	88.2%
Angiotensin II	36	36	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	18	18	50.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	****	****	****	0	NaN	0	NaN	0	NaN	0	NaN
Benralizumab	181,796	163,638	100.0%	11,116	100.0%	6,133	100.0%	794	100.0%	115	100.0%
0-17 years	1,796	1,481	0.9%	204	1.8%	99	1.6%	12	1.5%	0	0.0%
18-24 years	1,607	1,333	0.8%	186	1.7%	****	****	****	****	****	****
25-40 years	8,905	7,223	4.4%	1,091	9.8%	****	****	****	****	****	****
41-64 years	50,529	41,307	25.2%	5,735	51.6%	3,030	49.4%	****	****	****	****
≥ 65 years	118,959	112,294	68.6%	3,900	35.1%	2,396	39.1%	307	38.7%	62	53.9%
Benznidazole	64	43	100.0%	****	****	****	****	0	NaN	0	NaN
0-17 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	****	****	****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	****	****	****	0	0.0%	****	****	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	46	30	69.8%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Copanlisib	4,359	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	3,779	3,779	86.8%	0	0.0%	0	NaN	0	NaN	0	NaN
Emicizumab	21,760	20,771	100.0%	436	100.0%	375	100.0%	109	100.0%	69	100.0%
0-17 years	5,440	4,901	23.6%	245	56.2%	207	55.2%	55	50.5%	32	46.4%
18-24 years	1,464	1,307	6.3%	85	19.5%	52	13.9%	*****	*****	*****	*****
25-40 years	5,900	5,733	27.6%	64	14.7%	63	16.8%	26	23.9%	14	20.3%
41-64 years	5,951	5,836	28.1%	39	8.9%	49	13.1%	16	14.7%	11	15.9%
≥ 65 years	3,005	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Enasidenib	3,160	1,609	100.0%	930	100.0%	571	100.0%	39	100.0%	11	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	414	235	14.6%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	2,707	1,349	83.8%	817	87.8%	498	87.2%	*****	*****	*****	*****
Ertugliflozin	42,568	22,683	100.0%	12,369	100.0%	6,470	100.0%	793	100.0%	253	100.0%
0-17 years	26	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	211	135	0.6%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	3,447	2,087	9.2%	901	7.3%	420	6.5%	*****	*****	*****	*****
41-64 years	28,675	15,733	69.4%	8,277	66.9%	4,162	64.3%	*****	*****	*****	*****
≥ 65 years	10,209	4,704	20.7%	3,129	25.3%	1,873	28.9%	357	45.0%	146	57.7%
Ertugliflozin and Sitagliptin	2,760	1,359	100.0%	840	100.0%	487	100.0%	63	100.0%	11	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Treatment Episodes by Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	1,731	877	64.5%	489	58.2%	317	65.1%	*****	*****	*****	*****
≥ 65 years	759	316	23.3%	288	34.3%	133	27.3%	*****	*****	*****	*****
Ertugliflozin and Metformin	3,698	2,118	100.0%	987	100.0%	505	100.0%	64	100.0%	24	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	11	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	425	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	2,533	1,492	70.4%	657	66.6%	338	66.9%	*****	*****	*****	*****
≥ 65 years	729	345	16.3%	231	23.4%	117	23.2%	25	39.1%	11	45.8%
Glecaprevir and Pibrentasvir	98,261	46,972	100.0%	48,581	100.0%	2,647	100.0%	59	100.0%	*****	*****
0-17 years	25	*****	*****	13	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	1,568	*****	*****	648	1.3%	*****	*****	0	0.0%	0	0.0%
25-40 years	19,507	9,991	21.3%	9,007	18.5%	*****	*****	*****	*****	*****	*****
41-64 years	58,988	28,521	60.7%	28,648	59.0%	1,767	66.8%	*****	*****	*****	*****
≥ 65 years	18,173	7,598	16.2%	10,265	21.1%	*****	*****	*****	*****	0	0.0%
Guselkumab	95,624	35,629	100.0%	39,998	100.0%	17,390	100.0%	2,111	100.0%	496	100.0%
0-17 years	112	71	0.2%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	3,482	1,337	3.8%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	21,922	8,198	23.0%	9,598	24.0%	3,594	20.7%	*****	*****	*****	*****
41-64 years	55,136	20,124	56.5%	23,468	58.7%	10,033	57.7%	1,218	57.7%	293	59.1%
≥ 65 years	14,972	5,899	16.6%	5,349	13.4%	3,228	18.6%	394	18.7%	102	20.6%
Inotuzumab Ozogamicin	3,185	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	55	55	1.7%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	108	108	3.4%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	307	307	9.6%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	665	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	2,050	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Latanoprostene Bunod Ophthalmic Solution	225,692	117,940	100.0%	86,064	100.0%	19,276	100.0%	1,895	100.0%	517	100.0%
0-17 years	127	79	0.1%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	206	142	0.1%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	1,749	1,059	0.9%	541	0.6%	132	0.7%	*****	*****	*****	*****
41-64 years	25,226	14,878	12.6%	8,086	9.4%	2,011	10.4%	*****	*****	*****	*****
≥ 65 years	198,384	101,782	86.3%	77,346	89.9%	17,115	88.8%	1,663	87.8%	478	92.5%
Letermovir	9,789	5,878	100.0%	2,687	100.0%	1,156	100.0%	56	100.0%	12	100.0%
0-17 years	124	78	1.3%	29	1.1%	17	1.5%	0	0.0%	0	0.0%
18-24 years	351	229	3.9%	89	3.3%	*****	*****	*****	*****	*****	*****
25-40 years	1,499	944	16.1%	397	14.8%	*****	*****	*****	*****	*****	*****
41-64 years	4,011	2,436	41.4%	1,068	39.7%	487	42.1%	*****	*****	*****	*****
≥ 65 years	3,804	2,191	37.3%	1,104	41.1%	473	40.9%	*****	*****	*****	*****
Macimorelin Acetate	47	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	13	13	28.3%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Meropenem and Vaborbactam	4,580	4,556	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	200	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	1,204	1,191	26.1%	*****	*****	0	0.0%	*****	*****	0	NaN
≥ 65 years	3,160	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Neratinib Maleate	7,350	4,477	100.0%	1,632	100.0%	1,121	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	195	11.9%	139	12.4%	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
41-64 years	4,265	2,553	57.0%	980	60.0%	650	58.0%	*****	*****	*****	*****
≥ 65 years	2,192	1,388	31.0%	457	28.0%	332	29.6%	*****	*****	*****	*****
Netarsudil	662,039	380,905	100.0%	210,231	100.0%	62,312	100.0%	6,721	100.0%	1,870	100.0%
0-17 years	510	332	0.1%	131	0.1%	*****	*****	*****	*****	0	0.0%
18-24 years	489	295	0.1%	143	0.1%	*****	*****	*****	*****	0	0.0%
25-40 years	4,987	3,121	0.8%	1,375	0.7%	442	0.7%	*****	*****	*****	*****
41-64 years	63,176	37,784	9.9%	18,423	8.8%	6,063	9.7%	*****	*****	*****	*****
≥ 65 years	592,877	339,373	89.1%	190,159	90.5%	55,718	89.4%	5,935	88.3%	1,692	90.5%
Ozenoxacin	1,945	1,807	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	426	400	22.1%	26	20.3%	0	0.0%	0	0.0%	0	NaN
18-24 years	176	163	9.0%	*****	*****	0	0.0%	*****	*****	0	NaN
25-40 years	409	380	21.0%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	756	704	39.0%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	178	160	8.9%	*****	*****	*****	*****	0	0.0%	0	NaN
Secnidazole	12,618	12,536	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	142	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	2,317	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	6,180	6,135	48.9%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	3,600	3,578	28.5%	22	27.5%	0	0.0%	0	NaN	0	NaN
≥ 65 years	379	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Semaglutide	2,884,431	1,412,148	100.0%	907,360	100.0%	461,181	100.0%	79,139	100.0%	24,603	100.0%
0-17 years	1,189	699	0.0%	302	0.0%	170	0.0%	*****	*****	*****	*****
18-24 years	14,854	8,329	0.6%	4,381	0.5%	1,885	0.4%	*****	*****	*****	*****
25-40 years	210,112	113,362	8.0%	61,252	6.8%	30,307	6.6%	4,138	5.2%	1,053	4.3%
41-64 years	1,369,868	680,401	48.2%	417,158	46.0%	221,565	48.0%	38,827	49.1%	11,917	48.4%
≥ 65 years	1,288,408	609,357	43.2%	424,267	46.8%	207,254	44.9%	35,937	45.4%	11,593	47.1%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Treatment Episodes by Duration										
	1-30 Days			31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Sofosbuvir Velpatasvir Voxilaprevir	7,744	2,983	100.0%	4,491	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	33	18	0.6%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	431	192	6.4%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	4,750	1,918	64.3%	2,631	58.6%	*****	*****	*****	*****	0	NaN
≥ 65 years	2,530	855	28.7%	1,624	36.2%	51	19.2%	0	0.0%	0	NaN
Vestronidase Alfa Vjbk	54	36	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	30	18	50.0%	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	32,958	1	28	28	70	1,735	71.4	106.5
0-17 years	15	5	28	28	56	84	35.3	19.4
18-24 years	11	4	28	28	28	70	28.6	15.9
25-40 years	1,355	1	28	28	75	1,735	71.7	112.7
41-64 years	12,219	1	28	28	70	1,585	73.1	115.5
≥ 65 years	19,358	1	28	28	71	1,568	70.4	100.1
Acalabrutinib	35,219	1	30	31	90	1,823	87.7	114.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	52	9	30	58	105	433	88.6	97.3
41-64 years	3,674	1	30	30	90	1,823	86.1	117.8
≥ 65 years	31,493	1	30	32	90	1,641	87.9	114.5
Angiotensin II	36	1	1	1	1	2	1.0	0.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	18	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	2	1.1	0.3
Benralizumab	181,796	1	1	1	1	1,414	14.5	53.1
0-17 years	1,796	1	1	1	28	681	24.9	55.8
18-24 years	1,607	1	1	1	28	924	23.2	58.2
25-40 years	8,905	1	1	1	28	1,400	25.6	65.1
41-64 years	50,529	1	1	1	28	1,344	25.4	68.5
≥ 65 years	118,959	1	1	1	1	1,414	8.7	42.6
Benznidazole	64	1	30	30	60	176	39.2	27.4
0-17 years	*****	1	7	7	30	30	15.0	13.9
18-24 years	*****	30	30	30	30	30	30.0	0.0
25-40 years	*****	6	6	30	102	102	46.0	50.0
41-64 years	46	7	30	30	60	176	42.0	27.4
≥ 65 years	*****	7	15	45	60	60	38.3	24.2
Copanlisib	4,359	1	1	1	1	84	1.1	2.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	28	56	84	36.0	32.9
41-64 years	566	1	1	1	1	21	1.0	0.8

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	3,779	1	1	1	1	28	1.0	0.6
Emicizumab	21,760	1	1	1	1	1,575	12.8	75.9
0-17 years	5,440	1	1	1	1	1,575	25.1	103.1
18-24 years	1,464	1	1	1	22	1,276	26.5	104.5
25-40 years	5,900	1	1	1	1	1,431	9.2	66.5
41-64 years	5,951	1	1	1	1	1,551	6.9	59.3
≥ 65 years	3,005	1	1	1	1	1,172	2.5	31.6
Enasidenib	3,160	1	30	30	90	1,619	75.9	101.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	60	180	55.7	55.9
25-40 years	*****	1	30	30	60	180	50.3	44.5
41-64 years	414	3	30	30	86	750	67.4	79.5
≥ 65 years	2,707	1	30	32	90	1,619	77.5	105.1
Ertugliflozin	42,568	1	30	30	90	1,544	76.2	108.2
0-17 years	26	4	30	30	30	98	29.4	16.3
18-24 years	211	1	30	30	60	559	49.6	49.5
25-40 years	3,447	1	30	30	60	1,061	60.4	76.9
41-64 years	28,675	1	30	30	90	1,529	68.9	92.7
≥ 65 years	10,209	1	30	60	90	1,544	102.8	147.4
Ertugliflozin and Sitagliptin	2,760	1	30	42	90	1,124	84.9	104.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	60	180	56.3	54.2
25-40 years	*****	10	30	30	90	450	66.1	71.1
41-64 years	1,731	1	30	30	90	1,124	85.1	109.3
≥ 65 years	759	1	30	60	90	821	91.1	101.2
Ertugliflozin and Metformin	3,698	1	30	30	90	1,380	74.0	108.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	11	15	30	30	30	160	45.8	42.4
25-40 years	425	1	30	30	60	848	62.5	91.8
41-64 years	2,533	1	30	30	75	1,380	68.7	98.7
≥ 65 years	729	1	30	56	90	991	99.8	143.3
Glecaprevir and Pibrentasvir	98,261	1	28	46	56	1,106	46.3	28.1
0-17 years	25	14	28	56	84	140	60.8	33.2
18-24 years	1,568	1	28	28	56	336	43.8	29.1
25-40 years	19,507	1	28	28	56	1,106	43.4	26.5

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	58,988	1	28	42	56	1,092	46.7	29.9
≥ 65 years	18,173	1	28	56	56	389	48.5	22.6
Guselkumab	95,624	1	30	56	60	1,843	77.5	113.3
0-17 years	112	1	28	30	56	407	41.6	50.6
18-24 years	3,482	1	30	42	56	1,626	68.3	91.8
25-40 years	21,922	1	30	31	58	1,536	73.3	105.1
41-64 years	55,136	1	30	54	60	1,843	78.4	113.8
≥ 65 years	14,972	1	28	56	88	1,627	82.5	126.5
Inotuzumab Ozogamicin	3,185	1	1	1	1	56	1.1	1.7
0-17 years	55	1	1	1	1	1	1.0	0.0
18-24 years	108	1	1	1	1	1	1.0	0.0
25-40 years	307	1	1	1	1	2	1.0	0.1
41-64 years	665	1	1	1	1	38	1.1	1.6
≥ 65 years	2,050	1	1	1	1	56	1.1	1.9
Ophthalmic Solution	225,692	1	25	30	60	1,739	56.2	77.1
0-17 years	127	1	27	30	50	469	48.5	52.4
18-24 years	206	1	25	30	50	900	47.8	79.3
25-40 years	1,749	1	25	30	50	990	50.2	65.1
41-64 years	25,226	1	25	30	56	1,724	53.5	72.9
≥ 65 years	198,384	1	25	30	60	1,739	56.6	77.8
Letermovir	9,789	1	28	28	56	1,430	57.0	69.2
0-17 years	124	7	28	28	56	270	49.2	42.0
18-24 years	351	2	28	28	56	1,008	52.1	82.3
25-40 years	1,499	1	28	28	56	981	52.6	59.7
41-64 years	4,011	1	28	28	56	1,430	55.9	63.5
≥ 65 years	3,804	1	28	28	58	1,405	60.6	77.3
Macimorelin Acetate	47	1	1	1	1	31	4.7	9.7
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	16	30	30	15.5	20.5
25-40 years	*****	1	1	1	1	28	3.1	7.5
41-64 years	26	1	1	1	1	31	5.5	10.8
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Vaborbactam	4,580	1	1	1	1	668	2.0	10.7
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	200	1	1	1	1	33	3.3	5.8
41-64 years	1,204	1	1	1	1	668	2.7	19.8
≥ 65 years	3,160	1	1	1	1	104	1.6	3.8
Neratinib Maleate	7,350	1	30	30	60	937	68.9	85.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	30	30	30	30	29.6	0.9
25-40 years	*****	1	30	30	67	744	73.6	94.7
41-64 years	4,265	1	30	30	60	937	70.1	88.3
≥ 65 years	2,192	1	30	30	60	904	64.7	75.9
Netarsudil	662,039	1	25	30	60	1,637	57.3	83.1
0-17 years	510	1	25	30	50	721	49.7	63.0
18-24 years	489	1	25	30	60	652	55.1	67.3
25-40 years	4,987	1	25	30	50	991	52.9	72.9
41-64 years	63,176	1	25	30	60	1,527	57.8	84.9
≥ 65 years	592,877	1	25	30	60	1,637	57.3	83.0
Ozenoxacin	1,945	2	30	30	30	450	29.8	16.0
0-17 years	426	2	30	30	30	90	28.7	10.3
18-24 years	176	5	30	30	30	450	30.9	33.7
25-40 years	409	2	30	30	30	180	30.0	14.2
41-64 years	756	2	30	30	30	150	29.6	13.2
≥ 65 years	178	5	30	30	30	120	32.1	14.9
Secnidazole	12,618	1	1	1	1	168	2.8	7.5
0-17 years	142	1	1	1	1	60	2.4	6.8
18-24 years	2,317	1	1	1	1	90	2.6	6.7
25-40 years	6,180	1	1	1	1	168	2.8	7.9
41-64 years	3,600	1	1	1	1	90	2.9	7.3
≥ 65 years	379	1	1	1	1	60	3.6	8.7
Semaglutide	2,884,431	1	28	37	84	1,782	85.6	126.4
0-17 years	1,189	1	28	30	84	970	65.6	85.2
18-24 years	14,854	1	28	30	84	1,568	66.9	89.2
25-40 years	210,112	1	28	30	84	1,658	73.8	105.8
41-64 years	1,369,868	1	28	31	84	1,766	86.1	127.8
≥ 65 years	1,288,408	1	28	42	84	1,782	87.3	128.3
Voxilaprevir	7,744	1	28	56	84	497	59.0	34.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	33	10	28	28	56	140	48.2	30.3
25-40 years	431	1	28	56	84	224	55.2	32.2
41-64 years	4,750	1	28	56	84	497	58.5	36.6
≥ 65 years	2,530	1	28	56	84	308	60.8	28.9
Vestronidase Alfa Vjvk	54	1	1	28	56	180	40.2	47.3
0-17 years	30	1	1	14	56	180	40.4	53.4
18-24 years	*****	28	33	66	117	140	75.0	45.4
25-40 years	*****	1	28	28	28	140	28.2	30.2
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Abemaciclib</i>	12,091	6,821	56.4%	2,787	23.1%	2,083	17.2%	305	2.5%	95	0.8%
<i>Acalabrutinib</i>	11,134	5,150	46.3%	2,700	24.3%	2,602	23.4%	574	5.2%	108	1.0%
<i>Angiotensin II</i>	28	28	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Benralizumab</i>	24,071	20,364	84.6%	2,168	9.0%	1,291	5.4%	215	0.9%	33	0.1%
<i>Benznidazole</i>	51	31	60.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Copanlisib</i>	304	304	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Emicizumab</i>	2,033	1,650	81.2%	113	5.6%	158	7.8%	61	3.0%	51	2.5%
<i>Enasidenib</i>	1,480	752	50.8%	412	27.8%	285	19.3%	*****	*****	*****	*****
<i>Ertugliflozin</i>	18,637	9,805	52.6%	5,145	27.6%	3,164	17.0%	378	2.0%	145	0.8%
<i>Ertugliflozin and Sitagliptin</i>	836	400	47.8%	227	27.2%	165	19.7%	*****	*****	*****	*****
<i>Ertugliflozin and Metformin</i>	1,348	727	53.9%	354	26.3%	224	16.6%	30	2.2%	13	1.0%
<i>Glecaprevir and Pibrentasvir</i>	74,786	27,243	36.4%	45,011	60.2%	2,475	3.3%	*****	*****	*****	*****
<i>Guselkumab</i>	25,685	11,484	44.7%	8,168	31.8%	4,880	19.0%	905	3.5%	248	1.0%
<i>Inotuzumab</i>	592	592	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ozogamicin</i>											
<i>Latanoprostene</i>											
<i>Bunod Ophthalmic Solution</i>	54,803	25,414	46.4%	22,619	41.3%	5,735	10.5%	781	1.4%	254	0.5%
<i>Letermovir</i>	4,466	2,686	60.1%	1,165	26.1%	581	13.0%	*****	*****	*****	*****
<i>Macimorelin</i>	46	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Meropenem and Vaborbactam</i>	4,045	4,031	99.7%	14	0.3%	0	0.0%	0	0.0%	0	0.0%
<i>Neratinib Maleate</i>	2,965	1,875	63.2%	584	19.7%	425	14.3%	*****	*****	*****	*****
<i>Netarsudil</i>	151,751	74,399	49.0%	54,464	35.9%	19,223	12.7%	2,745	1.8%	920	0.6%
<i>Ozenoxacin</i>	1,641	1,528	93.1%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Secnidazole</i>	9,558	9,507	99.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Semaglutide</i>	982,602	429,789	43.7%	329,231	33.5%	174,956	17.8%	36,130	3.7%	12,496	1.3%
<i>Sofosbuvir</i>											
<i>Velpatasvir</i>	5,567	1,661	29.8%	3,660	65.7%	*****	*****	*****	*****	0	0.0%
<i>Voxilaprevir</i>											
<i>Vestronidase Alfa Vjbk</i>	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Abemaciclib</i>	12,091	1	28	28	84	1,735	80.5	127.8
<i>Acalabrutinib</i>	11,134	1	30	60	120	1,823	109.5	147.0
<i>Angiotensin II</i>	28	1	1	1	1	2	1.0	0.2
<i>Benralizumab</i>	24,071	1	1	1	28	1,400	25.7	72.1
<i>Benznidazole</i>	51	1	30	30	60	176	41.7	29.8
<i>Copanlisib</i>	304	1	1	1	1	28	1.3	2.9
<i>Emicizumab</i>	2,033	1	1	1	28	1,575	67.1	199.0
<i>Enasidenib</i>	1,480	1	30	30	90	1,619	80.1	118.3
<i>Ertugliflozin</i>	18,637	1	30	30	90	1,544	79.3	117.2
<i>Ertugliflozin and Sitagliptin</i>	836	1	30	60	96	1,124	104.1	137.4
<i>Ertugliflozin and Metformin</i>	1,348	1	30	30	90	1,380	83.7	128.6
<i>Glecaprevir and Pibrentasvir</i>	74,786	1	28	56	56	1,092	50.9	29.1
<i>Guselkumab</i>	25,685	1	28	56	86	1,843	92.5	142.9
<i>Inotuzumab Ozogamicin</i>	592	1	1	1	1	30	1.2	1.9
<i>Latanoprostene Bunod Ophthalmic Solution</i>	54,803	1	25	38	75	1,739	66.9	100.9
<i>Letermovir</i>	4,466	1	28	28	70	1,430	58.8	71.9
<i>Macimorelin Acetate</i>	46	1	1	1	1	31	4.8	9.8
<i>Meropenem and Vaborbactam</i>	4,045	1	1	1	1	49	1.5	3.1
<i>Neratinib Maleate</i>	2,965	1	30	30	60	937	72.2	98.4
<i>Netarsudil</i>	151,751	1	25	37	84	1,637	72.3	110.4
<i>Ozenoxacin</i>	1,641	2	30	30	30	450	29.7	15.5
<i>Secnidazole</i>	9,558	1	1	1	1	168	2.7	7.3
<i>Semaglutide</i>	982,602	1	28	56	90	1,782	97.9	146.5
<i>Sofosbuvir Velpatasvir Voxilaprevir</i>	5,567	1	28	84	84	497	66.8	35.3
<i>Vestronidase Alfa Vjbk</i>	*****	1	14	42	140	180	63.0	66.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Abemaciclib	12,091	6,821	100.0%	2,787	100.0%	2,083	100.0%	305	100.0%	95	100.0%
Female	11,902	6,712	98.4%	2,743	98.4%	*****	*****	*****	*****	*****	*****
Male	189	109	1.6%	44	1.6%	*****	*****	*****	*****	*****	*****
Acalabrutinib	11,134	5,150	100.0%	2,700	100.0%	2,602	100.0%	574	100.0%	108	100.0%
Female	4,162	2,059	40.0%	996	36.9%	882	33.9%	197	34.3%	28	25.9%
Male	6,972	3,091	60.0%	1,704	63.1%	1,720	66.1%	377	65.7%	80	74.1%
Angiotensin II	28	28	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Benralizumab	24,071	20,364	100.0%	2,168	100.0%	1,291	100.0%	215	100.0%	33	100.0%
Female	15,605	13,146	64.6%	1,445	66.7%	843	65.3%	*****	*****	*****	*****
Male	8,466	7,218	35.4%	723	33.3%	448	34.7%	*****	*****	*****	*****
Benznidazole	51	31	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	27	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	24	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Copanlisib	304	304	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	144	144	47.4%	0	NaN	0	NaN	0	NaN	0	NaN
Male	160	160	52.6%	0	NaN	0	NaN	0	NaN	0	NaN
Emicizumab	2,033	1,650	100.0%	113	100.0%	158	100.0%	61	100.0%	51	100.0%
Female	286	*****	*****	0	0.0%	*****	*****	0	0.0%	*****	*****
Male	1,747	*****	*****	113	100.0%	*****	*****	61	100.0%	*****	*****
Enasidenib	1,480	752	100.0%	412	100.0%	285	100.0%	*****	*****	*****	*****
Female	629	319	42.4%	174	42.2%	122	42.8%	*****	*****	*****	*****
Male	851	433	57.6%	238	57.8%	163	57.2%	*****	*****	*****	*****
Ertugliflozin	18,637	9,805	100.0%	5,145	100.0%	3,164	100.0%	378	100.0%	145	100.0%
Female	9,224	5,016	51.2%	2,508	48.7%	1,474	46.6%	168	44.4%	58	40.0%
Male	9,413	4,789	48.8%	2,637	51.3%	1,690	53.4%	210	55.6%	87	60.0%
Ertugliflozin and Sitagliptin	836	400	100.0%	227	100.0%	165	100.0%	*****	*****	*****	*****
Female	405	194	48.5%	112	49.3%	77	46.7%	*****	*****	*****	*****
Male	431	206	51.5%	115	50.7%	88	53.3%	*****	*****	*****	*****
Ertugliflozin and Metformin	1,348	727	100.0%	354	100.0%	224	100.0%	30	100.0%	13	100.0%
Female	573	318	43.7%	157	44.4%	82	36.6%	*****	*****	*****	*****
Male	775	409	56.3%	197	55.6%	142	63.4%	*****	*****	*****	*****
Glecaprevir and Pibrentasvir	74,786	27,243	100.0%	45,011	100.0%	2,475	100.0%	*****	*****	*****	*****
Female	30,524	11,325	41.6%	18,297	40.7%	877	35.4%	*****	*****	0	0.0%
Male	44,262	15,918	58.4%	26,714	59.3%	1,598	64.6%	*****	*****	*****	*****
Guselkumab	25,685	11,484	100.0%	8,168	100.0%	4,880	100.0%	905	100.0%	248	100.0%
Female	12,958	5,896	51.3%	4,054	49.6%	2,460	50.4%	436	48.2%	112	45.2%

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	12,727	5,588	48.7%	4,114	50.4%	2,420	49.6%	469	51.8%	136	54.8%
Inotuzumab											
Ozogamicin	592	592	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	282	282	47.6%	0	NaN	0	NaN	0	NaN	0	NaN
Male	310	310	52.4%	0	NaN	0	NaN	0	NaN	0	NaN
Latanoprostene											
Bunod Ophthalmic											
Solution	54,803	25,414	100.0%	22,619	100.0%	5,735	100.0%	781	100.0%	254	100.0%
Female	32,003	14,990	59.0%	13,145	58.1%	3,271	57.0%	454	58.1%	143	56.3%
Male	22,800	10,424	41.0%	9,474	41.9%	2,464	43.0%	327	41.9%	111	43.7%
Letemovir	4,466	2,686	100.0%	1,165	100.0%	581	100.0%	*****	*****	*****	*****
Female	1,997	1,241	46.2%	510	43.8%	231	39.8%	*****	*****	*****	*****
Male	2,469	1,445	53.8%	655	56.2%	350	60.2%	*****	*****	*****	*****
Macimorelin	46	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	24	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Male	22	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Meropenem and											
Vaborbactam											
Vaborbactam	4,045	4,031	100.0%	14	100.0%	0	NaN	0	NaN	0	NaN
Female	2,141	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	1,904	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Neratinib Maleate	2,965	1,875	100.0%	*****	*****	425	100.0%	74	100.0%	*****	*****
Female	2,941	*****	*****	*****	*****	425	100.0%	74	100.0%	*****	*****
Male	24	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Netarsudil	151,751	74,399	100.0%	54,464	100.0%	19,223	100.0%	2,745	100.0%	920	100.0%
Female	86,133	43,071	57.9%	30,337	55.7%	10,613	55.2%	1,586	57.8%	526	57.2%
Male	65,618	31,328	42.1%	24,127	44.3%	8,610	44.8%	1,159	42.2%	394	42.8%
Ozenoxacin	1,641	1,528	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
Female	982	913	59.8%	*****	*****	*****	*****	0	0.0%	0	NaN
Male	659	615	40.2%	*****	*****	0	0.0%	*****	*****	0	NaN
Secnidazole	9,558	9,507	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	9,535	9,484	99.8%	*****	*****	*****	*****	0	NaN	0	NaN
Male	23	23	0.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
Semaglutide	982,602	429,789	100.0%	329,231	100.0%	174,956	100.0%	36,130	100.0%	12,496	100.0%
Female	562,761	249,843	58.1%	187,706	57.0%	99,471	56.9%	19,493	54.0%	6,248	50.0%
Male	419,841	179,946	41.9%	141,525	43.0%	75,485	43.1%	16,637	46.0%	6,248	50.0%
Sofosbuvir											
Velpatasvir											
Voxilaprevir	5,567	1,661	100.0%	3,660	100.0%	*****	*****	*****	*****	0	NaN
Female	1,456	480	28.9%	929	25.4%	*****	*****	*****	*****	0	NaN
Male	4,111	1,181	71.1%	2,731	74.6%	*****	*****	*****	*****	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Number of Patients by First Treatment Episode Duration												
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients		
Vestronidase Alfa												
Vjbk	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	12,091	1	28	28	84	1,735	80.5	127.8
Female	11,902	1	28	28	84	1,735	80.6	128.1
Male	189	5	28	28	84	759	77.1	106.8
Acalabrutinib	11,134	1	30	60	120	1,823	109.5	147.0
Female	4,162	1	30	36	120	1,615	100.5	134.0
Male	6,972	1	30	60	141	1,823	114.9	154.0
Angiotensin II	28	1	1	1	1	2	1.0	0.2
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	2	1.1	0.2
Benralizumab	24,071	1	1	1	28	1,400	25.7	72.1
Female	15,605	1	1	1	28	1,400	26.7	75.1
Male	8,466	1	1	1	28	988	23.9	66.2
Benznidazole	51	1	30	30	60	176	41.7	29.8
Female	27	1	19	30	60	176	36.4	33.4
Male	24	7	30	60	60	102	47.7	24.4
Copanlisib	304	1	1	1	1	28	1.3	2.9
Female	144	1	1	1	1	28	1.5	3.5
Male	160	1	1	1	1	28	1.2	2.1
Emicizumab	2,033	1	1	1	28	1,575	67.1	199.0
Female	286	1	1	1	1	957	10.3	77.1
Male	1,747	1	1	1	28	1,575	76.4	210.9
Enasidenib	1,480	1	30	30	90	1,619	80.1	118.3
Female	629	5	30	30	90	876	78.1	97.5
Male	851	1	30	30	90	1,619	81.7	131.7
Ertugliflozin	18,637	1	30	30	90	1,544	79.3	117.2
Female	9,224	1	30	30	90	1,394	74.7	109.4
Male	9,413	1	30	30	90	1,544	83.9	124.2
Ertugliflozin and Sitagliptin	836	1	30	60	96	1,124	104.1	137.4
Female	405	3	30	60	90	826	103.9	135.3
Male	431	1	30	60	120	1,124	104.3	139.5
Ertugliflozin and Metformin	1,348	1	30	30	90	1,380	83.7	128.6
Female	573	1	30	30	90	1,119	76.7	117.0
Male	775	1	30	30	90	1,380	88.8	136.3
Glecaprevir and Pibrentasvir	74,786	1	28	56	56	1,092	50.9	29.1
Female	30,524	1	28	56	56	532	49.8	27.8

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	44,262	1	28	56	56	1,092	51.7	29.9
Guselkumab	25,685	1	28	56	86	1,843	92.5	142.9
Female	12,958	1	28	50	84	1,646	90.6	137.0
Male	12,727	1	28	56	86	1,843	94.5	148.6
Inotuzumab Ozogamicin	592	1	1	1	1	30	1.2	1.9
Female	282	1	1	1	1	15	1.0	0.8
Male	310	1	1	1	1	30	1.3	2.5
Latanoprostene Bunod Ophthalmic Solution	54,803	1	25	38	75	1,739	66.9	100.9
Female	32,003	1	25	37	75	1,739	65.8	98.5
Male	22,800	1	25	38	75	1,724	68.4	104.2
Letermovir	4,466	1	28	28	70	1,430	58.8	71.9
Female	1,997	1	28	28	56	1,430	57.2	74.3
Male	2,469	1	28	28	84	1,405	60.0	69.9
Macimorelin Acetate	46	1	1	1	1	31	4.8	9.8
Female	24	1	1	1	1	30	7.0	11.9
Male	22	1	1	1	1	31	2.4	6.4
Meropenem and Vaborbactam	4,045	1	1	1	1	49	1.5	3.1
Female	2,141	1	1	1	1	49	1.5	2.8
Male	1,904	1	1	1	1	47	1.6	3.5
Neratinib Maleate	2,965	1	30	30	60	937	72.2	98.4
Female	2,941	1	30	30	60	937	72.6	98.8
Male	24	28	30	30	30	60	31.9	6.8
Netarsudil	151,751	1	25	37	84	1,637	72.3	110.4
Female	86,133	1	25	30	80	1,637	71.6	111.2
Male	65,618	1	25	38	90	1,598	73.2	109.4
Ozenoxacin	1,641	2	30	30	30	450	29.7	15.5
Female	982	2	30	30	30	150	29.4	12.1
Male	659	2	30	30	30	450	30.2	19.4
Secnidazole	9,558	1	1	1	1	168	2.7	7.3
Female	9,535	1	1	1	1	168	2.7	7.3
Male	23	1	1	1	1	30	3.6	8.3
Semaglutide	982,602	1	28	56	90	1,782	97.9	146.5
Female	562,761	1	28	50	90	1,705	94.4	139.9
Male	419,841	1	28	56	90	1,782	102.5	154.7

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sofosbuvir Velpatasvir Voxilaprevir	5,567	1	28	84	84	497	66.8	35.3
Female	1,456	1	28	84	84	378	63.7	32.5
Male	4,111	1	28	84	84	497	67.9	36.1
Vestronidase Alfa Vjbk	*****	1	14	42	140	180	63.0	66.1
Female	*****	1	1	35	140	140	58.7	66.2
Male	*****	14	21	42	118	180	69.5	75.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Abemaciclib	12,091	6,821	100.0%	2,787	100.0%	2,083	100.0%	305	100.0%	95	100.0%
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	87	4.2%	*****	*****	*****	*****
41-64 years	4,417	2,408	35.3%	991	35.6%	826	39.7%	139	45.6%	53	55.8%
≥ 65 years	7,181	4,146	60.8%	1,673	60.0%	1,170	56.2%	*****	*****	*****	*****
Acalabrutinib	11,134	5,150	100.0%	2,700	100.0%	2,602	100.0%	574	100.0%	108	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	19	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	1,164	*****	*****	*****	*****	*****	*****	*****	*****	14	13.0%
≥ 65 years	9,951	4,619	89.7%	2,398	88.8%	2,324	89.3%	516	89.9%	94	87.0%
Angiotensin II	28	28	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	13	13	46.4%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Benralizumab	24,071	20,364	100.0%	2,168	100.0%	1,291	100.0%	215	100.0%	33	100.0%
0-17 years	370	300	1.5%	47	2.2%	*****	*****	*****	*****	0	0.0%
18-24 years	327	272	1.3%	38	1.8%	*****	*****	*****	*****	*****	*****
25-40 years	1,699	1,361	6.7%	203	9.4%	122	9.5%	*****	*****	*****	*****
41-64 years	8,409	6,560	32.2%	1,080	49.8%	640	49.6%	*****	*****	*****	*****
≥ 65 years	13,266	11,871	58.3%	800	36.9%	492	38.1%	89	41.4%	14	42.4%
Benznidazole	51	31	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	35	20	64.5%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Copanlisib	304	304	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	227	227	74.7%	0	NaN	0	NaN	0	NaN	0	NaN
Emicizumab	2,033	1,650	100.0%	113	100.0%	158	100.0%	61	100.0%	51	100.0%
0-17 years	643	446	27.0%	65	57.5%	85	53.8%	25	41.0%	22	43.1%
18-24 years	190	*****	*****	23	20.4%	19	12.0%	*****	*****	*****	*****
25-40 years	442	366	22.2%	*****	*****	36	22.8%	*****	*****	*****	*****
41-64 years	456	409	24.8%	*****	*****	18	11.4%	*****	*****	*****	*****
≥ 65 years	302	*****	*****	*****	*****	0	0.0%	*****	*****	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Enasidenib	1,480	752	100.0%	412	100.0%	285	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	195	100	13.3%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	1,264	640	85.1%	354	85.9%	245	86.0%	*****	*****	*****	*****
Ertugliflozin	18,637	9,805	100.0%	5,145	100.0%	3,164	100.0%	378	100.0%	145	100.0%
0-17 years	13	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
18-24 years	101	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	1,564	924	9.4%	*****	*****	229	7.2%	*****	*****	*****	*****
41-64 years	12,974	6,913	70.5%	3,585	69.7%	2,244	70.9%	*****	*****	*****	*****
≥ 65 years	3,985	1,896	19.3%	1,131	22.0%	680	21.5%	183	48.4%	95	65.5%
Ertugliflozin and Sitagliptin	836	400	100.0%	227	100.0%	165	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	17	7.5%	*****	*****	*****	*****	0	0.0%
41-64 years	515	264	66.0%	122	53.7%	98	59.4%	*****	*****	*****	*****
≥ 65 years	251	102	25.5%	88	38.8%	50	30.3%	*****	*****	*****	*****
Ertugliflozin and Metformin	1,348	727	100.0%	354	100.0%	224	100.0%	30	100.0%	13	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	20	8.9%	*****	*****	*****	*****
41-64 years	959	525	72.2%	252	71.2%	160	71.4%	*****	*****	*****	*****
≥ 65 years	236	105	14.4%	69	19.5%	44	19.6%	*****	*****	*****	*****
Glecaprevir and Pibrentasvir	74,786	27,243	100.0%	45,011	100.0%	2,475	100.0%	*****	*****	*****	*****
0-17 years	23	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	1,211	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	15,058	6,019	22.1%	8,574	19.0%	*****	*****	*****	*****	0	0.0%
41-64 years	44,253	16,362	60.1%	26,189	58.2%	1,652	66.7%	*****	*****	*****	*****
≥ 65 years	14,241	4,321	15.9%	9,620	21.4%	*****	*****	*****	*****	0	0.0%
Guselkumab	25,685	11,484	100.0%	8,168	100.0%	4,880	100.0%	905	100.0%	248	100.0%
0-17 years	37	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	934	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	5,796	2,593	22.6%	1,930	23.6%	1,020	20.9%	199	22.0%	54	21.8%
41-64 years	14,568	6,357	55.4%	4,677	57.3%	2,827	57.9%	554	61.2%	153	61.7%
≥ 65 years	4,350	2,060	17.9%	1,252	15.3%	878	18.0%	*****	*****	*****	*****
Inotuzumab											
Ozogamicin	592	592	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	21	21	3.5%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	26	26	4.4%	0	NaN	0	NaN	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Patients by First Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	68	68	11.5%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	127	127	21.5%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	350	350	59.1%	0	NaN	0	NaN	0	NaN	0	NaN
Latanoprostene											
Bunod											
Ophthalmic Solution											
	54,803	25,414	100.0%	22,619	100.0%	5,735	100.0%	781	100.0%	254	100.0%
0-17 years	43	26	0.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	63	45	0.2%	*****	*****	0	0.0%	*****	*****	0	0.0%
25-40 years	471	275	1.1%	155	0.7%	*****	*****	*****	*****	0	0.0%
41-64 years	6,604	3,597	14.2%	2,314	10.2%	*****	*****	*****	*****	18	7.1%
≥ 65 years	47,622	21,471	84.5%	20,121	89.0%	5,103	89.0%	691	88.5%	236	92.9%
Letemovir											
	4,466	2,686	100.0%	1,165	100.0%	581	100.0%	*****	*****	*****	*****
0-17 years	54	31	1.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	175	111	4.1%	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	624	387	14.4%	158	13.6%	*****	*****	*****	*****	0	0.0%
41-64 years	1,787	1,083	40.3%	448	38.5%	*****	*****	*****	*****	*****	*****
≥ 65 years	1,826	1,074	40.0%	503	43.2%	229	39.4%	*****	*****	*****	*****
Macimorelin											
Acetate											
	46	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	26	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Meropenem and Vaborbactam											
	4,045	4,031	100.0%	14	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	127	127	3.2%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	1,018	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	2,886	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Neratinib											
Maleate											
	2,965	1,875	100.0%	584	100.0%	425	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	90	15.4%	*****	*****	*****	*****	*****	*****
41-64 years	1,681	1,036	55.3%	343	58.7%	244	57.4%	*****	*****	*****	*****
≥ 65 years	903	611	32.6%	151	25.9%	*****	*****	*****	*****	*****	*****
Netarsudil											
	151,751	74,399	100.0%	54,464	100.0%	19,223	100.0%	2,745	100.0%	920	100.0%
0-17 years	171	106	0.1%	47	0.1%	*****	*****	*****	*****	0	0.0%
18-24 years	183	105	0.1%	58	0.1%	*****	*****	*****	*****	0	0.0%
25-40 years	1,302	733	1.0%	401	0.7%	148	0.8%	*****	*****	*****	*****

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Patients by First Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
41-64 years	16,824	9,094	12.2%	5,301	9.7%	2,052	10.7%	*****	*****	*****	*****
≥ 65 years	133,271	64,361	86.5%	48,657	89.3%	16,988	88.4%	2,436	88.7%	829	90.1%
Ozenoxacin	1,641	1,528	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	372	350	22.9%	22	20.2%	0	0.0%	0	0.0%	0	NaN
18-24 years	156	143	9.4%	*****	*****	0	0.0%	*****	*****	0	NaN
25-40 years	345	321	21.0%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	632	590	38.6%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	136	124	8.1%	*****	*****	*****	*****	0	0.0%	0	NaN
Secnidazole	9,558	9,507	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	121	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	1,808	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	4,706	4,682	49.2%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	2,632	2,616	27.5%	16	32.7%	0	0.0%	0	NaN	0	NaN
≥ 65 years	291	291	3.1%	0	0.0%	0	0.0%	0	NaN	0	NaN
Semaglutide	982,602	429,789	100.0%	329,231	100.0%	174,956	100.0%	36,130	100.0%	12,496	100.0%
0-17 years	459	251	0.1%	123	0.0%	*****	*****	*****	*****	*****	*****
18-24 years	5,849	3,076	0.7%	1,819	0.6%	*****	*****	*****	*****	*****	*****
25-40 years	76,894	37,782	8.8%	23,604	7.2%	12,947	7.4%	2,003	5.5%	558	4.5%
41-64 years	458,381	204,236	47.5%	146,307	44.4%	83,839	47.9%	17,958	49.7%	6,041	48.3%
≥ 65 years	441,019	184,444	42.9%	157,378	47.8%	77,274	44.2%	16,051	44.4%	5,872	47.0%
Sofosbuvir											
Velpatasvir											
Voxilaprevir	5,567	1,661	100.0%	3,660	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	21	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	307	*****	*****	*****	*****	15	6.2%	0	0.0%	0	NaN
41-64 years	3,365	1,040	62.6%	2,142	58.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	1,874	506	30.5%	1,322	36.1%	46	19.0%	0	0.0%	0	NaN
Vestronidase											
Alfa Vjbk	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	12,091	1	28	28	84	1,735	80.5	127.8
0-17 years	*****	5	21	28	28	56	27.5	16.5
18-24 years	*****	14	21	28	49	70	35.0	24.2
25-40 years	*****	1	28	28	84	1,735	82.7	134.1
41-64 years	4,417	1	28	28	84	1,585	89.3	149.0
≥ 65 years	7,181	1	28	28	84	1,568	75.0	112.0
Acalabrutinib	11,134	1	30	60	120	1,823	109.5	147.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	19	30	30	120	180	433	142.0	121.1
41-64 years	1,164	1	30	60	120	1,823	111.1	157.9
≥ 65 years	9,951	1	30	60	120	1,641	109.3	145.7
Angiotensin II	28	1	1	1	1	2	1.0	0.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	13	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	2	1.1	0.3
Benralizumab	24,071	1	1	1	28	1,400	25.7	72.1
0-17 years	370	1	1	21	28	387	27.9	45.0
18-24 years	327	1	1	1	28	924	25.3	64.1
25-40 years	1,699	1	1	1	28	1,400	32.7	81.3
41-64 years	8,409	1	1	1	28	1,324	36.4	84.4
≥ 65 years	13,266	1	1	1	1	985	18.0	61.5
Benznidazole	51	1	30	30	60	176	41.7	29.8
0-17 years	*****	1	4	7	19	30	11.3	12.8
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	6	6	30	102	102	46.0	50.0
41-64 years	35	7	30	30	60	176	45.9	29.8
≥ 65 years	*****	7	15	45	60	60	38.3	24.2
Copanlisib	304	1	1	1	1	28	1.3	2.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	NaN
25-40 years	*****	1	1	1	28	28	10.0	15.6
41-64 years	*****	1	1	1	1	21	1.3	2.3
≥ 65 years	227	1	1	1	1	28	1.2	2.5

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Emicizumab	2,033	1	1	1	28	1,575	67.1	199.0
0-17 years	643	1	1	22	56	1,575	97.7	225.0
18-24 years	190	1	1	14	56	1,276	104.8	240.9
25-40 years	442	1	1	1	28	1,431	63.2	191.9
41-64 years	456	1	1	1	1	1,551	49.4	189.2
≥ 65 years	302	1	1	1	1	1,172	10.5	90.3
Enasidenib	1,480	1	30	30	90	1,619	80.1	118.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	60	180	180	90.0	79.4
25-40 years	*****	12	30	30	60	169	51.1	44.1
41-64 years	195	5	30	30	90	750	77.2	95.9
≥ 65 years	1,264	1	30	30	90	1,619	81.0	122.2
Ertugliflozin	18,637	1	30	30	90	1,544	79.3	117.2
0-17 years	13	5	30	30	30	98	32.6	20.9
18-24 years	101	10	30	30	60	223	50.7	38.5
25-40 years	1,564	1	30	30	71	880	59.3	64.2
41-64 years	12,974	1	30	30	90	1,529	71.1	95.4
≥ 65 years	3,985	1	30	60	90	1,544	115.1	176.8
Ertugliflozin and Sitagliptin	836	1	30	60	96	1,124	104.1	137.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	180	180	80.0	86.6
25-40 years	*****	15	30	60	127	390	88.5	89.7
41-64 years	515	1	30	30	101	1,124	106.5	150.8
≥ 65 years	251	1	30	60	90	821	103.6	118.5
Ertugliflozin and Metformin	1,348	1	30	30	90	1,380	83.7	128.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	15	30	30	30	90	34.9	21.2
25-40 years	*****	1	30	30	60	810	67.7	100.1
41-64 years	959	1	30	30	90	1,380	76.3	111.9
≥ 65 years	236	2	30	60	120	991	125.2	188.1
Glecaprevir and Pibrentasvir	74,786	1	28	56	56	1,092	50.9	29.1
0-17 years	23	14	28	56	84	140	63.7	33.1
18-24 years	1,211	1	28	56	56	336	47.7	29.8
25-40 years	15,058	1	28	56	56	448	47.3	26.1
41-64 years	44,253	1	28	56	56	1,092	51.6	31.6

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	14,241	1	28	56	56	389	52.9	22.6
Guselkumab	25,685	1	28	56	86	1,843	92.5	142.9
0-17 years	37	1	28	28	30	112	30.6	24.1
18-24 years	934	1	28	31	69	1,626	80.4	122.9
25-40 years	5,796	1	28	41	84	1,536	90.0	139.1
41-64 years	14,568	1	28	56	88	1,843	96.1	147.3
≥ 65 years	4,350	1	28	56	84	1,579	87.0	136.6
Inotuzumab Ozogamicin	592	1	1	1	1	30	1.2	1.9
0-17 years	21	1	1	1	1	1	1.0	0.0
18-24 years	26	1	1	1	1	1	1.0	0.0
25-40 years	68	1	1	1	1	1	1.0	0.0
41-64 years	127	1	1	1	1	21	1.2	1.8
≥ 65 years	350	1	1	1	1	30	1.2	2.3
Latanoprostene Bunod Ophthalmic Solution	54,803	1	25	38	75	1,739	66.9	100.9
0-17 years	43	18	30	30	60	220	48.3	38.9
18-24 years	63	3	25	30	43	565	43.7	69.1
25-40 years	471	1	25	30	50	461	49.7	54.2
41-64 years	6,604	1	25	30	60	1,724	60.4	89.9
≥ 65 years	47,622	1	25	38	75	1,739	68.0	102.7
Letermovir	4,466	1	28	28	70	1,430	58.8	71.9
0-17 years	54	7	28	29	84	270	59.1	50.9
18-24 years	175	11	28	28	56	1,008	54.8	84.6
25-40 years	624	1	28	28	61	672	55.0	58.1
41-64 years	1,787	1	28	28	70	1,430	58.3	69.1
≥ 65 years	1,826	1	28	28	84	1,405	60.9	77.9
Macimorelin Acetate	46	1	1	1	1	31	4.8	9.8
0-17 years	*****	1	1	1	1	1	1.0	NaN
18-24 years	*****	1	1	16	30	30	15.5	20.5
25-40 years	*****	1	1	1	1	28	3.1	7.5
41-64 years	26	1	1	1	1	31	5.5	10.8
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Meropenem and Vaborbactam	4,045	1	1	1	1	49	1.5	3.1
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	127	1	1	1	1	25	2.0	3.8
41-64 years	1,018	1	1	1	1	47	1.8	4.0
≥ 65 years	2,886	1	1	1	1	49	1.4	2.7
Neratinib Maleate	2,965	1	30	30	60	937	72.2	98.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	28	29	30	30	30	29.5	1.0
25-40 years	*****	1	30	30	60	744	75.2	104.4
41-64 years	1,681	1	30	30	60	937	76.0	105.9
≥ 65 years	903	1	30	30	60	904	64.2	79.5
Netarsudil	151,751	1	25	37	84	1,637	72.3	110.4
0-17 years	171	1	25	30	60	480	54.4	68.8
18-24 years	183	1	25	30	60	652	53.6	64.5
25-40 years	1,302	1	25	30	60	988	60.9	81.6
41-64 years	16,824	1	25	30	75	1,527	68.6	104.1
≥ 65 years	133,271	1	25	37	86	1,637	72.9	111.5
Ozenoxacin	1,641	2	30	30	30	450	29.7	15.5
0-17 years	372	2	30	30	30	90	28.7	10.1
18-24 years	156	5	30	30	30	450	31.6	35.6
25-40 years	345	2	30	30	30	120	29.9	10.6
41-64 years	632	2	30	30	30	150	29.3	11.8
≥ 65 years	136	5	30	30	30	120	31.9	14.7
Secnidazole	9,558	1	1	1	1	168	2.7	7.3
0-17 years	121	1	1	1	1	60	2.6	7.4
18-24 years	1,808	1	1	1	1	90	2.6	7.0
25-40 years	4,706	1	1	1	1	168	2.6	7.3
41-64 years	2,632	1	1	1	1	90	2.9	7.5
≥ 65 years	291	1	1	1	1	30	2.8	7.0
Semaglutide	982,602	1	28	56	90	1,782	97.9	146.5
0-17 years	459	2	28	30	84	784	69.5	85.9
18-24 years	5,849	1	28	30	84	1,568	72.5	101.5
25-40 years	76,894	1	28	32	84	1,658	82.9	120.6
41-64 years	458,381	1	28	50	90	1,766	99.5	149.2
≥ 65 years	441,019	1	28	56	90	1,782	99.1	148.1
Sofosbuvir Velpatasvir Voxilaprevir	5,567	1	28	84	84	497	66.8	35.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	21	10	28	38	57	140	51.7	32.9
25-40 years	307	3	28	84	84	224	62.9	33.9
41-64 years	3,365	1	28	84	84	497	66.7	38.4
≥ 65 years	1,874	2	28	84	84	308	67.7	29.1
Vestronidase Alfa Vjbk	*****	1	14	42	140	180	63.0	66.1
0-17 years	*****	1	14	14	56	180	53.0	74.0
18-24 years	*****	28	28	56	140	140	74.7	58.3
25-40 years	*****	1	1	71	140	140	70.5	98.3
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Abemaciclib</i>	20,867	12,247	58.7%	5,211	25.0%	3,051	14.6%	300	1.4%	58	0.3%
<i>Acalabrutinib</i>	24,085	12,444	51.7%	6,801	28.2%	4,339	18.0%	448	1.9%	53	0.2%
<i>Angiotensin II</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Benralizumab</i>	157,725	143,274	90.8%	8,948	5.7%	4,842	3.1%	579	0.4%	82	0.1%
<i>Benznidazole</i>	13	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Copanlisib</i>	4,055	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Emicizumab</i>	19,727	19,121	96.9%	323	1.6%	217	1.1%	48	0.2%	18	0.1%
<i>Enasidenib</i>	1,680	857	51.0%	518	30.8%	286	17.0%	*****	*****	*****	*****
<i>Ertugliflozin</i>	23,931	12,878	53.8%	7,224	30.2%	3,306	13.8%	415	1.7%	108	0.5%
<i>Ertugliflozin and Sitagliptin</i>	1,924	959	49.8%	613	31.9%	322	16.7%	*****	*****	*****	*****
<i>Ertugliflozin and Metformin</i>	2,350	1,391	59.2%	633	26.9%	281	12.0%	34	1.4%	11	0.5%
<i>Glecaprevir and Pibrentasvir</i>	23,475	19,729	84.0%	3,570	15.2%	*****	*****	*****	*****	*****	*****
<i>Guselkumab</i>	69,939	24,145	34.5%	31,830	45.5%	12,510	17.9%	1,206	1.7%	248	0.4%
<i>Inotuzumab Ozogamicin</i>	2,593	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Latanoprostene Bunod Ophthalmic Solution</i>	170,889	92,526	54.1%	63,445	37.1%	13,541	7.9%	1,114	0.7%	263	0.2%
<i>Letermovir</i>	5,323	3,192	60.0%	1,522	28.6%	575	10.8%	*****	*****	*****	*****
<i>Macimorelin Acetate</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Meropenem and Vaborbactam</i>	535	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Neratinib Maleate</i>	4,385	2,602	59.3%	1,048	23.9%	696	15.9%	*****	*****	*****	*****
<i>Netarsudil</i>	510,288	306,506	60.1%	155,767	30.5%	43,089	8.4%	3,976	0.8%	950	0.2%
<i>Ozenoxacin</i>	304	279	91.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Secnidazole</i>	3,060	3,029	99.0%	31	1.0%	0	0.0%	0	0.0%	0	0.0%
<i>Semaglutide</i>	1,901,829	982,359	51.7%	578,129	30.4%	286,225	15.0%	43,009	2.3%	12,107	0.6%
<i>Sofosbuvir Velpatasvir Voxilaprevir</i>	2,177	1,322	60.7%	831	38.2%	24	1.1%	0	0.0%	0	0.0%
<i>Vestronidase Alfa Vjbk</i>	44	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Abemaciclib</i>	20,867	1	28	28	56	1,452	66.1	91.6
<i>Acalabrutinib</i>	24,085	1	30	30	90	1,468	77.6	94.7
<i>Angiotensin II</i>	*****	1	1	1	1	1	1.0	0.0
<i>Benralizumab</i>	157,725	1	1	1	1	1,414	12.7	49.4
<i>Benznidazole</i>	13	12	30	30	30	60	29.4	10.9
<i>Copanlisib</i>	4,055	1	1	1	1	84	1.1	2.4
<i>Emicizumab</i>	19,727	1	1	1	1	1,251	7.2	44.2
<i>Enasidenib</i>	1,680	1	30	30	90	1,119	72.1	84.1
<i>Ertugliflozin</i>	23,931	1	30	30	90	1,398	73.7	100.7
<i>Ertugliflozin and Sitagliptin</i>	1,924	1	30	31	90	780	76.5	84.3
<i>Ertugliflozin and Metformin</i>	2,350	1	30	30	83	1,063	68.5	95.4
<i>Glecaprevir and Pibrentasvir</i>	23,475	1	28	28	28	1,106	31.6	17.9
<i>Guselkumab</i>	69,939	1	30	56	56	1,637	71.9	99.7
<i>Inotuzumab Ozogamicin</i>	2,593	1	1	1	1	56	1.1	1.7
<i>Latanoprostene Bunod Ophthalmic Solution</i>	170,889	1	25	30	55	1,625	52.7	67.4
<i>Letermovir</i>	5,323	1	28	28	56	1,213	55.5	66.9
<i>Macimorelin Acetate</i>	*****	1	1	1	1	1	1.0	NaN
<i>Meropenem and Vaborbactam</i>	535	1	1	1	3	668	5.4	30.0
<i>Neratinib Maleate</i>	4,385	1	30	30	60	900	66.6	75.6
<i>Netarsudil</i>	510,288	1	25	30	57	1,524	52.9	72.4
<i>Ozenoxacin</i>	304	3	30	30	30	180	30.2	18.7
<i>Secnidazole</i>	3,060	1	1	1	1	90	3.1	8.3
<i>Semaglutide</i>	1,901,829	1	28	30	84	1,648	79.3	114.2
<i>Sofosbuvir Velpatasvir Voxilaprevir</i>	2,177	1	28	28	56	342	39.3	20.1
<i>Vestronidase Alfa Vjbk</i>	44	1	1	28	45	168	35.0	41.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Abemaciclib	20,867	12,247	100.0%	5,211	100.0%	3,051	100.0%	300	100.0%	58	100.0%
Female	20,553	12,078	98.6%	5,126	98.4%	*****	*****	*****	*****	*****	*****
Male	314	169	1.4%	85	1.6%	*****	*****	*****	*****	*****	*****
Acalabrutinib	24,085	12,444	100.0%	6,801	100.0%	4,339	100.0%	448	100.0%	53	100.0%
Female	9,019	4,630	37.2%	2,588	38.1%	1,617	37.3%	160	35.7%	24	45.3%
Male	15,066	7,814	62.8%	4,213	61.9%	2,722	62.7%	288	64.3%	29	54.7%
Angiotensin II	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Benralizumab	157,725	143,274	100.0%	8,948	100.0%	4,842	100.0%	579	100.0%	82	100.0%
Female	100,779	91,133	63.6%	5,964	66.7%	3,231	66.7%	395	68.2%	56	68.3%
Male	56,946	52,141	36.4%	2,984	33.3%	1,611	33.3%	184	31.8%	26	31.7%
Benznidazole	13	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Copanlisib	4,055	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	1,917	1,917	47.3%	0	0.0%	0	NaN	0	NaN	0	NaN
Male	2,138	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Emicizumab	19,727	19,121	100.0%	323	100.0%	217	100.0%	48	100.0%	18	100.0%
Female	258	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Male	19,469	*****	*****	*****	*****	*****	*****	*****	*****	18	100.0%
Enasidenib	1,680	857	100.0%	518	100.0%	286	100.0%	*****	*****	*****	*****
Female	764	400	46.7%	228	44.0%	*****	*****	*****	*****	*****	*****
Male	916	457	53.3%	290	56.0%	*****	*****	*****	*****	*****	*****
Ertugliflozin	23,931	12,878	100.0%	7,224	100.0%	3,306	100.0%	415	100.0%	108	100.0%
Female	11,013	6,122	47.5%	3,209	44.4%	1,469	44.4%	167	40.2%	46	42.6%
Male	12,918	6,756	52.5%	4,015	55.6%	1,837	55.6%	248	59.8%	62	57.4%
Ertugliflozin and Sitagliptin	1,924	959	100.0%	613	100.0%	322	100.0%	*****	*****	*****	*****
Female	807	441	46.0%	226	36.9%	128	39.8%	*****	*****	*****	*****
Male	1,117	518	54.0%	387	63.1%	194	60.2%	*****	*****	*****	*****
Ertugliflozin and Metformin	2,350	1,391	100.0%	633	100.0%	281	100.0%	*****	*****	*****	*****
Female	850	509	36.6%	226	35.7%	96	34.2%	*****	*****	*****	*****
Male	1,500	882	63.4%	407	64.3%	185	65.8%	*****	*****	*****	*****
Glecaprevir and Pibrentasvir	23,475	19,729	100.0%	3,570	100.0%	*****	*****	*****	*****	*****	*****
Female	9,481	8,083	41.0%	1,324	37.1%	*****	*****	0	0.0%	0	0.0%
Male	13,994	11,646	59.0%	2,246	62.9%	*****	*****	*****	*****	*****	*****
Guselkumab	69,939	24,145	100.0%	31,830	100.0%	12,510	100.0%	1,206	100.0%	248	100.0%
Female	32,732	11,279	46.7%	14,652	46.0%	6,090	48.7%	577	47.8%	134	54.0%
Male	37,207	12,866	53.3%	17,178	54.0%	6,420	51.3%	629	52.2%	114	46.0%

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
Inotuzumab											
Ozogamicin	2,593	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Female	1,296	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	1,297	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Latanoprostene											
Bunod											
Ophthalmic											
Solution	170,889	92,526	100.0%	63,445	100.0%	13,541	100.0%	1,114	100.0%	263	100.0%
Female	102,519	56,294	60.8%	37,423	59.0%	7,977	58.9%	669	60.1%	156	59.3%
Male	68,370	36,232	39.2%	26,022	41.0%	5,564	41.1%	445	39.9%	107	40.7%
Letemovir											
5,323	3,192	100.0%	1,522	100.0%	575	100.0%	*****	*****	*****	*****	
Female	2,358	1,427	44.7%	677	44.5%	240	41.7%	*****	*****	*****	*****
Male	2,965	1,765	55.3%	845	55.5%	335	58.3%	*****	*****	*****	*****
Macimorelin											
Acetate											
*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN	
Female	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Meropenem and											
Vaborbactam											
535	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Female	288	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	247	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
Neratinib											
Maleate											
4,385	2,602	100.0%	1,048	100.0%	696	100.0%	*****	*****	*****	*****	
Female	4,337	2,572	98.8%	*****	*****	*****	*****	*****	*****	*****	*****
Male	48	30	1.2%	*****	*****	*****	*****	0	0.0%	0	0.0%
Netarsudil											
510,288	306,506	100.0%	155,767	100.0%	43,089	100.0%	3,976	100.0%	950	100.0%	
Female	299,304	182,211	59.4%	89,554	57.5%	24,727	57.4%	2,250	56.6%	562	59.2%
Male	210,984	124,295	40.6%	66,213	42.5%	18,362	42.6%	1,726	43.4%	388	40.8%
Ozenoxacin											
304	279	100.0%	*****	*****	*****	*****	0	NaN	0	NaN	
Female	192	*****	*****	*****	*****	*****	0	NaN	0	NaN	
Male	112	*****	*****	*****	*****	*****	0	NaN	0	NaN	
Secnidazole											
3,060	3,029	100.0%	31	100.0%	0	NaN	0	NaN	0	NaN	
Female	*****	*****	*****	31	100.0%	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
1,901,82											
Semaglutide											
9	982,359	100.0%	578,129	100.0%	286,225	100.0%	43,009	100.0%	12,107	100.0%	
	1,060,92										
Female	4	558,343	56.8%	318,571	55.1%	155,492	54.3%	22,464	52.2%	6,054	50.0%
Male	840,905	424,016	43.2%	259,558	44.9%	130,733	45.7%	20,545	47.8%	6,053	50.0%
Sofosbuvir											
Velpatasvir											
Voxilaprevir	2,177	1,322	100.0%	831	100.0%	24	100.0%	0	NaN	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Female	602	379	28.7%	*****	*****	*****	*****	0	NaN	0	NaN
Male	1,575	943	71.3%	*****	*****	*****	*****	0	NaN	0	NaN
Vestronidase											
Alfa Vjvk	44	31	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	*****	31	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Male	*****	0	0.0%	*****	*****	*****	*****	0	NaN	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	20,867	1	28	28	56	1,452	66.1	91.6
Female	20,553	1	28	28	56	1,452	66.0	91.6
Male	314	8	28	28	84	758	73.1	93.9
Acalabrutinib	24,085	1	30	30	90	1,468	77.6	94.7
Female	9,019	1	30	30	90	1,468	77.7	96.0
Male	15,066	1	30	30	90	1,293	77.6	93.9
Angiotensin II	*****	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Benralizumab	157,725	1	1	1	1	1,414	12.7	49.4
Female	100,779	1	1	1	1	1,414	13.3	51.0
Male	56,946	1	1	1	1	1,243	11.7	46.3
Benznidazole	13	12	30	30	30	60	29.4	10.9
Female	*****	30	30	30	30	30	30.0	0.0
Male	*****	12	18	26	30	60	28.7	16.9
Copanlisib	4,055	1	1	1	1	84	1.1	2.4
Female	1,917	1	1	1	1	1	1.0	0.0
Male	2,138	1	1	1	1	84	1.2	3.3
Emicizumab	19,727	1	1	1	1	1,251	7.2	44.2
Female	258	1	1	1	1	685	9.7	61.0
Male	19,469	1	1	1	1	1,251	7.1	43.9
Enasidenib	1,680	1	30	30	90	1,119	72.1	84.1
Female	764	1	30	30	90	1,119	70.5	84.7
Male	916	1	30	35	90	976	73.4	83.6
Ertugliflozin	23,931	1	30	30	90	1,398	73.7	100.7
Female	11,013	1	30	30	90	1,398	70.7	97.3
Male	12,918	1	30	30	90	1,241	76.4	103.4
Ertugliflozin and Sitagliptin	1,924	1	30	31	90	780	76.5	84.3
Female	807	1	30	30	90	780	73.3	85.7
Male	1,117	1	30	60	90	748	78.8	83.2
Ertugliflozin and Metformin	2,350	1	30	30	83	1,063	68.5	95.4
Female	850	1	30	30	82	1,063	69.9	103.3
Male	1,500	1	30	30	84	974	67.7	90.6
Glecaprevir and Pibrentasvir	23,475	1	28	28	28	1,106	31.6	17.9

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	9,481	1	28	28	28	336	31.3	16.0
Male	13,994	1	28	28	28	1,106	31.8	19.1
Guselkumab	69,939	1	30	56	56	1,637	71.9	99.7
Female	32,732	1	30	56	56	1,637	73.5	103.5
Male	37,207	1	30	53	56	1,627	70.5	96.1
Inotuzumab Ozogamicin	2,593	1	1	1	1	56	1.1	1.7
Female	1,296	1	1	1	1	56	1.1	1.9
Male	1,297	1	1	1	1	38	1.1	1.3
Latanoprostene Bunod Ophthalmic Solution	170,889	1	25	30	55	1,625	52.7	67.4
Female	102,519	1	25	30	50	1,625	52.1	67.3
Male	68,370	1	25	30	60	1,619	53.7	67.5
Letermovir	5,323	1	28	28	56	1,213	55.5	66.9
Female	2,358	1	28	28	56	1,213	54.4	65.0
Male	2,965	1	28	28	56	1,148	56.3	68.3
Macimorelin Acetate	*****	1	1	1	1	1	1.0	NaN
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	*****	1	1	1	1	1	1.0	NaN
Meropenem and Vaborbactam	535	1	1	1	3	668	5.4	30.0
Female	288	1	1	1	2	668	6.2	40.2
Male	247	1	1	1	4	57	4.6	7.7
Neratinib Maleate	4,385	1	30	30	60	900	66.6	75.6
Female	4,337	1	30	30	60	900	66.6	75.7
Male	48	15	30	30	60	360	62.3	71.1
Netarsudil	510,288	1	25	30	57	1,524	52.9	72.4
Female	299,304	1	25	30	56	1,524	52.2	72.0
Male	210,984	1	25	30	60	1,493	53.9	73.1
Ozenoxacin	304	3	30	30	30	180	30.2	18.7
Female	192	3	30	30	30	180	30.3	19.3
Male	112	4	30	30	30	127	30.1	17.8
Secnidazole	3,060	1	1	1	1	90	3.1	8.3
Female	*****	1	1	1	1	90	3.1	8.3
Male	*****	1	1	1	1	1	1.0	0.0
Semaglutide	1,901,829	1	28	30	84	1,648	79.3	114.2
Female	1,060,924	1	28	30	84	1,630	76.9	110.4

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	840,905	1	28	30	84	1,648	82.3	118.8
Sofosbuvir Velpatasvir Voxilaprevir	2,177	1	28	28	56	342	39.3	20.1
Female	602	3	28	28	56	140	38.4	18.5
Male	1,575	1	28	28	56	342	39.6	20.7
Vestronidase Alfa Vjbk	44	1	1	28	45	168	35.0	41.1
Female	*****	1	1	28	32	168	33.1	40.0
Male	*****	33	33	75	117	117	75.0	59.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
Abemaciclib	20,867	12,247	100.0%	5,211	100.0%	3,051	100.0%	300	100.0%	58	100.0%
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	872	533	4.4%	*****	*****	118	3.9%	*****	*****	*****	*****
41-64 years	7,802	4,699	38.4%	1,883	36.1%	1,093	35.8%	*****	*****	*****	*****
≥ 65 years	12,177	7,003	57.2%	3,121	59.9%	1,840	60.3%	179	59.7%	34	58.6%
Acalabrutinib	24,085	12,444	100.0%	6,801	100.0%	4,339	100.0%	448	100.0%	53	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	33	18	0.1%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	2,510	1,326	10.7%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	21,542	11,100	89.2%	6,080	89.4%	3,907	90.0%	*****	*****	*****	*****
Angiotensin II	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Benralizumab	157,725	143,274	100.0%	8,948	100.0%	4,842	100.0%	579	100.0%	82	100.0%
0-17 years	1,426	1,181	0.8%	157	1.8%	*****	*****	*****	*****	0	0.0%
18-24 years	1,280	1,061	0.7%	148	1.7%	*****	*****	*****	*****	0	0.0%
25-40 years	7,206	5,862	4.1%	888	9.9%	409	8.4%	*****	*****	*****	*****
41-64 years	42,120	34,747	24.3%	4,655	52.0%	2,390	49.4%	*****	*****	*****	*****
≥ 65 years	105,693	100,423	70.1%	3,100	34.6%	1,904	39.3%	218	37.7%	48	58.5%
Benznidazole	13	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
Coplanisib	4,055	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	3,552	3,552	87.7%	0	0.0%	0	NaN	0	NaN	0	NaN
Emicizumab	19,727	19,121	100.0%	323	100.0%	217	100.0%	48	100.0%	18	100.0%
0-17 years	4,797	4,455	23.3%	180	55.7%	122	56.2%	*****	*****	*****	*****
18-24 years	1,274	*****	*****	62	19.2%	33	15.2%	*****	*****	*****	*****
25-40 years	5,458	5,367	28.1%	48	14.9%	27	12.4%	*****	*****	*****	*****
41-64 years	5,495	5,427	28.4%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	2,703	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
Enasidenib	1,680	857	100.0%	518	100.0%	286	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	219	135	15.8%	*****	*****	*****	*****	*****	*****	0	0.0%
≥ 65 years	1,443	709	82.7%	463	89.4%	253	88.5%	*****	*****	*****	*****
Ertugliflozin	23,931	12,878	100.0%	7,224	100.0%	3,306	100.0%	415	100.0%	108	100.0%
0-17 years	13	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	110	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	1,883	1,163	9.0%	503	7.0%	*****	*****	*****	*****	*****	*****
41-64 years	15,701	8,820	68.5%	4,692	65.0%	1,918	58.0%	*****	*****	*****	*****
≥ 65 years	6,224	2,808	21.8%	1,998	27.7%	1,193	36.1%	174	41.9%	51	47.2%
Ertugliflozin and Sitagliptin	1,924	959	100.0%	613	100.0%	322	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	1,216	613	63.9%	367	59.9%	*****	*****	15	53.6%	*****	*****
≥ 65 years	508	214	22.3%	200	32.6%	*****	*****	*****	*****	0	0.0%
Ertugliflozin and	2,350	1,391	100.0%	633	100.0%	281	100.0%	34	100.0%	11	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	66	10.4%	*****	*****	*****	*****	*****	*****
41-64 years	1,574	967	69.5%	405	64.0%	178	63.3%	*****	*****	*****	*****
≥ 65 years	493	240	17.3%	162	25.6%	73	26.0%	*****	*****	*****	*****
Glecaprevir and Pibrentasvir	23,475	19,729	100.0%	3,570	100.0%	*****	*****	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	4,449	3,972	20.1%	433	12.1%	*****	*****	*****	*****	*****	*****
41-64 years	14,735	12,159	61.6%	2,459	68.9%	*****	*****	*****	*****	0	0.0%
≥ 65 years	3,932	3,277	16.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
Guselkumab	69,939	24,145	100.0%	31,830	100.0%	12,510	100.0%	1,206	100.0%	248	100.0%
0-17 years	75	43	0.2%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	2,548	891	3.7%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	16,126	5,605	23.2%	7,668	24.1%	2,574	20.6%	*****	*****	*****	*****
41-64 years	40,568	13,767	57.0%	18,791	59.0%	7,206	57.6%	664	55.1%	140	56.5%
≥ 65 years	10,622	3,839	15.9%	4,097	12.9%	2,350	18.8%	270	22.4%	66	26.6%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
Inotuzumab											
Ozogamicin	2,593	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
0-17 years	34	34	1.3%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	82	82	3.2%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	239	239	9.2%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	538	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	1,700	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Latanoprostene Bunod Ophthalmic Solution											
	170,889	92,526	100.0%	63,445	100.0%	13,541	100.0%	1,114	100.0%	263	100.0%
0-17 years	84	53	0.1%	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	143	97	0.1%	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	1,278	784	0.8%	386	0.6%	95	0.7%	*****	*****	*****	*****
41-64 years	18,622	11,281	12.2%	5,772	9.1%	1,421	10.5%	*****	*****	*****	*****
≥ 65 years	150,762	80,311	86.8%	57,225	90.2%	12,012	88.7%	972	87.3%	242	92.0%
Letemovir											
	5,323	3,192	100.0%	1,522	100.0%	575	100.0%	*****	*****	*****	*****
0-17 years	70	47	1.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	176	118	3.7%	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	875	557	17.4%	239	15.7%	*****	*****	*****	*****	*****	*****
41-64 years	2,224	1,353	42.4%	620	40.7%	*****	*****	*****	*****	*****	*****
≥ 65 years	1,978	1,117	35.0%	601	39.5%	244	42.4%	*****	*****	*****	*****
Macimorelin Acetate											
	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Meropenem and Vaborbactam											
	535	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	186	*****	*****	*****	*****	0	0.0%	*****	*****	0	NaN
≥ 65 years	274	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
Neratinib Maleate											
	4,385	2,602	100.0%	1,048	100.0%	696	100.0%	*****	*****	*****	*****
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	105	10.0%	*****	*****	*****	*****	0	0.0%
41-64 years	2,584	1,517	58.3%	637	60.8%	406	58.3%	24	64.9%	0	0.0%
≥ 65 years	1,289	777	29.9%	306	29.2%	*****	*****	*****	*****	*****	*****
Netarsudil	510,288	306,506	100.0%	155,767	100.0%	43,089	100.0%	3,976	100.0%	950	100.0%
0-17 years	339	226	0.1%	84	0.1%	*****	*****	*****	*****	0	0.0%
18-24 years	306	190	0.1%	85	0.1%	*****	*****	*****	*****	0	0.0%
25-40 years	3,685	2,388	0.8%	974	0.6%	294	0.7%	*****	*****	*****	*****
41-64 years	46,352	28,690	9.4%	13,122	8.4%	4,011	9.3%	*****	*****	*****	*****
≥ 65 years	459,606	275,012	89.7%	141,502	90.8%	38,730	89.9%	3,499	88.0%	863	90.8%
Ozenoxacin	304	279	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	54	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	20	20	7.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	64	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	124	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	42	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Secnidazole	3,060	3,029	100.0%	31	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	21	21	0.7%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	509	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	1,474	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	968	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	88	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Semaglutide	1,901,829	982,359	100.0%	578,129	100.0%	286,225	100.0%	43,009	100.0%	12,107	100.0%
0-17 years	730	448	0.0%	179	0.0%	92	0.0%	*****	*****	*****	*****
18-24 years	9,005	5,253	0.5%	2,562	0.4%	1,067	0.4%	*****	*****	*****	*****
25-40 years	133,218	75,580	7.7%	37,648	6.5%	17,360	6.1%	2,135	5.0%	495	4.1%
41-64 years	911,487	476,165	48.5%	270,851	46.8%	137,726	48.1%	20,869	48.5%	5,876	48.5%
≥ 65 years	847,389	424,913	43.3%	266,889	46.2%	129,980	45.4%	19,886	46.2%	5,721	47.3%
Sofosbuvir											
Velpatasvir											
Voxilaprevir	2,177	1,322	100.0%	831	100.0%	24	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	12	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	124	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	1,385	878	66.4%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	656	349	26.4%	*****	*****	*****	*****	0	NaN	0	NaN
Vestronidase											
Alfa Vjbk	44	31	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	25	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
≥ 65 years	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN	

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	20,867	1	28	28	56	1,452	66.1	91.6
0-17 years	*****	28	28	28	56	84	40.4	20.3
18-24 years	*****	4	28	28	28	31	25.0	9.3
25-40 years	872	1	28	28	56	1,412	65.7	98.4
41-64 years	7,802	1	28	28	56	1,356	63.9	90.0
≥ 65 years	12,177	1	28	28	60	1,452	67.7	92.2
Acalabrutinib	24,085	1	30	30	90	1,468	77.6	94.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	33	9	30	30	60	368	57.8	64.6
41-64 years	2,510	1	30	30	90	1,170	74.5	91.4
≥ 65 years	21,542	1	30	30	90	1,468	78.0	95.1
Angiotensin II	*****	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Benralizumab	157,725	1	1	1	1	1,414	12.7	49.4
0-17 years	1,426	1	1	1	30	681	24.1	58.2
18-24 years	1,280	1	1	1	30	672	22.6	56.6
25-40 years	7,206	1	1	1	28	804	23.9	60.6
41-64 years	42,120	1	1	1	28	1,344	23.2	64.6
≥ 65 years	105,693	1	1	1	1	1,414	7.5	39.5
Benznidazole	13	12	30	30	30	60	29.4	10.9
0-17 years	*****	30	30	30	30	30	30.0	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	12	22	30	30	60	29.3	11.9
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Copanlisib	4,055	1	1	1	1	84	1.1	2.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	15	56	70	84	45.8	32.9

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	3,552	1	1	1	1	1	1.0	0.0
Emicizumab	19,727	1	1	1	1	1,251	7.2	44.2
0-17 years	4,797	1	1	1	1	1,193	15.3	66.9
18-24 years	1,274	1	1	1	2	1,169	14.9	53.6
25-40 years	5,458	1	1	1	1	1,251	4.8	39.3
41-64 years	5,495	1	1	1	1	980	3.4	26.2
≥ 65 years	2,703	1	1	1	1	602	1.6	13.9
Enasidenib	1,680	1	30	30	90	1,119	72.1	84.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	30	30	30.0	0.0
25-40 years	*****	1	30	30	60	180	49.4	46.8
41-64 years	219	3	30	30	60	420	58.7	60.2
≥ 65 years	1,443	1	30	40	90	1,119	74.5	87.3
Ertugliflozin	23,931	1	30	30	90	1,398	73.7	100.7
0-17 years	13	4	23	30	30	43	26.2	9.9
18-24 years	110	1	30	30	60	559	48.6	58.0
25-40 years	1,883	1	30	30	60	1,061	61.4	86.1
41-64 years	15,701	1	30	30	83	1,398	67.0	90.3
≥ 65 years	6,224	1	30	60	90	1,275	94.9	124.5
Ertugliflozin and Sitagliptin	1,924	1	30	31	90	780	76.5	84.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	30	90	42.0	26.8
25-40 years	*****	10	30	30	60	450	58.5	61.9
41-64 years	1,216	1	30	30	90	780	76.0	84.2
≥ 65 years	508	5	30	60	90	720	84.9	90.9
Ertugliflozin and Metformin	2,350	1	30	30	83	1,063	68.5	95.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	95	160	160	95.0	91.9
25-40 years	*****	1	30	30	60	848	59.8	87.3
41-64 years	1,574	1	30	30	60	1,063	64.0	89.5
≥ 65 years	493	1	30	39	90	887	87.7	114.1
Glecaprevir and Pibrentasvir	23,475	1	28	28	28	1,106	31.6	17.9
0-17 years	*****	28	28	28	28	28	28.0	0.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	1	28	28	28	280	30.7	21.8
25-40 years	4,449	1	28	28	28	1,106	30.2	23.6
41-64 years	14,735	1	28	28	28	420	31.8	16.8
≥ 65 years	3,932	1	28	28	28	168	32.6	13.2
Guselkumab	69,939	1	30	56	56	1,637	71.9	99.7
0-17 years	75	1	30	30	56	407	47.0	58.9
18-24 years	2,548	1	30	49	56	1,505	63.9	76.9
25-40 years	16,126	1	30	31	56	1,530	67.3	89.1
41-64 years	40,568	1	30	50	56	1,637	72.1	98.3
≥ 65 years	10,622	1	28	56	96	1,627	80.6	122.1
Inotuzumab Ozogamicin	2,593	1	1	1	1	56	1.1	1.7
0-17 years	34	1	1	1	1	1	1.0	0.0
18-24 years	82	1	1	1	1	1	1.0	0.0
25-40 years	239	1	1	1	1	2	1.0	0.1
41-64 years	538	1	1	1	1	38	1.1	1.6
≥ 65 years	1,700	1	1	1	1	56	1.1	1.9
Latanoprostene Bunod Ophthalmic Solution	170,889	1	25	30	55	1,625	52.7	67.4
0-17 years	84	1	25	30	45	469	48.6	58.3
18-24 years	143	1	25	30	50	900	49.5	83.6
25-40 years	1,278	1	25	30	50	990	50.4	68.7
41-64 years	18,622	1	25	30	50	1,370	51.0	65.7
≥ 65 years	150,762	1	25	30	56	1,625	53.0	67.6
Letermovir	5,323	1	28	28	56	1,213	55.5	66.9
0-17 years	70	7	28	28	56	148	41.6	31.9
18-24 years	176	2	28	28	56	812	49.4	80.0
25-40 years	875	1	28	28	56	981	50.9	60.8
41-64 years	2,224	1	28	28	56	749	53.9	58.5
≥ 65 years	1,978	1	28	28	56	1,213	60.3	76.8
Macimorelin Acetate	1	1	1	1	1	1	1.0	NaN
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	*****	1	1	1	1	1	1.0	NaN
Meropenem and Vaborbactam	535	1	1	1	3	668	5.4	30.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	7	33	5.5	7.7
41-64 years	186	1	1	1	4	668	7.8	49.3
≥ 65 years	274	1	1	1	3	104	3.8	9.5
Neratinib Maleate	4,385	1	30	30	60	900	66.6	75.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	6	30	30	90	540	72.4	86.9
41-64 years	2,584	1	30	30	60	720	66.3	74.4
≥ 65 years	1,289	4	30	30	60	900	65.0	73.3
Netarsudil	510,288	1	25	30	57	1,524	52.9	72.4
0-17 years	339	2	25	30	50	721	47.4	59.9
18-24 years	306	1	25	30	60	518	56.0	68.9
25-40 years	3,685	1	25	30	50	991	50.1	69.4
41-64 years	46,352	1	25	30	57	1,447	53.9	76.4
≥ 65 years	459,606	1	25	30	58	1,524	52.8	72.0
Ozenoxacin	304	3	30	30	30	180	30.2	18.7
0-17 years	54	5	30	30	30	60	28.5	12.0
18-24 years	20	5	23	30	30	30	25.2	8.9
25-40 years	64	5	21	30	30	180	30.8	26.4
41-64 years	124	3	30	30	30	127	30.7	18.6
≥ 65 years	42	5	30	30	30	90	32.5	15.7
Secnidazole	3,060	1	1	1	1	90	3.1	8.3
0-17 years	21	1	1	1	1	2	1.1	0.3
18-24 years	509	1	1	1	1	31	2.4	5.7
25-40 years	1,474	1	1	1	1	90	3.5	9.5
41-64 years	968	1	1	1	1	64	2.8	6.8
≥ 65 years	88	1	1	1	1	60	6.1	12.5
Semaglutide	1,901,829	1	28	30	84	1,648	79.3	114.2
0-17 years	730	1	28	30	65	970	63.1	84.7
18-24 years	9,005	1	28	30	77	1,208	63.2	79.9

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
25-40 years	133,218	1	28	30	84	1,614	68.5	95.9
41-64 years	911,487	1	28	30	84	1,648	79.3	115.1
≥ 65 years	847,389	1	28	30	84	1,621	81.2	116.2
Sofosbuvir Velpatasvir Voxilaprevir	2,177	1	28	28	56	342	39.3	20.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	28	28	28	56	112	42.0	25.3
25-40 years	124	1	28	28	56	90	36.3	15.9
41-64 years	1,385	1	28	28	56	342	38.5	21.5
≥ 65 years	656	1	28	28	56	140	41.3	17.3
Vestronidase Alfa Vjbk	44	1	1	28	45	168	35.0	41.1
0-17 years	25	1	1	1	56	168	37.8	50.0
18-24 years	*****	33	33	76	117	117	75.3	42.0
25-40 years	*****	1	28	28	28	28	22.9	10.9
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Abemaciclib</i>	20,867	1	3	7	17	1,275	18.7	50.6
<i>Acalabrutinib</i>	24,085	1	2	5	13	998	14.7	38.4
<i>Angiotensin II</i>	8	44	55	62	74	167	74.1	38.9
<i>Benralizumab</i>	157,725	1	35	55	57	1,350	53.4	43.2
<i>Benznidazole</i>	13	2	5	10	19	187	24.2	49.5
<i>Copanlisib</i>	4,055	2	6	6	13	510	11.0	18.2
<i>Emicizumab</i>	19,727	1	22	27	28	1,142	26.9	30.1
<i>Enasidenib</i>	1,680	1	3	6	19	891	32.3	86.4
<i>Ertugliflozin</i>	23,931	1	3	6	18	1,079	20.1	48.9
<i>Ertugliflozin and Sitagliptin</i>	1,924	1	3	6	17	1,016	19.8	51.2
<i>Ertugliflozin and Metformin</i>	2,350	1	3	7	22	805	22.7	51.8
<i>Glecaprevir and Pibrentasvir</i>	23,475	1	2	6	13	1,612	16.3	55.6
<i>Guselkumab</i>	69,939	1	8	19	35	1,541	33.9	65.5
<i>Inotuzumab Ozogamicin</i>	2,593	1	6	6	13	776	14.6	32.3
<i>Latanoprostene Bunod Ophthalmic Solution</i>	170,889	1	10	26	57	1,538	49.1	78.1
<i>Letermovir</i>	5,323	1	3	7	17	1,389	20.3	56.2
<i>Macimorelin Acetate</i>	1	47	47	47	47	47	47.0	NaN
<i>Meropenem and Vaborbactam</i>	535	1	5	20	77	1,006	71.2	128.4
<i>Neratinib Maleate</i>	4,385	1	3	7	19	678	16.8	31.9
<i>Netarsudil</i>	510,288	1	7	19	45	1,555	41.4	75.5
<i>Ozenoxacin</i>	304	1	20	59	161	1,292	118.4	158.6
<i>Secnidazole</i>	3,060	1	11	42	114	1,491	97.3	150.1
<i>Semaglutide</i>	1,901,829	1	4	11	29	1,617	31.6	72.6
<i>Sofosbuvir Velpatasvir Voxilaprevir</i>	2,177	1	2	5	11	1,680	19.1	79.2
<i>Vestronidase Alfa Vjbk</i>	44	1	6	15	27	279	25.8	43.6

NaN: Not a Number

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	20,867	1	3	7	17	1,275	18.7	50.6
Female	20,553	1	3	7	17	1,275	18.7	50.9
Male	314	1	3	6	18	192	14.3	20.5
Acalabrutinib	24,085	1	2	5	13	998	14.7	38.4
Female	9,019	1	2	5	14	806	15.2	39.3
Male	15,066	1	2	5	13	998	14.4	37.8
Angiotensin II	8	44	55	62	74	167	74.1	38.9
Female	3	44	44	62	62	62	56.0	10.4
Male	5	55	55	69	79	167	85.0	46.9
Benralizumab	157,725	1	35	55	57	1,350	53.4	43.2
Female	100,779	1	34	55	57	1,350	53.4	44.4
Male	56,946	1	38	55	56	1,262	53.3	41.1
Benznidazole	13	2	5	10	19	187	24.2	49.5
Female	7	3	5	8	19	19	10.1	6.4
Male	6	2	5	11	28	187	40.5	72.3
Copanlisib	4,055	2	6	6	13	510	11.0	18.2
Female	1,917	3	6	6	13	510	11.5	19.7
Male	2,138	2	6	6	13	490	10.6	16.9
Emicizumab	19,727	1	22	27	28	1,142	26.9	30.1
Female	258	1	8	23	27	490	24.6	36.5
Male	19,469	1	22	27	28	1,142	27.0	30.0
Enasidenib	1,680	1	3	6	19	891	32.3	86.4
Female	764	1	3	6	20	679	36.6	93.1
Male	916	1	3	6	18	891	28.7	80.2
Ertugliflozin	23,931	1	3	6	18	1,079	20.1	48.9
Female	11,013	1	3	6	18	1,046	19.4	47.5
Male	12,918	1	3	6	18	1,079	20.6	50.1
Ertugliflozin and Sitagliptin	1,924	1	3	6	17	1,016	19.8	51.2
Female	807	1	3	6	17	598	18.5	45.7
Male	1,117	1	3	6	17	1,016	20.7	54.8
Ertugliflozin and Metformin	2,350	1	3	7	22	805	22.7	51.8
Female	850	1	3	7	19	427	19.8	41.2
Male	1,500	1	3	8	24	805	24.4	56.8
Glecaprevir and Pibrentasvir	23,475	1	2	6	13	1,612	16.3	55.6
Female	9,481	1	3	6	13	1,393	18.0	60.3

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	13,994	1	2	6	12	1,612	15.1	52.1
Guselkumab	69,939	1	8	19	35	1,541	33.9	65.5
Female	32,732	1	8	19	35	1,508	33.4	64.7
Male	37,207	1	8	19	35	1,541	34.3	66.3
Inotuzumab Ozogamicin	2,593	1	6	6	13	776	14.6	32.3
Female	1,296	1	6	6	13	776	14.9	36.3
Male	1,297	1	6	6	13	514	14.4	27.6
Latanoprostene Bunod Ophthalmic Solution	170,889	1	10	26	57	1,538	49.1	78.1
Female	102,519	1	10	25	56	1,524	48.1	76.0
Male	68,370	1	10	27	59	1,538	50.7	81.1
Letermovir	5,323	1	3	7	17	1,389	20.3	56.2
Female	2,358	1	3	7	18	891	20.2	51.2
Male	2,965	1	3	7	17	1,389	20.5	59.9
Macimorelin Acetate	1	47	47	47	47	47	47.0	NaN
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	1	47	47	47	47	47	47.0	NaN
Meropenem and Vaborbactam	535	1	5	20	77	1,006	71.2	128.4
Female	288	1	5	20	79	832	71.4	118.8
Male	247	1	4	19	71	1,006	70.9	139.0
Neratinib Maleate	4,385	1	3	7	19	678	16.8	31.9
Female	4,337	1	3	7	19	678	16.8	31.9
Male	48	1	3	8	20	182	18.4	30.4
Netarsudil	510,288	1	7	19	45	1,555	41.4	75.5
Female	299,304	1	7	19	44	1,488	40.7	74.5
Male	210,984	1	8	19	46	1,555	42.6	77.0
Ozenoxacin	304	1	20	59	161	1,292	118.4	158.6
Female	192	1	22	62	166	1,292	130.4	178.8
Male	112	1	19	54	148	677	97.8	113.9
Secnidazole	3,060	1	11	42	114	1,491	97.3	150.1
Female	3,057	1	11	42	114	1,491	97.4	150.2
Male	3	1	1	2	88	88	30.3	49.9
Semaglutide	1,901,829	1	4	11	29	1,617	31.6	72.6
Female	1,060,924	1	4	11	29	1,617	31.9	73.6
Male	840,905	1	4	11	29	1,502	31.3	71.2

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Distribution of Treatment Episode Gap Durations, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sofosbuvir Velpatasvir Voxilaprevir	2,177	1	2	5	11	1,680	19.1	79.2
Female	602	1	2	5	11	566	16.6	49.9
Male	1,575	1	2	5	10	1,680	20.1	87.8
Vestronidase Alfa Vjbk	44	1	6	15	27	279	25.8	43.6
Female	42	1	6	15	27	279	26.1	44.4
Male	2	2	2	19	35	35	18.5	23.3

NaN: Not a Number

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	20,867	1	3	7	17	1,275	18.7	50.6
0-17 years	9	1	7	12	22	34	15.1	10.7
18-24 years	7	4	11	17	21	26	15.7	7.2
25-40 years	872	1	3	7	16	1,022	17.2	45.6
41-64 years	7,802	1	3	7	17	1,014	17.8	42.2
≥ 65 years	12,177	1	3	7	18	1,275	19.4	55.7
Acalabrutinib	24,085	1	2	5	13	998	14.7	38.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	33	1	4	7	13	55	9.5	9.9
41-64 years	2,510	1	2	5	14	853	16.5	45.2
≥ 65 years	21,542	1	2	5	13	998	14.5	37.5
Angiotensin II	8	44	55	62	74	167	74.1	38.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	5	44	55	62	62	167	78.0	50.3
≥ 65 years	3	55	55	69	79	79	67.7	12.1
Benralizumab	157,725	1	35	55	57	1,350	53.4	43.2
0-17 years	1,426	1	19	37	59	992	47.6	61.1
18-24 years	1,280	1	18	40	57	930	48.0	58.4
25-40 years	7,206	1	23	50	57	1,054	49.9	55.4
41-64 years	42,120	1	27	54	57	1,350	50.2	55.8
≥ 65 years	105,693	1	55	55	57	1,328	55.0	35.2
Benznidazole	13	2	5	10	19	187	24.2	49.5
0-17 years	1	5	5	5	5	5	5.0	NaN
18-24 years	1	3	3	3	3	3	3.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	11	2	7	10	19	187	27.8	53.3
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Copanlisib	4,055	2	6	6	13	510	11.0	18.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	2	48	48	59	69	69	58.5	14.8
25-40 years	8	2	4	7	11	32	9.5	9.7
41-64 years	493	4	6	6	13	139	10.6	11.1

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	3,552	3	6	6	13	510	11.0	19.0
Emicizumab	19,727	1	22	27	28	1,142	26.9	30.1
0-17 years	4,797	1	19	27	28	991	25.5	32.7
18-24 years	1,274	1	11	26	28	615	25.0	35.8
25-40 years	5,458	1	25	27	29	999	28.4	32.2
41-64 years	5,495	1	24	27	28	1,142	27.0	26.7
≥ 65 years	2,703	1	23	27	28	685	27.2	23.7
Enasidenib	1,680	1	3	6	19	891	32.3	86.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	4	2	8	24	56	76	31.5	32.7
25-40 years	14	1	6	14	70	598	106.9	208.2
41-64 years	219	1	3	6	20	689	31.0	86.6
≥ 65 years	1,443	1	3	6	19	891	31.8	84.3
Ertugliflozin	23,931	1	3	6	18	1,079	20.1	48.9
0-17 years	13	1	3	12	30	50	17.2	16.6
18-24 years	110	1	4	10	30	511	32.2	67.3
25-40 years	1,883	1	3	7	19	988	19.8	45.2
41-64 years	15,701	1	3	6	16	926	18.2	44.6
≥ 65 years	6,224	1	3	7	23	1,079	24.5	58.9
Ertugliflozin and Sitagliptin	1,924	1	3	6	17	1,016	19.8	51.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	5	2	4	7	8	133	30.8	57.2
25-40 years	195	1	3	6	17	598	21.0	53.7
41-64 years	1,216	1	3	6	17	502	18.8	42.5
≥ 65 years	508	1	3	6	16	1,016	21.5	66.8
Ertugliflozin and Metformin	2,350	1	3	7	22	805	22.7	51.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	2	1	1	23	44	44	22.5	30.4
25-40 years	281	1	3	9	27	524	28.6	58.1
41-64 years	1,574	1	3	7	21	805	21.6	51.6
≥ 65 years	493	1	3	8	21	589	23.1	48.4
Glecaprevir and Pibrentasvir	23,475	1	2	6	13	1,612	16.3	55.6
0-17 years	2	2	2	3	4	4	3.0	1.4
18-24 years	357	1	3	7	15	945	25.1	83.9
25-40 years	4,449	1	3	6	14	1,074	21.1	66.3

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	14,735	1	2	6	12	1,612	15.2	53.2
≥ 65 years	3,932	1	3	6	12	1,114	14.1	47.1
Guselkumab	69,939	1	8	19	35	1,541	33.9	65.5
0-17 years	75	1	12	24	45	749	52.8	116.4
18-24 years	2,548	1	8	20	37	1,233	37.8	71.0
25-40 years	16,126	1	9	19	34	1,280	35.9	71.2
41-64 years	40,568	1	8	18	33	1,541	32.0	63.8
≥ 65 years	10,622	1	7	21	55	1,361	37.0	60.6
Inotuzumab Ozogamicin	2,593	1	6	6	13	776	14.6	32.3
0-17 years	34	5	6	6	18	61	13.3	12.6
18-24 years	82	3	6	6	16	776	24.5	85.9
25-40 years	239	4	6	6	13	481	17.4	37.5
41-64 years	538	2	6	6	13	293	13.4	21.6
≥ 65 years	1,700	1	6	6	13	521	14.2	29.7
Latanoprostene Bunod Ophthalmic Solution	170,889	1	10	26	57	1,538	49.1	78.1
0-17 years	84	1	9	23	45	501	43.2	66.7
18-24 years	143	1	9	27	69	693	55.6	90.7
25-40 years	1,278	1	10	25	60	1,181	57.4	102.4
41-64 years	18,622	1	10	27	60	1,267	50.8	80.4
≥ 65 years	150,762	1	10	26	57	1,538	48.8	77.6
Letermovir	5,323	1	3	7	17	1,389	20.3	56.2
0-17 years	70	1	3	6	17	527	21.3	64.3
18-24 years	176	1	4	9	22	709	24.7	66.4
25-40 years	875	1	4	8	19	693	23.0	58.7
41-64 years	2,224	1	3	7	17	970	20.0	54.4
≥ 65 years	1,978	1	3	7	16	1,389	19.1	55.8
Macimorelin Acetate	1	47	47	47	47	47	47.0	NaN
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	1	47	47	47	47	47	47.0	NaN
Meropenem and Vaborbactam	535	1	5	20	77	1,006	71.2	128.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	2	7	7	9	10	10	8.5	2.1
25-40 years	73	1	4	6	17	754	48.3	120.4
41-64 years	186	1	4	21	70	1,006	74.4	143.8
≥ 65 years	274	1	5	29	91	727	75.6	119.2
Neratinib Maleate	4,385	1	3	7	19	678	16.8	31.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	48	48	48	48	48	48.0	NaN
25-40 years	511	1	4	8	20	333	18.7	32.2
41-64 years	2,584	1	3	7	18	602	16.3	30.0
≥ 65 years	1,289	1	3	7	19	678	17.2	35.2
Netarsudil	510,288	1	7	19	45	1,555	41.4	75.5
0-17 years	339	1	7	20	54	698	46.0	76.9
18-24 years	306	1	7	20	56	842	50.4	84.4
25-40 years	3,685	1	6	17	47	1,295	44.2	88.4
41-64 years	46,352	1	6	18	45	1,335	42.1	78.6
≥ 65 years	459,606	1	8	19	45	1,555	41.3	75.1
Ozenoxacin	304	1	20	59	161	1,292	118.4	158.6
0-17 years	54	1	22	53	136	676	98.7	121.5
18-24 years	20	4	23	82	186	738	148.9	186.3
25-40 years	64	1	15	57	114	1,292	117.6	198.6
41-64 years	124	1	23	64	192	1,032	129.7	157.2
≥ 65 years	42	1	19	53	145	641	96.9	119.0
Secnidazole	3,060	1	11	42	114	1,491	97.3	150.1
0-17 years	21	1	19	53	88	1,491	165.4	347.7
18-24 years	509	1	12	43	110	1,007	96.9	154.3
25-40 years	1,474	1	11	42	111	1,137	94.7	143.5
41-64 years	968	1	12	44	123	1,428	101.4	153.4
≥ 65 years	88	1	9	36	106	616	82.0	118.1
Semaglutide	1,901,829	1	4	11	29	1,617	31.6	72.6
0-17 years	730	1	5	14	33	500	33.2	57.7
18-24 years	9,005	1	5	13	35	1,235	36.3	77.3
25-40 years	133,218	1	4	11	29	1,502	32.7	75.1
41-64 years	911,487	1	4	10	28	1,617	31.1	73.0
≥ 65 years	847,389	1	4	11	29	1,499	32.0	71.7
Sofosbuvir Velpatasvir Voxilaprevir	2,177	1	2	5	11	1,680	19.1	79.2

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of Treatment Episode Gap Durations, days									
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation	
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	12	1	3	6	17	79	14.0	21.6	
25-40 years	124	1	2	6	14	677	27.2	89.0	
41-64 years	1,385	1	2	5	11	1,680	19.9	86.8	
≥ 65 years	656	1	2	5	11	860	16.1	58.3	
Vestronidase Alfa Vjbk	44	1	6	15	27	279	25.8	43.6	
0-17 years	25	1	6	27	27	279	29.4	53.7	
18-24 years	3	2	2	35	69	69	35.3	33.5	
25-40 years	16	2	6	14	18	105	18.3	24.2	
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN

NaN: Not a Number

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Abemaciclib</i>	6,498	1	3	8	21	1,111	23.3	62.0
<i>Acalabrutinib</i>	6,640	1	2	5	16	979	18.4	49.7
<i>Angiotensin II</i>	3	55	55	62	69	69	62.0	7.0
<i>Benralizumab</i>	20,099	1	26	27	55	1,350	41.3	61.2
<i>Benznidazole</i>	13	2	5	10	19	187	24.2	49.5
<i>Copanlisib</i>	276	2	6	6	6	174	9.4	15.9
<i>Emicizumab</i>	1,273	1	7	25	30	999	30.4	61.3
<i>Enasidenib</i>	674	1	3	7	20	891	37.2	100.5
<i>Ertugliflozin</i>	9,104	1	3	7	20	1,046	21.6	53.5
<i>Ertugliflozin and Sitagliptin</i>	513	1	3	7	19	1,016	24.3	67.5
<i>Ertugliflozin and Metformin</i>	751	1	3	8	25	589	23.5	49.6
<i>Glecaprevir and Pibrentasvir</i>	20,837	1	3	6	13	1,612	16.0	52.7
<i>Guselkumab</i>	18,025	1	7	17	35	1,470	35.6	77.9
<i>Inotuzumab Ozogamicin</i>	480	1	6	6	13	308	14.7	24.2
<i>Latanoprostene Bunod Ophthalmic Solution</i>	36,222	1	12	35	78	1,538	67.7	108.1
<i>Letermovir</i>	2,447	1	4	9	21	1,389	21.3	57.3
<i>Macimorelin Acetate</i>	1	47	47	47	47	47	47.0	NaN
<i>Meropenem and Vaborbactam</i>	334	1	10	33	100	1,006	86.9	139.3
<i>Neratinib Maleate</i>	1,621	1	4	10	25	678	22.5	43.2
<i>Netarsudil</i>	102,305	1	9	26	63	1,502	59.3	108.6
<i>Ozenoxacin</i>	182	1	20	65	186	738	129.5	148.8
<i>Secnidazole</i>	1,803	1	7	40	116	1,491	101.2	165.0
<i>Semaglutide</i>	575,261	1	5	13	35	1,617	39.7	90.8
<i>Sofosbuvir Velpatasvir Voxilaprevir</i>	1,681	1	2	5	12	1,680	19.6	82.8
<i>Vestronidase Alfa Vjbk</i>	8	1	6	23	35	69	24.8	22.4

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	6,498	1	3	8	21	1,111	23.3	62.0
Female	6,403	1	3	8	21	1,111	23.4	62.3
Male	95	1	2	6	21	192	18.1	29.2
Acalabrutinib	6,640	1	2	5	16	979	18.4	49.7
Female	2,500	1	3	6	17	806	20.2	53.4
Male	4,140	1	2	5	15	979	17.4	47.3
Angiotensin II	3	55	55	62	69	69	62.0	7.0
Female	1	62	62	62	62	62	62.0	NaN
Male	2	55	55	62	69	69	62.0	9.9
Benralizumab	20,099	1	26	27	55	1,350	41.3	61.2
Female	13,014	1	26	27	55	1,350	41.7	63.3
Male	7,085	1	27	27	55	1,251	40.7	56.9
Benznidazole	13	2	5	10	19	187	24.2	49.5
Female	7	3	5	8	19	19	10.1	6.4
Male	6	2	5	11	28	187	40.5	72.3
Copanlisib	276	2	6	6	6	174	9.4	15.9
Female	124	6	6	6	6	139	10.5	17.6
Male	152	2	6	6	6	174	8.4	14.4
Emicizumab	1,273	1	7	25	30	999	30.4	61.3
Female	41	1	6	20	33	111	26.6	28.6
Male	1,232	1	7	25	30	999	30.5	62.1
Enasidenib	674	1	3	7	20	891	37.2	100.5
Female	299	1	3	6	22	670	36.3	93.9
Male	375	1	3	7	19	891	37.9	105.6
Ertugliflozin	9,104	1	3	7	20	1,046	21.6	53.5
Female	4,356	1	3	7	19	1,046	21.7	56.1
Male	4,748	1	3	7	20	988	21.6	50.9
Ertugliflozin and Sitagliptin	513	1	3	7	19	1,016	24.3	67.5
Female	238	1	3	7	18	598	22.7	59.6
Male	275	1	2	7	21	1,016	25.6	73.7
Ertugliflozin and Metformin	751	1	3	8	25	589	23.5	49.6
Female	297	1	3	7	22	427	21.9	43.8
Male	454	1	3	9	27	589	24.5	53.1
Glecaprevir and Pibrentasvir	20,837	1	3	6	13	1,612	16.0	52.7
Female	8,453	1	3	6	13	1,114	17.4	55.4

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	12,384	1	2	6	12	1,612	15.0	50.7
Guselkumab	18,025	1	7	17	35	1,470	35.6	77.9
Female	8,871	1	7	17	34	1,299	34.1	74.5
Male	9,154	1	7	18	36	1,470	37.0	81.1
Inotuzumab Ozogamicin	480	1	6	6	13	308	14.7	24.2
Female	237	1	6	6	13	222	13.9	20.7
Male	243	4	6	6	13	308	15.4	27.2
Latanoprostene Bunod Ophthalmic Solution	36,222	1	12	35	78	1,538	67.7	108.1
Female	21,284	1	12	34	77	1,425	66.2	106.2
Male	14,938	1	13	37	81	1,538	69.8	110.8
Letermovir	2,447	1	4	9	21	1,389	21.3	57.3
Female	1,092	1	4	9	21	891	20.3	47.7
Male	1,355	1	4	8	20	1,389	22.0	64.0
Macimorelin Acetate	1	47	47	47	47	47	47.0	NaN
Female	0	NaN	N	NaN	N	NaN	NaN	NaN
Male	1	47	47	47	47	47	47.0	NaN
Meropenem and Vaborbactam	334	1	10	33	0	1,006	86.9	139.3
Female	188	1	10	30	7	582	83.4	118.4
Male	146	1	9	35	96	1,006	91.6	162.6
Neratinib Maleate	1,621	1	4	10	25	678	22.5	43.2
Female	1,604	1	4	10	25	678	22.5	43.3
Male	17	2	6	17	33	88	24.8	25.0
Netarsudil	102,305	1	9	26	63	1,502	59.3	108.6
Female	58,410	1	9	25	61	1,488	58.3	108.3
Male	43,895	1	9	27	65	1,502	60.6	108.9
Ozenoxacin	182	1	20	65	6	738	129.5	148.8
Female	118	1	26	74	1	738	138.4	155.9
Male	64	1	15	48	9	677	113.1	134.3
Secnidazole	1,803	1	7	40	6	1,491	101.2	165.0
Female	1,800	1	7	41	6	1,491	101.3	165.1
Male	3	1	1	2	88	88	30.3	49.9
Semaglutide	575,261	1	5	13	35	1,617	39.7	90.8
Female	325,299	1	5	13	34	1,617	39.4	91.2
Male	249,962	1	5	13	35	1,502	40.2	90.4

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Sex

	Distribution of First Treatment Episode Gap Duration, days							
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sofosbuvir Velpatasvir Voxilaprevir	1,681	1	2	5	12	1,680	19.6	82.8
Female	460	1	2	6	13	378	15.5	38.6
Male	1,221	1	2	5	11	1,680	21.2	94.1
Vestronidase Alfa Vjbk	8	1	6	23	35	69	24.8	22.4
Female	6	1	10	23	35	69	26.8	23.9
Male	2	2	2	19	35	35	18.5	23.3

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Abemaciclib	6,498	1	3	8	21	1,111	23.3	62.0
0-17 years	3	16	16	27	34	34	25.7	9.1
18-24 years	2	21	21	24	26	26	23.5	3.5
25-40 years	292	1	3	8	20	1,022	21.4	64.1
41-64 years	2,456	1	3	8	20	1,014	21.2	51.1
≥ 65 years	3,745	1	3	8	22	1,111	24.8	68.1
Acalabrutinib	6,640	1	2	5	16	979	18.4	49.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	8	2	3	8	12	18	8.1	5.8
41-64 years	690	1	2	6	15	853	20.4	57.4
≥ 65 years	5,942	1	2	5	16	979	18.2	48.8
Angiotensin II	3	55	55	62	69	69	62.0	7.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	2	55	55	59	62	62	58.5	4.9
≥ 65 years	1	69	69	69	69	69	69.0	NaN
Benralizumab	20,099	1	26	27	55	1,350	41.3	61.2
0-17 years	286	1	12	27	46	699	40.8	68.1
18-24 years	232	1	13	27	52	382	40.3	50.0
25-40 years	1,305	1	14	27	52	1,004	41.9	66.6
41-64 years	6,754	1	15	27	54	1,350	42.3	72.7
≥ 65 years	11,522	1	27	27	55	1,328	40.7	52.5
Benznidazole	13	2	5	10	19	187	24.2	49.5
0-17 years	1	5	5	5	5	5	5.0	NaN
18-24 years	1	3	3	3	3	3	3.0	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	11	2	7	10	19	187	27.8	53.3
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Copanlisib	276	2	6	6	6	174	9.4	15.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	48	48	48	48	48	48.0	NaN
25-40 years	2	2	2	4	6	6	4.0	2.8
41-64 years	59	5	6	6	6	139	12.5	24.2

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	214	5	6	6	6	174	8.4	12.5
Emicizumab	1,273	1	7	25	30	999	30.4	61.3
0-17 years	424	1	6	20	28	934	27.1	63.7
18-24 years	120	1	5	20	29	238	23.1	27.9
25-40 years	317	1	9	26	31	999	31.6	68.1
41-64 years	257	1	20	27	33	621	33.9	54.9
≥ 65 years	155	1	13	25	29	685	36.7	68.4
Enasidenib	674	1	3	7	20	891	37.2	100.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	3	2	2	13	76	76	30.3	39.9
25-40 years	10	1	6	9	35	598	76.7	184.4
41-64 years	90	1	3	9	30	689	50.8	123.5
≥ 65 years	571	1	3	6	19	891	34.4	94.5
Ertugliflozin	9,104	1	3	7	20	1,046	21.6	53.5
0-17 years	5	2	3	14	25	33	15.4	13.6
18-24 years	43	1	4	8	29	265	29.4	52.9
25-40 years	732	1	3	8	22	988	22.3	55.7
41-64 years	6,310	1	3	7	18	881	18.2	42.3
≥ 65 years	2,014	1	3	9	29	1,046	32.2	77.3
Ertugliflozin and Sitagliptin	513	1	3	7	19	1,016	24.3	67.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	2	4	4	6	8	8	6.0	2.8
25-40 years	39	1	2	7	21	598	42.9	109.4
41-64 years	323	1	2	6	19	198	19.6	35.7
≥ 65 years	149	1	3	8	19	1,016	29.8	98.7
Ertugliflozin and Metformin	751	1	3	8	25	589	23.5	49.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	2	1	1	23	44	44	22.5	30.4
25-40 years	89	1	3	14	40	524	35.3	71.0
41-64 years	520	1	3	7	22	445	19.7	38.1
≥ 65 years	140	1	5	11	28	589	30.1	66.9
Glecaprevir and Pibrentasvir	20,837	1	3	6	13	1,612	16.0	52.7
0-17 years	2	2	2	3	4	4	3.0	1.4
18-24 years	327	1	3	7	15	945	23.5	80.4
25-40 years	4,030	1	3	6	14	899	20.4	64.2

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Gap Duration, days									
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation	
41-64 years	12,877	1	2	6	13	1,612	14.9	49.7	
≥ 65 years	3,601	1	3	6	12	1,114	14.1	44.7	
Guselkumab	18,025	1	7	17	35	1,470	35.6	77.9	
0-17 years	23	2	6	17	41	170	32.7	42.1	
18-24 years	673	1	7	19	41	911	40.9	75.4	
25-40 years	4,144	1	7	18	36	1,280	37.7	83.5	
41-64 years	10,304	1	7	16	33	1,470	34.3	78.0	
≥ 65 years	2,881	1	7	20	42	1,361	35.9	69.7	
Inotuzumab Ozogamicin	480	1	6	6	13	308	14.7	24.2	
0-17 years	13	5	6	6	6	35	10.3	9.5	
18-24 years	19	3	6	7	20	47	14.5	13.0	
25-40 years	52	6	6	6	16	86	15.4	17.3	
41-64 years	110	2	6	6	13	97	12.3	15.3	
≥ 65 years	286	1	6	6	13	308	15.7	28.7	
Latanoprostene Bunod Ophthalmic Solution	36,222	1	12	35	78	1,538	67.7	108.1	
0-17 years	27	1	4	25	55	501	54.9	97.1	
18-24 years	37	1	18	49	76	619	75.9	114.1	
25-40 years	288	1	12	38	85	820	74.2	111.4	
41-64 years	4,345	1	12	36	77	1,266	67.2	104.6	
≥ 65 years	31,525	1	12	35	79	1,538	67.7	108.5	
Letermovir	2,447	1	4	9	21	1,389	21.3	57.3	
0-17 years	32	1	4	7	20	63	13.8	15.8	
18-24 years	97	1	5	11	21	371	18.5	39.1	
25-40 years	346	1	5	10	22	660	23.6	55.6	
41-64 years	1,014	1	4	9	21	745	21.8	53.4	
≥ 65 years	958	1	4	8	19	1,389	20.4	63.9	
Macimorelin Acetate	1	47	47	47	47	47	47.0	NaN	
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	
≥ 65 years	1	47	47	47	47	47	47.0	NaN	
Meropenem and Vaborbactam	334	1	10	33	100	1,006	86.9	139.3	
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	1	10	10	10	10	10	10.0	NaN
25-40 years	24	1	7	10	22	754	73.0	165.8
41-64 years	110	1	11	35	92	1,006	90.1	153.4
≥ 65 years	199	1	11	37	108	727	87.3	128.1
Neratinib Maleate	1,621	1	4	10	25	678	22.5	43.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	48	48	48	48	48	48.0	NaN
25-40 years	205	1	4	11	26	236	25.2	39.9
41-64 years	935	1	4	9	24	602	21.6	39.9
≥ 65 years	480	1	3	10	26	678	22.9	50.2
Netarsudil	102,305	1	9	26	63	1,502	59.3	108.6
0-17 years	94	1	12	28	73	698	65.5	111.2
18-24 years	99	1	8	22	72	426	55.9	82.8
25-40 years	826	1	7	23	60	1,291	61.2	123.1
41-64 years	10,640	1	7	23	61	1,335	57.3	104.6
≥ 65 years	90,646	1	9	26	63	1,502	59.5	108.9
Ozenoxacin	182	1	20	65	186	738	129.5	148.8
0-17 years	37	1	26	53	154	350	97.9	100.4
18-24 years	17	5	30	96	191	738	162.8	198.2
25-40 years	37	1	15	54	154	586	108.5	145.4
41-64 years	73	1	28	116	229	677	154.9	154.9
≥ 65 years	18	5	19	53	124	641	102.9	152.2
Secnidazole	1,803	1	7	40	116	1,491	101.2	165.0
0-17 years	12	1	3	54	141	1,491	224.0	448.1
18-24 years	328	1	9	37	111	1,007	101.2	168.1
25-40 years	865	1	7	39	111	1,137	94.6	150.9
41-64 years	563	1	7	44	126	1,428	110.7	176.0
≥ 65 years	35	1	13	40	94	370	69.3	83.5
Semaglutide	575,261	1	5	13	35	1,617	39.7	90.8
0-17 years	263	1	5	14	35	500	35.3	67.8
18-24 years	3,248	1	5	15	37	1,235	40.7	90.6
25-40 years	43,626	1	5	13	33	1,502	37.4	86.4
41-64 years	272,839	1	5	13	34	1,617	39.0	91.2
≥ 65 years	255,285	1	5	14	36	1,499	40.9	91.2

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022, by Age Group

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Sofosbuvir Velpatasvir Voxilaprevir	1,681	1	2	5	12	1,680	19.6	82.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	10	3	5	7	21	79	16.4	23.1
25-40 years	92	1	3	6	14	677	23.8	78.8
41-64 years	1,059	1	2	5	12	1,680	20.5	91.3
≥ 65 years	520	1	2	5	11	860	17.2	63.7
Vestronidase Alfa Vjbk	8	1	6	23	35	69	24.8	22.4
0-17 years	3	1	1	10	35	35	15.3	17.6
18-24 years	3	2	2	35	69	69	35.3	33.5
25-40 years	2	19	19	23	27	27	23.0	5.7
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

NaN: Not a Number

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2021

	Censoring Reason												
	End of exposure episode ²		Occurrence of request-defined censoring criteria ³		Evidence of death ⁴		Disenrollment ⁵		End of data partner data ⁶		End of query period ⁷		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Abemaciclib</i>	32,958	32,336	98.1%	0	0.0%	426	1.3%	3,445	10.5%	2,815	8.5%	0	0.0%
<i>Acalabrutinib</i>	35,219	34,296	97.4%	0	0.0%	747	2.1%	5,126	14.6%	4,812	13.7%	0	0.0%
<i>Angiotensin II</i>	36	36	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Benralizumab</i>	181,796	181,377	99.8%	0	0.0%	91	0.1%	4,354	2.4%	3,537	1.9%	0	0.0%
<i>Benznidazole</i>	64	63	98.4%	0	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Copanlisib</i>	4,359	4,358	100.0%	0	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Emicizumab</i>	21,760	21,724	99.8%	0	0.0%	*****	*****	599	2.8%	468	2.2%	0	0.0%
<i>Enasidenib</i>	3,160	2,823	89.3%	0	0.0%	354	11.2%	235	7.4%	179	5.7%	0	0.0%
<i>Ertugliflozin</i>	42,568	42,416	99.6%	0	0.0%	77	0.2%	10,641	25.0%	8,927	21.0%	0	0.0%
<i>Ertugliflozin and Sitagliptin</i>	2,760	2,740	99.3%	0	0.0%	*****	*****	311	11.3%	198	7.2%	0	0.0%
<i>Ertugliflozin and Metformin</i>	3,698	3,684	99.6%	0	0.0%	*****	*****	746	20.2%	597	16.1%	0	0.0%
<i>Glecaprevir and Pibrentasvir</i>	98,261	98,054	99.8%	0	0.0%	196	0.2%	7,566	7.7%	5,420	5.5%	0	0.0%
<i>Guselkumab</i>	95,624	94,375	98.7%	0	0.0%	94	0.1%	12,596	13.2%	8,996	9.4%	0	0.0%
<i>Inotuzumab Ozogamicin</i>	3,185	3,184	100.0%	0	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Latanoprostene Bunod Ophthalmic Solution</i>	225,692	224,168	99.3%	0	0.0%	838	0.4%	17,179	7.6%	15,335	6.8%	0	0.0%
<i>Letermovir</i>	9,789	9,573	97.8%	0	0.0%	193	2.0%	800	8.2%	597	6.1%	0	0.0%
<i>Macimorelin Acetate</i>	47	47	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Meropenem and Vaborbactam</i>	4,580	4,579	100.0%	0	0.0%	16	0.3%	*****	*****	*****	*****	0	0.0%
<i>Neratinib Maleate</i>	7,350	7,293	99.2%	0	0.0%	49	0.7%	609	8.3%	337	4.6%	0	0.0%
<i>Netarsudil</i>	662,039	656,715	99.2%	0	0.0%	3,648	0.6%	45,228	6.8%	39,335	5.9%	0	0.0%
<i>Ozenoxacin</i>	1,945	1,937	99.6%	0	0.0%	0	0.0%	83	4.3%	41	2.1%	0	0.0%
<i>Secnidazole</i>	12,618	12,618	100.0%	0	0.0%	0	0.0%	50	0.4%	21	0.2%	0	0.0%

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2021

	Censoring Reason												
	End of exposure episode ²		Occurrence of request-defined censoring criteria ³		Evidence of death ⁴		Disenrollment ⁵		End of data partner data ⁶		End of query period ⁷		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Semaglutide</i>	2,884,431	2,834,746	98.3%	0	0.0%	6,550	0.2%	495,138	17.2%	424,430	14.7%	0	0.0%
<i>Sofosbuvir Velpatasvir Voxilaprevir</i>	7,744	7,726	99.8%	0	0.0%	17	0.2%	474	6.1%	235	3.0%	0	0.0%
<i>Vestronidase Alfa Vjvk</i>	54	54	100.0%	0	0.0%	0	0.0%	*****	*****	*****	*****	0	0.0%

¹An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

²Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

³Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

⁴Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

⁵Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁶Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

⁷Represents episodes censored due to user-specified study end date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Abemaciclib		Acalabrutinib		Angiotensin II		Benralizumab	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	306,047,206	N/A	306,047,206	N/A	306,047,206	N/A	306,047,206	N/A
Had required coverage type (medical and/or drug coverage)	221,674,713	84,372,493	221,674,713	84,372,493	221,674,713	84,372,493	221,674,713	84,372,493
Enrolled during specified age range	221,629,435	45,278	221,629,435	45,278	221,629,435	45,278	221,629,435	45,278
Had requestable medical charts	221,629,435	0	221,629,435	0	221,629,435	0	221,629,435	0
Met demographic requirements (sex, race, and Hispanic origin)	220,724,881	904,554	220,724,881	904,554	220,724,881	904,554	220,724,881	904,554
Members with a valid index event								
Had any cohort-defining claim during the query period	13,564	220,711,317	11,864	220,713,017	*****	220,724,845	26,149	220,698,732
Claim recorded during specified age range	13,564	0	11,864	0	*****	0	26,149	0
Episode defining index claim recorded during the query period	13,564	0	11,864	0	*****	0	26,149	0
Met exposure incidence criteria	13,564	0	11,864	0	*****	0	26,149	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	12,091	1,473	11,134	730	28	*****	24,071	2,078
Met inclusion and exclusion criteria	12,091	0	11,134	0	28	0	24,071	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	12,091	0	11,134	0	28	0	24,071	0
Final cohort								
Number of members	12,091	N/A	11,134	N/A	28	N/A	24,071	N/A
Number of episodes	12,091	N/A	11,134	N/A	28	N/A	24,071	N/A

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Benznidazole		Copanlisib		Emicizumab		Enasidenib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	306,047,206	N/A	306,047,206	N/A	306,047,206	N/A	306,047,206	N/A
Had required coverage type (medical and/or drug coverage)	221,674,713	84,372,493	221,674,713	84,372,493	221,674,713	84,372,493	221,674,713	84,372,493
Enrolled during specified age range	221,629,435	45,278	221,629,435	45,278	221,629,435	45,278	221,629,435	45,278
Had requestable medical charts	221,629,435	0	221,629,435	0	221,629,435	0	221,629,435	0
Met demographic requirements (sex, race, and Hispanic origin)	220,724,881	904,554	220,724,881	904,554	220,724,881	904,554	220,724,881	904,554
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	220,724,825	323	220,724,558	2,418	220,722,463	1,613	220,723,268
Claim recorded during specified age range	*****	0	323	0	2,418	0	1,613	0
Episode defining index claim recorded during the query period	*****	0	323	0	2,418	0	1,613	0
Met exposure incidence criteria	*****	0	323	0	2,418	0	1,613	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	51	*****	304	19	2,033	385	1,480	133
Met inclusion and exclusion criteria	51	0	304	0	2,033	0	1,480	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	51	0	304	0	2,033	0	1,480	0
Final cohort								
Number of members	51	N/A	304	N/A	2,033	N/A	1,480	N/A
Number of episodes	51	N/A	304	N/A	2,033	N/A	1,480	N/A

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Ertugliflozin		Ertugliflozin and Sitagliptin		Ertugliflozin and Metformin		Glecaprevir and Pibrentasvir	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	306,047,206	N/A	306,047,206	N/A	306,047,206	N/A	306,047,206	N/A
Had required coverage type (medical and/or drug coverage)	221,674,713	84,372,493	221,674,713	84,372,493	221,674,713	84,372,493	221,674,713	84,372,493
Enrolled during specified age range	221,629,435	45,278	221,629,435	45,278	221,629,435	45,278	221,629,435	45,278
Had requestable medical charts	221,629,435	0	221,629,435	0	221,629,435	0	221,629,435	0
Met demographic requirements (sex, race, and Hispanic origin)	220,724,881	904,554	220,724,881	904,554	220,724,881	904,554	220,724,881	904,554
Members with a valid index event								
Had any cohort-defining claim during the query period	28,248	220,696,633	1,097	220,723,784	1,957	220,722,924	86,168	220,638,713
Claim recorded during specified age range	28,248	0	1,097	0	1,957	0	86,168	0
Episode defining index claim recorded during the query period	28,248	0	1,097	0	1,957	0	86,168	0
Met exposure incidence criteria	28,248	0	1,097	0	1,957	0	86,168	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	18,637	9,611	836	261	1,348	609	74,786	11,382
Met inclusion and exclusion criteria	18,637	0	836	0	1,348	0	74,786	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	18,637	0	836	0	1,348	0	74,786	0
Final cohort								
Number of members	18,637	N/A	836	N/A	1,348	N/A	74,786	N/A
Number of episodes	18,637	N/A	836	N/A	1,348	N/A	74,786	N/A

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Guselkumab		Inotuzumab Ozogamicin		Latanoprostene Bunod Ophthalmic Solution		Letermovir	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	306,047,206	N/A	306,047,206	N/A	306,047,206	N/A	306,047,206	N/A
Had required coverage type (medical and/or drug coverage)	221,674,713	84,372,493	221,674,713	84,372,493	221,674,713	84,372,493	221,674,713	84,372,493
Enrolled during specified age range	221,629,435	45,278	221,629,435	45,278	221,629,435	45,278	221,629,435	45,278
Had requestable medical charts	221,629,435	0	221,629,435	0	221,629,435	0	221,629,435	0
Met demographic requirements (sex, race, and Hispanic origin)	220,724,881	904,554	220,724,881	904,554	220,724,881	904,554	220,724,881	904,554
Members with a valid index event								
Had any cohort-defining claim during the query period	29,104	220,695,777	672	220,724,209	58,110	220,666,771	5,040	220,719,841
Claim recorded during specified age range	29,104	0	672	0	58,110	0	5,040	0
Episode defining index claim recorded during the query period	29,104	0	672	0	58,110	0	5,040	0
Met exposure incidence criteria	29,104	0	672	0	58,110	0	5,040	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	25,685	3,419	592	80	54,803	3,307	4,466	574
Met inclusion and exclusion criteria	25,685	0	592	0	54,803	0	4,466	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	25,685	0	592	0	54,803	0	4,466	0
Final cohort								
Number of members	25,685	N/A	592	N/A	54,803	N/A	4,466	N/A
Number of episodes	25,685	N/A	592	N/A	54,803	N/A	4,466	N/A

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Macimorelin Acetate		Meropenem and Vaborbactam		Neratinib Maleate		Netarsudil	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	306,047,206	N/A	306,047,206	N/A	306,047,206	N/A	306,047,206	N/A
Had required coverage type (medical and/or drug coverage)	221,674,713	84,372,493	221,674,713	84,372,493	221,674,713	84,372,493	221,674,713	84,372,493
Enrolled during specified age range	221,629,435	45,278	221,629,435	45,278	221,629,435	45,278	221,629,435	45,278
Had requestable medical charts	221,629,435	0	221,629,435	0	221,629,435	0	221,629,435	0
Met demographic requirements (sex, race, and Hispanic origin)	220,724,881	904,554	220,724,881	904,554	220,724,881	904,554	220,724,881	904,554
Members with a valid index event								
Had any cohort-defining claim during the query period	*****	220,724,833	4,437	220,720,444	3,399	220,721,482	*****	220,563,376
Claim recorded during specified age range	*****	0	4,437	0	3,399	0	161,504	*****
Episode defining index claim recorded during the query period	*****	0	4,437	0	3,399	0	161,504	0
Met exposure incidence criteria	*****	0	4,437	0	3,399	0	161,504	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	46	*****	4,045	392	2,965	434	151,751	9,753
Met inclusion and exclusion criteria	46	0	4,045	0	2,965	0	151,751	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	46	0	4,045	0	2,965	0	151,751	0
Final cohort								
Number of members	46	N/A	4,045	N/A	2,965	N/A	151,751	N/A
Number of episodes	46	N/A	4,045	N/A	2,965	N/A	151,751	N/A

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022


	Ozenoxacin		Secnidazole		Semaglutide		Sofosbuvir Velpatasvir	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	306,047,206	N/A	306,047,206	N/A	306,047,206	N/A	306,047,206	N/A
Had required coverage type (medical and/or drug coverage)	221,674,713	84,372,493	221,674,713	84,372,493	221,674,713	84,372,493	221,674,713	84,372,493
Enrolled during specified age range	221,629,435	45,278	221,629,435	45,278	221,629,435	45,278	221,629,435	45,278
Had requestable medical charts	221,629,435	0	221,629,435	0	221,629,435	0	221,629,435	0
Met demographic requirements (sex, race, and Hispanic origin)	220,724,881	904,554	220,724,881	904,554	220,724,881	904,554	220,724,881	904,554
Members with a valid index event								
Had any cohort-defining claim during the query period	1,876	220,723,005	10,980	220,713,901	1,130,462	219,594,419	6,278	220,718,603
Claim recorded during specified age range	1,876	0	10,980	0	1,130,462	0	6,278	0
Episode defining index claim recorded during the query period	1,876	0	10,980	0	1,130,462	0	6,278	0
Met exposure incidence criteria	1,876	0	10,980	0	1,130,462	0	6,278	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	1,641	235	9,558	1,422	982,602	147,860	5,567	711
Met inclusion and exclusion criteria	1,641	0	9,558	0	982,602	0	5,567	0
Members with required post-index follow-up								
Had sufficient post-index continuous enrollment	1,641	0	9,558	0	982,602	0	5,567	0
Final cohort								
Number of members	1,641	N/A	9,558	N/A	982,602	N/A	5,567	N/A
Number of episodes	1,641	N/A	9,558	N/A	982,602	N/A	5,567	N/A

Table 10. Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

	Vestronidase Alfa Vjbk	
	Remaining	Excluded
Members meeting enrollment and demographic requirements		
Enrolled at any point during the query period	306,047,206	N/A
Had required coverage type (medical and/or drug coverage)	221,674,713	84,372,493
Enrolled during specified age range	221,629,435	45,278
Had requestable medical charts	221,629,435	0
Met demographic requirements (sex, race, and Hispanic origin)	220,724,881	904,554
Members with a valid index event		
Had any cohort-defining claim during the query period	*****	*****
Claim recorded during specified age range	*****	0
Episode defining index claim recorded during the query period	*****	0
Met exposure incidence criteria	*****	0
Members with required pre-index history		
Had sufficient pre-index continuous enrollment	*****	0
Met inclusion and exclusion criteria	*****	0
Members with required post-index follow-up		
Had sufficient post-index continuous enrollment	*****	0
Final cohort		
Number of members	*****	N/A
Number of episodes	*****	N/A


*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Figure 1a. Patient Entry into Study by Month for Abemaciclib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022



The FDA approval date for this drug was on September 28, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1b. Patient Entry into Study by Month for Acalabrutinib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022




The FDA approval date for this drug was on October 31, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1c. Patient Entry into Study by Month for Angiotensin II in the Sentinel Distributed Database (SDD) from December 21, 2017 to December 31, 2022

*The FDA approval date for this drug was on December 21, 2017, as listed on the FDA website
<https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>*

*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1d. Patient Entry into Study by Month for Benralizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022



The FDA approval date for this drug was on November 14, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1e. Patient Entry into Study by Month for Benznidazole in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

The FDA approval date for this drug was on August 29, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1f. Patient Entry into Study by Month for Copanlisib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

The FDA approval date for this drug was on September 14, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1g. Patient Entry into Study by Month for Emicizumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022




The FDA approval date for this drug was on November 16, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1h. Patient Entry into Study by Month for Enasidenib in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022



The FDA approval date for this drug was on August 1, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1i. Patient Entry into Study by Month for Ertugliflozin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022



The FDA approval date for this drug was on December 19, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1j. Patient Entry into Study by Month for Ertugliflozin and Sitagliptin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

The FDA approval date for this drug was on December 19, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1k. Patient Entry into Study by Month for Ertugliflozin and Metformin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

The FDA approval date for this drug was on December 19, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 11. Patient Entry into Study by Month for Glecaprevir and Pibrentasvir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022



The FDA approval date for this drug was on August 3, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1m. Patient Entry into Study by Month for Guselkumab in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022




The FDA approval date for this drug was on July 13, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1n. Patient Entry into Study by Month for Inotuzumab Ozogamicin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

The FDA approval date for this drug was on August 17, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1o. Patient Entry into Study by Month for Latanoprostene Bunod Ophthalmic Solution in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022



The FDA approval date for this drug was on November 2, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1p. Patient Entry into Study by Month for Letemovir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022



The FDA approval date for this drug was on November 8, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1q. Patient Entry into Study by Month for Macimorelin Acetate in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

The FDA approval date for this drug was on December 20, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1r. Patient Entry into Study by Month for Meropenem and Vaborbactam in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

The FDA approval date for this drug was on August 29, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>


*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Figure 1s. Patient Entry into Study by Month for Neratinib Maleate in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022




The FDA approval date for this drug was on July 17, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1t. Patient Entry into Study by Month for Netarsudil in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022




The FDA approval date for this drug was on December 18, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1u. Patient Entry into Study by Month for Ozenoxacin in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022




The FDA approval date for this drug was on December 11, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1v. Patient Entry into Study by Month for Secnidazole in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022




The FDA approval date for this drug was on September 15, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1w. Patient Entry into Study by Month for Semaglutide in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022



The FDA approval date for this drug was on December 5, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1x. Patient Entry into Study by Month for Sofosbuvir Velpatasvir Voxilaprevir in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022



The FDA approval date for this drug was on July 18, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

Figure 1y. Patient Entry into Study by Month for Vestronidase Alfa Vjkb in the Sentinel Distributed Database (SDD) from January 1, 2017 to December 31, 2022

The FDA approval date for this drug was on November 15, 2017, as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2017>

*****Data are not presented in this figure due to a small sample size or to ensure a small count cannot be recalculated through the counts presented.*

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 4, 2023)

Masked DP ID ¹	DP Start Date	DP End Date ¹
DP01	01/01/2005	07/31/2022
DP02	01/01/2000	07/31/2022
DP03	01/01/2000	12/31/2020
DP04	01/01/2008	12/31/2022
DP05	01/01/2000	05/31/2022
DP06	01/01/2010	09/30/2022
DP07	01/01/2000	08/31/2022
DP08	01/01/2000	08/31/2022
DP09	01/01/2000	10/31/2022
DP10	01/01/2004	11/30/2022
DP11	01/01/2008	08/31/2022
DP12	01/01/2006	10/31/2022
DP13	01/01/2007	09/30/2022
DP14	01/01/2014	12/31/2018

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
Abemaciclib	
abemaciclib	Verzenio
Acalabrutinib	
Acalabrutinib	Calquence
acalabrutinib	Calquence
acalabrutinib maleate	Calquence (acalabrutinib mal)
Angiotensin II	
angiotensin II acetate, human	Giapreza
Benralizumab	
benralizumab	Fasenra
benralizumab	Fasenra Pen
Benznidazole	
benznidazole	benznidazole
Copanlisib	
copanlisib di-HCl	Aliqopa
Emicizumab	
emicizumab-kxwh	Hemlibra
Enasidenib	
enasidenib mesylate	Idhifa
Ertugliflozin	
ertugliflozin	Steglatro
ertugliflozin pidolate	Steglatro
Ertugliflozin and Metformin	
ertugliflozin pidolate/metformin HCl	Segluromet
Ertugliflozin and Sitagliptin	
ertugliflozin pidolate/sitagliptin phosphate	Steglujan
Glecaprevir and Pibrentasvir	
glecaprevir/pibrentasvir	Mavyret
Guselkumab	
guselkumab	Tremfya
Inotuzumab Ozogamicin	
inotuzumab ozogamicin	Besponsa
Latanoprostene Bunod Ophthalmic Solution	
latanoprostene bunod	Vyzulta
Letermovir	
letermovir	Prevymis
Macimorelin Acetate	

Appendix B. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
macimorelin acetate	Macrilen
Meropenem and Vaborbactam	
meropenem/vaborbactam	Vabomere
Neratinib Maleate	
neratinib maleate	Nerlynx
Netarsudil	
netarsudil mesylate	Rhopressa
netarsudil mesylate/latanoprost	Rocklatan
Ozenoxacin	
ozenoxacin	Xepi
Secnidazole	
secnidazole	Solosec
Semaglutide	
semaglutide	Ozempic
semaglutide	Rybelsus
semaglutide	Wegovy
Sofosbuvir Velpatasvir Voxilaprevir	
sofosbuvir/velpatasvir/voxilaprevir	Vosevi
Vestronidase Alfa Vjvk	
vestronidase alfa-vjvk	Mepsevii

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
Angiotensin II			
82163		Procedure	CPT-4
Benralizumab			
J0517	Injection, benralizumab, 1 mg	Procedure	HCPCS
Copanlisib			
J9057	Injection, copanlisib, 1 mg	Procedure	HCPCS
Emicizumab			
J7170	Injection, emicizumab-kxwh, 0.5 mg	Procedure	HCPCS
Guselkumab			
J1628	Injection, guselkumab, 1 mg	Procedure	HCPCS
Inotuzumab Ozogamicin			
J9229	Injection, inotuzumab ozogamicin, 0.1 mg	Procedure	HCPCS
Meropenem and Vaborbactam			
J2186	Injection, meropenem, vaborbactam, 10 mg/10 mg, (20 mg)	Procedure	HCPCS
XW033N5	Introduction of Meropenem-vaborbactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW043N5	Introduction of Meropenem-vaborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
Vestronidase Alfa Vjbk			
J3397	Injection, vestronidase alfa-vjbk, 1 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
Acquired Hypothyroidism			
244.0	Postsurgical hypothyroidism	Diagnosis	ICD-9-CM
244.1	Other postablative hypothyroidism	Diagnosis	ICD-9-CM
244.2	Iodine hypothyroidism	Diagnosis	ICD-9-CM
244.3	Other iatrogenic hypothyroidism	Diagnosis	ICD-9-CM
244.8	Other specified acquired hypothyroidism	Diagnosis	ICD-9-CM
244.9	Unspecified hypothyroidism	Diagnosis	ICD-9-CM
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Alcohol Abuse			
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnesic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
760.71	Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.61	Alcohol rehabilitation	Procedure	ICD-9-CM
94.62	Alcohol detoxification	Procedure	ICD-9-CM
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
980.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
E860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-9-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
V79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Alzheimers			
290.0	Senile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.10	Presenile dementia, uncomplicated	Diagnosis	ICD-9-CM
290.11	Presenile dementia with delirium	Diagnosis	ICD-9-CM
290.12	Presenile dementia with delusional features	Diagnosis	ICD-9-CM
290.13	Presenile dementia with depressive features	Diagnosis	ICD-9-CM
290.20	Senile dementia with delusional features	Diagnosis	ICD-9-CM
290.21	Senile dementia with depressive features	Diagnosis	ICD-9-CM
290.3	Senile dementia with delirium	Diagnosis	ICD-9-CM
290.40	Vascular dementia, uncomplicated	Diagnosis	ICD-9-CM
290.41	Vascular dementia, with delirium	Diagnosis	ICD-9-CM
290.42	Vascular dementia, with delusions	Diagnosis	ICD-9-CM
290.43	Vascular dementia, with depressed mood	Diagnosis	ICD-9-CM
294.0	Amnestic disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
294.10	Dementia in conditions classified elsewhere without behavioral disturbance	Diagnosis	ICD-9-CM
294.11	Dementia in conditions classified elsewhere with behavioral disturbance	Diagnosis	ICD-9-CM
294.20	Dementia, unspecified, without behavioral disturbance	Diagnosis	ICD-9-CM
294.21	Dementia, unspecified, with behavioral disturbance	Diagnosis	ICD-9-CM
294.8	Other persistent mental disorders due to conditions classified elsewhere	Diagnosis	ICD-9-CM
331.0	Alzheimer's disease	Diagnosis	ICD-9-CM
331.11	Pick's disease	Diagnosis	ICD-9-CM
331.19	Other frontotemporal dementia	Diagnosis	ICD-9-CM
331.2	Senile degeneration of brain	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
797	Senility without mention of psychosis	Diagnosis	ICD-9-CM
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
Acute Myocardial Infarction			
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Anemia			
280.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-9-CM
280.1	Iron deficiency anemia secondary to inadequate dietary iron intake	Diagnosis	ICD-9-CM
280.8	Other specified iron deficiency anemias	Diagnosis	ICD-9-CM
280.9	Unspecified iron deficiency anemia	Diagnosis	ICD-9-CM
281.0	Pernicious anemia	Diagnosis	ICD-9-CM
281.1	Other vitamin B12 deficiency anemia	Diagnosis	ICD-9-CM
281.2	Folate-deficiency anemia	Diagnosis	ICD-9-CM
281.3	Other specified megaloblastic anemias not elsewhere classified	Diagnosis	ICD-9-CM
281.4	Protein-deficiency anemia	Diagnosis	ICD-9-CM
281.8	Anemia associated with other specified nutritional deficiency	Diagnosis	ICD-9-CM
281.9	Unspecified deficiency anemia	Diagnosis	ICD-9-CM
282.0	Hereditary spherocytosis	Diagnosis	ICD-9-CM
282.1	Hereditary elliptocytosis	Diagnosis	ICD-9-CM
282.2	Anemias due to disorders of glutathione metabolism	Diagnosis	ICD-9-CM
282.3	Other hemolytic anemias due to enzyme deficiency	Diagnosis	ICD-9-CM
282.40	Thalassemia, unspecified	Diagnosis	ICD-9-CM
282.41	Sickle-cell thalassemia without crisis	Diagnosis	ICD-9-CM
282.42	Sickle-cell thalassemia with crisis	Diagnosis	ICD-9-CM
282.43	Alpha thalassemia	Diagnosis	ICD-9-CM
282.44	Beta thalassemia	Diagnosis	ICD-9-CM
282.45	Delta-beta thalassemia	Diagnosis	ICD-9-CM
282.46	Thalassemia minor	Diagnosis	ICD-9-CM
282.47	Hemoglobin E-beta thalassemia	Diagnosis	ICD-9-CM
282.49	Other thalassemia	Diagnosis	ICD-9-CM
282.5	Sickle-cell trait	Diagnosis	ICD-9-CM
282.60	Sickle-cell disease, unspecified	Diagnosis	ICD-9-CM
282.61	Hb-SS disease without crisis	Diagnosis	ICD-9-CM
282.62	Hb-SS disease with crisis	Diagnosis	ICD-9-CM
282.63	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
282.64	Sickle-cell/Hb-C disease with crisis	Diagnosis	ICD-9-CM
282.68	Other sickle-cell disease without crisis	Diagnosis	ICD-9-CM
282.69	Other sickle-cell disease with crisis	Diagnosis	ICD-9-CM
282.7	Other hemoglobinopathies	Diagnosis	ICD-9-CM
282.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-9-CM
282.9	Unspecified hereditary hemolytic anemia	Diagnosis	ICD-9-CM
283.0	Autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.10	Unspecified non-autoimmune hemolytic anemia	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
283.19	Other non-autoimmune hemolytic anemias	Diagnosis	ICD-9-CM
283.2	Hemoglobinuria due to hemolysis from external causes	Diagnosis	ICD-9-CM
283.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-9-CM
284.01	Constitutional red blood cell aplasia	Diagnosis	ICD-9-CM
284.09	Other constitutional aplastic anemia	Diagnosis	ICD-9-CM
284.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
284.12	Other drug induced pancytopenia	Diagnosis	ICD-9-CM
284.19	Other pancytopenia	Diagnosis	ICD-9-CM
284.2	Myelophthisis	Diagnosis	ICD-9-CM
284.81	Red cell aplasia (acquired) (adult) (with thymoma)	Diagnosis	ICD-9-CM
284.89	Other specified aplastic anemias	Diagnosis	ICD-9-CM
284.9	Unspecified aplastic anemia	Diagnosis	ICD-9-CM
285.0	Sideroblastic anemia	Diagnosis	ICD-9-CM
285.1	Acute posthemorrhagic anemia	Diagnosis	ICD-9-CM
285.21	Anemia in chronic kidney disease	Diagnosis	ICD-9-CM
285.22	Anemia in neoplastic disease	Diagnosis	ICD-9-CM
285.29	Anemia of other chronic disease	Diagnosis	ICD-9-CM
285.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM
285.8	Other specified anemias	Diagnosis	ICD-9-CM
285.9	Unspecified anemia	Diagnosis	ICD-9-CM
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
493.00	Extrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.01	Extrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.02	Extrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.10	Intrinsic asthma, unspecified	Diagnosis	ICD-9-CM
493.11	Intrinsic asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.12	Intrinsic asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM
493.20	Chronic obstructive asthma, unspecified	Diagnosis	ICD-9-CM
493.21	Chronic obstructive asthma with status asthmaticus	Diagnosis	ICD-9-CM
493.22	Chronic obstructive asthma, with (acute) exacerbation	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
493.81	Exercise induced bronchospasm	Diagnosis	ICD-9-CM
493.82	Cough variant asthma	Diagnosis	ICD-9-CM
493.90	Asthma, unspecified, unspecified status	Diagnosis	ICD-9-CM
493.91	Asthma, unspecified with status asthmaticus	Diagnosis	ICD-9-CM
493.92	Asthma, unspecified, with (acute) exacerbation	Diagnosis	ICD-9-CM
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
Atrial Fibrillation			
427.31	Atrial fibrillation	Diagnosis	ICD-9-CM
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
600.00	Hypertrophy (benign) of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.01	Hypertrophy (benign) of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.10	Nodular prostate without urinary obstruction	Diagnosis	ICD-9-CM
600.11	Nodular prostate with urinary obstruction	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
600.20	Benign localized hyperplasia of prostate without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.21	Benign localized hyperplasia of prostate with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.3	Cyst of prostate	Diagnosis	ICD-9-CM
600.90	Hyperplasia of prostate, unspecified, without urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
600.91	Hyperplasia of prostate, unspecified, with urinary obstruction and other lower urinary tract symptoms [LUTS]	Diagnosis	ICD-9-CM
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
Breast Cancer			
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
233.0	Carcinoma in situ of breast	Diagnosis	ICD-9-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
Cardiac Arrest			
V12.53	Personal history of sudden cardiac arrest	Diagnosis	ICD-9-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
Chronic Kidney Disease			
016.00	Tuberculosis of kidney, confirmation unspecified	Diagnosis	ICD-9-CM
016.01	Tuberculosis of kidney, bacteriological or histological examination not done	Diagnosis	ICD-9-CM
016.02	Tuberculosis of kidney, bacteriological or histological examination unknown (at present)	Diagnosis	ICD-9-CM
016.03	Tuberculosis of kidney, tubercle bacilli found (in sputum) by microscopy	Diagnosis	ICD-9-CM
016.04	Tuberculosis of kidney, tubercle bacilli not found (in sputum) by microscopy, but found by bacterial culture	Diagnosis	ICD-9-CM
016.05	Tuberculosis of kidney, tubercle bacilli not found by bacteriological examination, but tuberculosis confirmed histologically	Diagnosis	ICD-9-CM
016.06	Tuberculosis of kidney, tubercle bacilli not found by bacteriological or histological examination, but tuberculosis confirmed by other methods [inoculation of animals]	Diagnosis	ICD-9-CM
095.4	Syphilis of kidney	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
223.0	Benign neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
271.4	Renal glycosuria	Diagnosis	ICD-9-CM
274.10	Gouty nephropathy, unspecified	Diagnosis	ICD-9-CM
283.11	Hemolytic-uremic syndrome	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
440.1	Atherosclerosis of renal artery	Diagnosis	ICD-9-CM
442.1	Aneurysm of renal artery	Diagnosis	ICD-9-CM
572.4	Hepatorenal syndrome	Diagnosis	ICD-9-CM
580.0	Acute glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
580.4	Acute glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
580.81	Acute glomerulonephritis with other specified pathological lesion in kidney in disease classified elsewhere	Diagnosis	ICD-9-CM
580.89	Other acute glomerulonephritis with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
580.9	Acute glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.0	Nephrotic syndrome with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.1	Nephrotic syndrome with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
581.2	Nephrotic syndrome with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
581.3	Nephrotic syndrome with lesion of minimal change glomerulonephritis	Diagnosis	ICD-9-CM
581.81	Nephrotic syndrome with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
581.89	Other nephrotic syndrome with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
581.9	Nephrotic syndrome with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.0	Chronic glomerulonephritis with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.1	Chronic glomerulonephritis with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
582.2	Chronic glomerulonephritis with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
582.4	Chronic glomerulonephritis with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
582.81	Chronic glomerulonephritis with other specified pathological lesion in kidney in diseases classified elsewhere	Diagnosis	ICD-9-CM
582.89	Other chronic glomerulonephritis with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
582.9	Chronic glomerulonephritis with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.0	Nephritis and nephropathy, not specified as acute or chronic, with lesion of proliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.1	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranous glomerulonephritis	Diagnosis	ICD-9-CM
583.2	Nephritis and nephropathy, not specified as acute or chronic, with lesion of membranoproliferative glomerulonephritis	Diagnosis	ICD-9-CM
583.4	Nephritis and nephropathy, not specified as acute or chronic, with lesion of rapidly progressive glomerulonephritis	Diagnosis	ICD-9-CM
583.6	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
583.7	Nephritis and nephropathy, not specified as acute or chronic, with lesion of renal medullary necrosis	Diagnosis	ICD-9-CM
583.81	Nephritis and nephropathy, not specified as acute or chronic, with other specified pathological lesion in kidney, in diseases classified elsewhere	Diagnosis	ICD-9-CM
583.89	Other nephritis and nephropathy, not specified as acute or chronic, with specified pathological lesion in kidney	Diagnosis	ICD-9-CM
583.9	Nephritis and nephropathy, not specified as acute or chronic, with unspecified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.5	Acute kidney failure with lesion of tubular necrosis	Diagnosis	ICD-9-CM
584.6	Acute kidney failure with lesion of renal cortical necrosis	Diagnosis	ICD-9-CM
584.7	Acute kidney failure with lesion of medullary [papillary] necrosis	Diagnosis	ICD-9-CM
584.8	Acute kidney failure with other specified pathological lesion in kidney	Diagnosis	ICD-9-CM
584.9	Acute kidney failure, unspecified	Diagnosis	ICD-9-CM
585.1	Chronic kidney disease, Stage I	Diagnosis	ICD-9-CM
585.2	Chronic kidney disease, Stage II (mild)	Diagnosis	ICD-9-CM
585.3	Chronic kidney disease, Stage III (moderate)	Diagnosis	ICD-9-CM
585.4	Chronic kidney disease, Stage IV (severe)	Diagnosis	ICD-9-CM
585.5	Chronic kidney disease, Stage V	Diagnosis	ICD-9-CM
585.6	End stage renal disease	Diagnosis	ICD-9-CM
585.9	Chronic kidney disease, unspecified	Diagnosis	ICD-9-CM
586	Unspecified renal failure	Diagnosis	ICD-9-CM
587	Unspecified renal sclerosis	Diagnosis	ICD-9-CM
588.0	Renal osteodystrophy	Diagnosis	ICD-9-CM
588.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-9-CM
588.81	Secondary hyperparathyroidism (of renal origin)	Diagnosis	ICD-9-CM
588.89	Other specified disorders resulting from impaired renal function	Diagnosis	ICD-9-CM
588.9	Unspecified disorder resulting from impaired renal function	Diagnosis	ICD-9-CM
591	Hydronephrosis	Diagnosis	ICD-9-CM
753.12	Congenital polycystic kidney, unspecified type	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
753.13	Congenital polycystic kidney, autosomal dominant	Diagnosis	ICD-9-CM
753.14	Congenital polycystic kidney, autosomal recessive	Diagnosis	ICD-9-CM
753.15	Congenital renal dysplasia	Diagnosis	ICD-9-CM
753.16	Congenital medullary cystic kidney	Diagnosis	ICD-9-CM
753.17	Congenital medullary sponge kidney	Diagnosis	ICD-9-CM
753.19	Other specified congenital cystic kidney disease	Diagnosis	ICD-9-CM
753.20	Unspecified obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
753.21	Congenital obstruction of ureteropelvic junction	Diagnosis	ICD-9-CM
753.22	Congenital obstruction of ureterovesical junction	Diagnosis	ICD-9-CM
753.23	Congenital ureterocele	Diagnosis	ICD-9-CM
753.29	Other obstructive defect of renal pelvis and ureter	Diagnosis	ICD-9-CM
794.4	Nonspecific abnormal results of kidney function study	Diagnosis	ICD-9-CM
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
Colorectal Cancer			
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
230.3	Carcinoma in situ of colon	Diagnosis	ICD-9-CM
230.4	Carcinoma in situ of rectum	Diagnosis	ICD-9-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Chronic Obstructive Pulmonary Disease			
490	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-9-CM
491.0	Simple chronic bronchitis	Diagnosis	ICD-9-CM
491.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-9-CM
491.20	Obstructive chronic bronchitis, without exacerbation	Diagnosis	ICD-9-CM
491.21	Obstructive chronic bronchitis, with (acute) exacerbation	Diagnosis	ICD-9-CM
491.22	Obstructive chronic bronchitis with acute bronchitis	Diagnosis	ICD-9-CM
491.8	Other chronic bronchitis	Diagnosis	ICD-9-CM
491.9	Unspecified chronic bronchitis	Diagnosis	ICD-9-CM
492.0	Emphysematous bleb	Diagnosis	ICD-9-CM
492.8	Other emphysema	Diagnosis	ICD-9-CM
494.0	Bronchiectasis without acute exacerbation	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
494.1	Bronchiectasis with acute exacerbation	Diagnosis	ICD-9-CM
496	Chronic airway obstruction, not elsewhere classified	Diagnosis	ICD-9-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
Coronary Angioplasty Bypass			
V45.81	Postprocedural aortocoronary bypass status	Diagnosis	ICD-9-CM
V45.82	Postprocedural percutaneous transluminal coronary angioplasty status	Diagnosis	ICD-9-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
Depression			
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Diabetes			
249.00	Secondary diabetes mellitus without mention of complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.01	Secondary diabetes mellitus without mention of complication, uncontrolled	Diagnosis	ICD-9-CM
249.10	Secondary diabetes mellitus with ketoacidosis, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.11	Secondary diabetes mellitus with ketoacidosis, uncontrolled	Diagnosis	ICD-9-CM
249.20	Secondary diabetes mellitus with hyperosmolarity, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
249.21	Secondary diabetes mellitus with hyperosmolarity, uncontrolled	Diagnosis	ICD-9-CM
249.30	Secondary diabetes mellitus with other coma, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.31	Secondary diabetes mellitus with other coma, uncontrolled	Diagnosis	ICD-9-CM
249.40	Secondary diabetes mellitus with renal manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.41	Secondary diabetes mellitus with renal manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.50	Secondary diabetes mellitus with ophthalmic manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.51	Secondary diabetes mellitus with ophthalmic manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.60	Secondary diabetes mellitus with neurological manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.61	Secondary diabetes mellitus with neurological manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.70	Secondary diabetes mellitus with peripheral circulatory disorders, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.71	Secondary diabetes mellitus with peripheral circulatory disorders, uncontrolled	Diagnosis	ICD-9-CM
249.80	Secondary diabetes mellitus with other specified manifestations, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.81	Secondary diabetes mellitus with other specified manifestations, uncontrolled	Diagnosis	ICD-9-CM
249.90	Secondary diabetes mellitus with unspecified complication, not stated as uncontrolled, or unspecified	Diagnosis	ICD-9-CM
249.91	Secondary diabetes mellitus with unspecified complication, uncontrolled	Diagnosis	ICD-9-CM
250.00	Diabetes mellitus without mention of complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.01	Diabetes mellitus without mention of complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.02	Diabetes mellitus without mention of complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.03	Diabetes mellitus without mention of complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.10	Diabetes with ketoacidosis, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.11	Diabetes with ketoacidosis, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.12	Diabetes with ketoacidosis, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.13	Diabetes with ketoacidosis, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.20	Diabetes with hyperosmolarity, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.21	Diabetes with hyperosmolarity, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.22	Diabetes with hyperosmolarity, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.23	Diabetes with hyperosmolarity, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.30	Diabetes with other coma, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.31	Diabetes with other coma, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.32	Diabetes with other coma, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.33	Diabetes with other coma, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
250.40	Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.41	Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.42	Diabetes with renal manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.43	Diabetes with renal manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.50	Diabetes with ophthalmic manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.51	Diabetes with ophthalmic manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.52	Diabetes with ophthalmic manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.53	Diabetes with ophthalmic manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.60	Diabetes with neurological manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.61	Diabetes with neurological manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.62	Diabetes with neurological manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.63	Diabetes with neurological manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.70	Diabetes with peripheral circulatory disorders, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.71	Diabetes with peripheral circulatory disorders, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.72	Diabetes with peripheral circulatory disorders, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.73	Diabetes with peripheral circulatory disorders, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.80	Diabetes with other specified manifestations, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.81	Diabetes with other specified manifestations, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.82	Diabetes with other specified manifestations, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.83	Diabetes with other specified manifestations, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
250.90	Diabetes with unspecified complication, type II or unspecified type, not stated as uncontrolled	Diagnosis	ICD-9-CM
250.91	Diabetes with unspecified complication, type I [juvenile type], not stated as uncontrolled	Diagnosis	ICD-9-CM
250.92	Diabetes with unspecified complication, type II or unspecified type, uncontrolled	Diagnosis	ICD-9-CM
250.93	Diabetes with unspecified complication, type I [juvenile type], uncontrolled	Diagnosis	ICD-9-CM
357.2	Polyneuropathy in diabetes	Diagnosis	ICD-9-CM
362.01	Background diabetic retinopathy	Diagnosis	ICD-9-CM
362.02	Proliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.03	Nonproliferative diabetic retinopathy NOS	Diagnosis	ICD-9-CM
362.04	Mild nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
362.05	Moderate nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
362.06	Severe nonproliferative diabetic retinopathy	Diagnosis	ICD-9-CM
366.41	Diabetic cataract	Diagnosis	ICD-9-CM
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Drug Abuse			
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnesic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-9-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
305.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
305.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM
305.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-9-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM
648.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-9-CM
648.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care	Diagnosis	ICD-9-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
648.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
648.33	Maternal drug dependence, antepartum	Diagnosis	ICD-9-CM
648.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
655.5	Suspected damage to fetus from drugs, affecting management of mother	Diagnosis	ICD-9-CM
655.50	Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care	Diagnosis	ICD-9-CM
655.51	Suspected damage to fetus from drugs, affecting management of mother, delivered	Diagnosis	ICD-9-CM
655.53	Suspected damage to fetus from drugs, affecting management of mother, antepartum	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
760.73	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents	Diagnosis	ICD-9-CM
760.75	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Diagnosis	ICD-9-CM
779.5	Drug withdrawal syndrome in newborn	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.64	Drug rehabilitation	Procedure	ICD-9-CM
94.65	Drug detoxification	Procedure	ICD-9-CM
94.66	Drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E854.1	Accidental poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Endometrial Cancer			
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
233.2	Carcinoma in situ of other and unspecified parts of uterus	Diagnosis	ICD-9-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Glaucoma			
365.00	Unspecified preglaucoma	Diagnosis	ICD-9-CM
365.01	Borderline glaucoma, open angle with borderline findings, low risk	Diagnosis	ICD-9-CM
365.02	Borderline glaucoma with anatomical narrow angle	Diagnosis	ICD-9-CM
365.03	Borderline glaucoma with steroid responders	Diagnosis	ICD-9-CM
365.04	Borderline glaucoma with ocular hypertension	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
365.10	Unspecified open-angle glaucoma	Diagnosis	ICD-9-CM
365.11	Primary open-angle glaucoma	Diagnosis	ICD-9-CM
365.12	Low tension open-angle glaucoma	Diagnosis	ICD-9-CM
365.13	Pigmentary open-angle glaucoma	Diagnosis	ICD-9-CM
365.15	Residual stage of open angle glaucoma	Diagnosis	ICD-9-CM
365.20	Unspecified primary angle-closure glaucoma	Diagnosis	ICD-9-CM
365.21	Intermittent angle-closure glaucoma	Diagnosis	ICD-9-CM
365.22	Acute angle-closure glaucoma	Diagnosis	ICD-9-CM
365.23	Chronic angle-closure glaucoma	Diagnosis	ICD-9-CM
365.24	Residual stage of angle-closure glaucoma	Diagnosis	ICD-9-CM
365.31	Corticosteroid-induced glaucoma, glaucomatous stage	Diagnosis	ICD-9-CM
365.32	Corticosteroid-induced glaucoma, residual stage	Diagnosis	ICD-9-CM
365.41	Glaucoma associated with chamber angle anomalies	Diagnosis	ICD-9-CM
365.42	Glaucoma associated with anomalies of iris	Diagnosis	ICD-9-CM
365.43	Glaucoma associated with other anterior segment anomalies	Diagnosis	ICD-9-CM
365.51	Phacolytic glaucoma	Diagnosis	ICD-9-CM
365.52	Pseudoexfoliation glaucoma	Diagnosis	ICD-9-CM
365.59	Glaucoma associated with other lens disorders	Diagnosis	ICD-9-CM
365.60	Glaucoma associated with unspecified ocular disorder	Diagnosis	ICD-9-CM
365.61	Glaucoma associated with pupillary block	Diagnosis	ICD-9-CM
365.62	Glaucoma associated with ocular inflammations	Diagnosis	ICD-9-CM
365.63	Glaucoma associated with vascular disorders of eye	Diagnosis	ICD-9-CM
365.64	Glaucoma associated with tumors or cysts	Diagnosis	ICD-9-CM
365.65	Glaucoma associated with ocular trauma	Diagnosis	ICD-9-CM
365.81	Hypersecretion glaucoma	Diagnosis	ICD-9-CM
365.82	Glaucoma with increased episcleral venous pressure	Diagnosis	ICD-9-CM
365.83	Aqueous misdirection	Diagnosis	ICD-9-CM
365.89	Other specified glaucoma	Diagnosis	ICD-9-CM
365.9	Unspecified glaucoma	Diagnosis	ICD-9-CM
377.14	Glaucomatous atrophy (cupping) of optic disc	Diagnosis	ICD-9-CM
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Heart Failure			
398.91	Rheumatic heart failure (congestive)	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
428.0	Congestive heart failure, unspecified	Diagnosis	ICD-9-CM
428.1	Left heart failure	Diagnosis	ICD-9-CM
428.20	Unspecified systolic heart failure	Diagnosis	ICD-9-CM
428.21	Acute systolic heart failure	Diagnosis	ICD-9-CM
428.22	Chronic systolic heart failure	Diagnosis	ICD-9-CM
428.23	Acute on chronic systolic heart failure	Diagnosis	ICD-9-CM
428.30	Unspecified diastolic heart failure	Diagnosis	ICD-9-CM
428.31	Acute diastolic heart failure	Diagnosis	ICD-9-CM
428.32	Chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.33	Acute on chronic diastolic heart failure	Diagnosis	ICD-9-CM
428.40	Unspecified combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.41	Acute combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.42	Chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.43	Acute on chronic combined systolic and diastolic heart failure	Diagnosis	ICD-9-CM
428.9	Unspecified heart failure	Diagnosis	ICD-9-CM
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
272.0	Pure hypercholesterolemia	Diagnosis	ICD-9-CM
272.1	Pure hyperglyceridemia	Diagnosis	ICD-9-CM
272.2	Mixed hyperlipidemia	Diagnosis	ICD-9-CM
272.3	Hyperchylomicronemia	Diagnosis	ICD-9-CM
272.4	Other and unspecified hyperlipidemia	Diagnosis	ICD-9-CM
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertension			
362.11	Hypertensive retinopathy	Diagnosis	ICD-9-CM
401.0	Essential hypertension, malignant	Diagnosis	ICD-9-CM
401.1	Essential hypertension, benign	Diagnosis	ICD-9-CM
401.9	Unspecified essential hypertension	Diagnosis	ICD-9-CM
402.00	Malignant hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.01	Malignant hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.10	Benign hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.11	Benign hypertensive heart disease with heart failure	Diagnosis	ICD-9-CM
402.90	Unspecified hypertensive heart disease without heart failure	Diagnosis	ICD-9-CM
402.91	Hypertensive heart disease, unspecified, with heart failure	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
403.00	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.01	Hypertensive chronic kidney disease, malignant, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.10	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.11	Hypertensive chronic kidney disease, benign, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
403.90	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
403.91	Hypertensive chronic kidney disease, unspecified, with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.00	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.01	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.02	Hypertensive heart and chronic kidney disease, malignant, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.03	Hypertensive heart and chronic kidney disease, malignant, with heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.10	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.11	Hypertensive heart and chronic kidney disease, benign, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.12	Hypertensive heart and chronic kidney disease, benign, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.13	Hypertensive heart and chronic kidney disease, benign, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.90	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.91	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and with chronic kidney disease stage I through stage IV, or unspecified	Diagnosis	ICD-9-CM
404.92	Hypertensive heart and chronic kidney disease, unspecified, without heart failure and with chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
404.93	Hypertensive heart and chronic kidney disease, unspecified, with heart failure and chronic kidney disease stage V or end stage renal disease	Diagnosis	ICD-9-CM
405.01	Secondary renovascular hypertension, malignant	Diagnosis	ICD-9-CM
405.09	Other secondary hypertension, malignant	Diagnosis	ICD-9-CM
405.11	Secondary renovascular hypertension, benign	Diagnosis	ICD-9-CM
405.19	Other secondary hypertension, benign	Diagnosis	ICD-9-CM
405.91	Secondary renovascular hypertension, unspecified	Diagnosis	ICD-9-CM
405.99	Other secondary hypertension, unspecified	Diagnosis	ICD-9-CM
437.2	Hypertensive encephalopathy	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Ischemic Heart Disease			
410.00	Acute myocardial infarction of anterolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.01	Acute myocardial infarction of anterolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.02	Acute myocardial infarction of anterolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.10	Acute myocardial infarction of other anterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.11	Acute myocardial infarction of other anterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.12	Acute myocardial infarction of other anterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.20	Acute myocardial infarction of inferolateral wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.21	Acute myocardial infarction of inferolateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.22	Acute myocardial infarction of inferolateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.30	Acute myocardial infarction of inferoposterior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.31	Acute myocardial infarction of inferoposterior wall, initial episode of care	Diagnosis	ICD-9-CM
410.32	Acute myocardial infarction of inferoposterior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.40	Acute myocardial infarction of other inferior wall, episode of care unspecified	Diagnosis	ICD-9-CM
410.41	Acute myocardial infarction of other inferior wall, initial episode of care	Diagnosis	ICD-9-CM
410.42	Acute myocardial infarction of other inferior wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.50	Acute myocardial infarction of other lateral wall, episode of care unspecified	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
410.51	Acute myocardial infarction of other lateral wall, initial episode of care	Diagnosis	ICD-9-CM
410.52	Acute myocardial infarction of other lateral wall, subsequent episode of care	Diagnosis	ICD-9-CM
410.60	Acute myocardial infarction, true posterior wall infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.61	Acute myocardial infarction, true posterior wall infarction, initial episode of care	Diagnosis	ICD-9-CM
410.62	Acute myocardial infarction, true posterior wall infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.70	Acute myocardial infarction, subendocardial infarction, episode of care unspecified	Diagnosis	ICD-9-CM
410.71	Acute myocardial infarction, subendocardial infarction, initial episode of care	Diagnosis	ICD-9-CM
410.72	Acute myocardial infarction, subendocardial infarction, subsequent episode of care	Diagnosis	ICD-9-CM
410.80	Acute myocardial infarction of other specified sites, episode of care unspecified	Diagnosis	ICD-9-CM
410.81	Acute myocardial infarction of other specified sites, initial episode of care	Diagnosis	ICD-9-CM
410.82	Acute myocardial infarction of other specified sites, subsequent episode of care	Diagnosis	ICD-9-CM
410.90	Acute myocardial infarction, unspecified site, episode of care unspecified	Diagnosis	ICD-9-CM
410.91	Acute myocardial infarction, unspecified site, initial episode of care	Diagnosis	ICD-9-CM
410.92	Acute myocardial infarction, unspecified site, subsequent episode of care	Diagnosis	ICD-9-CM
411.0	Postmyocardial infarction syndrome	Diagnosis	ICD-9-CM
411.1	Intermediate coronary syndrome	Diagnosis	ICD-9-CM
411.81	Acute coronary occlusion without myocardial infarction	Diagnosis	ICD-9-CM
411.89	Other acute and subacute form of ischemic heart disease	Diagnosis	ICD-9-CM
412	Old myocardial infarction	Diagnosis	ICD-9-CM
413.0	Angina decubitus	Diagnosis	ICD-9-CM
413.1	Prinzmetal angina	Diagnosis	ICD-9-CM
413.9	Other and unspecified angina pectoris	Diagnosis	ICD-9-CM
414.00	Coronary atherosclerosis of unspecified type of vessel, native or graft	Diagnosis	ICD-9-CM
414.01	Coronary atherosclerosis of native coronary artery	Diagnosis	ICD-9-CM
414.02	Coronary atherosclerosis of autologous vein bypass graft	Diagnosis	ICD-9-CM
414.03	Coronary atherosclerosis of nonautologous biological bypass graft	Diagnosis	ICD-9-CM
414.04	Coronary atherosclerosis of artery bypass graft	Diagnosis	ICD-9-CM
414.05	Coronary atherosclerosis of unspecified type of bypass graft	Diagnosis	ICD-9-CM
414.06	Coronary atherosclerosis, of native coronary artery of transplanted heart	Diagnosis	ICD-9-CM
414.07	Coronary atherosclerosis, of bypass graft (artery) (vein) of transplanted heart	Diagnosis	ICD-9-CM
414.12	Dissection of coronary artery	Diagnosis	ICD-9-CM
414.2	Chronic total occlusion of coronary artery	Diagnosis	ICD-9-CM
414.3	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-9-CM
414.4	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-9-CM
414.8	Other specified forms of chronic ischemic heart disease	Diagnosis	ICD-9-CM
414.9	Unspecified chronic ischemic heart disease	Diagnosis	ICD-9-CM
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
Lung Cancer			
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
231.2	Carcinoma in situ of bronchus and lung	Diagnosis	ICD-9-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Obesity			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
278.0	Overweight and obesity	Diagnosis	ICD-9-CM
278.00	Obesity, unspecified	Diagnosis	ICD-9-CM
278.01	Morbid obesity	Diagnosis	ICD-9-CM
278.03	Obesity hypoventilation syndrome	Diagnosis	ICD-9-CM
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
V85.3	Body Mass Index between 30-39, adult	Diagnosis	ICD-9-CM
V85.30	Body Mass Index 30.0-30.9, adult	Diagnosis	ICD-9-CM
V85.31	Body Mass Index 31.0-31.9, adult	Diagnosis	ICD-9-CM
V85.32	Body Mass Index 32.0-32.9, adult	Diagnosis	ICD-9-CM
V85.33	Body Mass Index 33.0-33.9, adult	Diagnosis	ICD-9-CM
V85.34	Body Mass Index 34.0-34.9, adult	Diagnosis	ICD-9-CM
V85.35	Body Mass Index 35.0-35.9, adult	Diagnosis	ICD-9-CM
V85.36	Body Mass Index 36.0-36.9, adult	Diagnosis	ICD-9-CM
V85.37	Body Mass Index 37.0-37.9, adult	Diagnosis	ICD-9-CM
V85.38	Body Mass Index 38.0-38.9, adult	Diagnosis	ICD-9-CM
V85.39	Body Mass Index 39.0-39.9, adult	Diagnosis	ICD-9-CM
V85.4	Body Mass Index 40 and over, adult	Diagnosis	ICD-9-CM
V85.41	Body Mass Index 40.0-44.9, adult	Diagnosis	ICD-9-CM
V85.42	Body Mass Index 45.0-49.9, adult	Diagnosis	ICD-9-CM
V85.43	Body Mass Index 50.0-59.9, adult	Diagnosis	ICD-9-CM
V85.44	Body Mass Index 60.0-69.9, adult	Diagnosis	ICD-9-CM
V85.45	Body Mass Index 70 and over, adult	Diagnosis	ICD-9-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Osteoporosis			
733.00	Unspecified osteoporosis	Diagnosis	ICD-9-CM
733.01	Senile osteoporosis	Diagnosis	ICD-9-CM
733.02	Idiopathic osteoporosis	Diagnosis	ICD-9-CM
733.03	Disuse osteoporosis	Diagnosis	ICD-9-CM
733.09	Other osteoporosis	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Prostate			
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
233.4	Carcinoma in situ of prostate	Diagnosis	ICD-9-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
V10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Rheumatoid Arthritis			
714.0	Rheumatoid arthritis	Diagnosis	ICD-9-CM
714.1	Felty's syndrome	Diagnosis	ICD-9-CM
714.2	Other rheumatoid arthritis with visceral or systemic involvement	Diagnosis	ICD-9-CM
714.30	Polyarticular juvenile rheumatoid arthritis, chronic or unspecified	Diagnosis	ICD-9-CM
714.31	Polyarticular juvenile rheumatoid arthritis, acute	Diagnosis	ICD-9-CM
714.32	Pauciarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
714.33	Monoarticular juvenile rheumatoid arthritis	Diagnosis	ICD-9-CM
715.00	Generalized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.04	Generalized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.09	Generalized osteoarthritis, involving multiple sites	Diagnosis	ICD-9-CM
715.10	Primary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.11	Primary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.12	Primary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
715.13	Primary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.14	Primary localized osteoarthritis, hand	Diagnosis	ICD-9-CM
715.15	Primary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.16	Primary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.17	Primary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.18	Primary localized osteoarthritis, other specified sites	Diagnosis	ICD-9-CM
715.20	Secondary localized osteoarthritis, unspecified site	Diagnosis	ICD-9-CM
715.21	Secondary localized osteoarthritis, shoulder region	Diagnosis	ICD-9-CM
715.22	Secondary localized osteoarthritis, upper arm	Diagnosis	ICD-9-CM
715.23	Secondary localized osteoarthritis, forearm	Diagnosis	ICD-9-CM
715.24	Secondary localized osteoarthritis, involving hand	Diagnosis	ICD-9-CM
715.25	Secondary localized osteoarthritis, pelvic region and thigh	Diagnosis	ICD-9-CM
715.26	Secondary localized osteoarthritis, lower leg	Diagnosis	ICD-9-CM
715.27	Secondary localized osteoarthritis, ankle and foot	Diagnosis	ICD-9-CM
715.28	Secondary localized osteoarthritis, other specified site	Diagnosis	ICD-9-CM
715.30	Localized osteoarthritis not specified whether primary or secondary, unspecified site	Diagnosis	ICD-9-CM
715.31	Localized osteoarthritis not specified whether primary or secondary, shoulder region	Diagnosis	ICD-9-CM
715.32	Localized osteoarthritis not specified whether primary or secondary, upper arm	Diagnosis	ICD-9-CM
715.33	Localized osteoarthritis not specified whether primary or secondary, forearm	Diagnosis	ICD-9-CM
715.34	Localized osteoarthritis not specified whether primary or secondary, hand	Diagnosis	ICD-9-CM
715.35	Localized osteoarthritis not specified whether primary or secondary, pelvic region and thigh	Diagnosis	ICD-9-CM
715.36	Localized osteoarthritis not specified whether primary or secondary, lower leg	Diagnosis	ICD-9-CM
715.37	Localized osteoarthritis not specified whether primary or secondary, ankle and foot	Diagnosis	ICD-9-CM
715.38	Localized osteoarthritis not specified whether primary or secondary, other specified sites	Diagnosis	ICD-9-CM
715.80	Osteoarthritis involving more than one site, but not specified as generalized, unspecified site	Diagnosis	ICD-9-CM
715.89	Osteoarthritis involving multiple sites, but not specified as generalized	Diagnosis	ICD-9-CM
715.90	Osteoarthritis, unspecified whether generalized or localized, unspecified site	Diagnosis	ICD-9-CM
715.91	Osteoarthritis, unspecified whether generalized or localized, shoulder region	Diagnosis	ICD-9-CM
715.92	Osteoarthritis, unspecified whether generalized or localized, upper arm	Diagnosis	ICD-9-CM
715.93	Osteoarthritis, unspecified whether generalized or localized, forearm	Diagnosis	ICD-9-CM
715.94	Osteoarthritis, unspecified whether generalized or localized, hand	Diagnosis	ICD-9-CM
715.95	Osteoarthritis, unspecified whether generalized or localized, pelvic region and thigh	Diagnosis	ICD-9-CM
715.96	Osteoarthritis, unspecified whether generalized or localized, lower leg	Diagnosis	ICD-9-CM
715.97	Osteoarthritis, unspecified whether generalized or localized, ankle and foot	Diagnosis	ICD-9-CM
715.98	Osteoarthritis, unspecified whether generalized or localized, other specified sites	Diagnosis	ICD-9-CM
720.0	Ankylosing spondylitis	Diagnosis	ICD-9-CM
721.0	Cervical spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.1	Cervical spondylosis with myelopathy	Diagnosis	ICD-9-CM
721.2	Thoracic spondylosis without myelopathy	Diagnosis	ICD-9-CM
721.3	Lumbosacral spondylosis without myelopathy	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
721.90	Spondylosis of unspecified site without mention of myelopathy	Diagnosis	ICD-9-CM
721.91	Spondylosis of unspecified site with myelopathy	Diagnosis	ICD-9-CM
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code	
		Category	Code Type
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Smoking			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
Transient Ischemic Attack			
430	Subarachnoid hemorrhage	Diagnosis	ICD-9-CM
431	Intracerebral hemorrhage	Diagnosis	ICD-9-CM
433.01	Occlusion and stenosis of basilar artery with cerebral infarction	Diagnosis	ICD-9-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
433.11	Occlusion and stenosis of carotid artery with cerebral infarction	Diagnosis	ICD-9-CM
433.21	Occlusion and stenosis of vertebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries with cerebral infarction	Diagnosis	ICD-9-CM
433.81	Occlusion and stenosis of other specified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
433.91	Occlusion and stenosis of unspecified precerebral artery with cerebral infarction	Diagnosis	ICD-9-CM
434.00	Cerebral thrombosis without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.01	Cerebral thrombosis with cerebral infarction	Diagnosis	ICD-9-CM
434.10	Cerebral embolism without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.11	Cerebral embolism with cerebral infarction	Diagnosis	ICD-9-CM
434.90	Unspecified cerebral artery occlusion without mention of cerebral infarction	Diagnosis	ICD-9-CM
434.91	Unspecified cerebral artery occlusion with cerebral infarction	Diagnosis	ICD-9-CM
435.0	Basilar artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM
997.02	Iatrogenic cerebrovascular infarction or hemorrhage	Diagnosis	ICD-9-CM
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request.

Code	Description	Code Category	Code Type
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
Obesity	
Amino Acids/Multivit-Minerals/Dietary Supplement/Protein Sup	Optifast 70
Benzphetamine HCl	Benzphetamine
Benzphetamine HCl	Regimex
Diethylpropion HCl	Diethylpropion
Diethylpropion HCl	Diethylpropion HCl (bulk)
Liraglutide	Saxenda
Liraglutide	Victoza 2-Pak
Liraglutide	Victoza 3-Pak
Lorcaserin HCl	Belviq
Lorcaserin HCl	Belviq XR
Naltrexone HCl/Bupropion HCl	Contrave
Orlistat	Alli
Orlistat	Xenical
Phendimetrazine Tartrate	Bontril PDM
Phendimetrazine Tartrate	Phendimetrazine Tartrate
Phentermine HCl	Adipex-P
Phentermine HCl	Lomaira
Phentermine HCl	Phentermine
Phentermine HCl	Phentermine HCl (bulk)
Phentermine HCl	Suprenza
Phentermine HCl/Topiramate	Qsymia
Resveratrol/Chromium Pico/Green Tea/EGCG/Caffeine/Digestive3	Resveratrol Diet
Smoking	
Nicotine	NTS Step 1
Nicotine	Nicoderm CQ
Nicotine	Nicotine
Nicotine	Nicotrol
Nicotine	Nicotrol NS
Nicotine Bitartrate	Nicotine Tartrate
Nicotine Polacrilex	Nicorelief
Nicotine Polacrilex	Nicorette
Nicotine Polacrilex	Nicotine (Polacrilex)
Nicotine Polacrilex	Nicotine Polacrilex (bulk)
Nicotine Polacrilex	Quit 2
Nicotine Polacrilex	Quit 4

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
Nicotine Polacrilex	Stop Smoking Aid
Varenicline Tartrate	Chantix
Varenicline Tartrate	Chantix Continuing Month Box
Varenicline Tartrate	Chantix Starting Month Box
Varenicline Tartrate	Tyrvaya
Varenicline Tartrate	Varenicline

Appendix F. Specifications Defining Parameters for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2017 (part2) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

- Query period:** 01/01/2017 - Most recent available data
- Coverage requirement:** Medical and Drug Coverage
- Pre-index enrollment requirement:** 183 days
- Post-index requirement:** 0 days
- Enrollment gap:** 45 days
- Age groups:** 0-17, 18-24, 25-40, 41-64, 65+ years
- Stratifications:** age group, sex, year-month
- Restrictions:** Male and Female
- Distribution of index-defining codes:** No
- Envelope macro:** Reclassify encounters during inpatient stay as inpatient
- Freeze data:** No

Exposure

Scenario	Index Exposure/Event	Cohort definition	Incident exposure washout period	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
1	Abemaciclib	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2017 (part2) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

2	Acalabrutinib	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	Angiotensin II	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
4	Benralizumab	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
5	Benznidazole	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
6	Copanlisib	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
7	Emicizumab	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
8	Enasidenib	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2017 (part2) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

9	Ertugliflozin	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
10	Ertugliflozin and sitagliptin	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
11	Ertugliflozin and metformin	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	Glecaprevir and pibrentasvir	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
13	Guselkumab	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
14	Inotuzumab ozogamicin	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
15	Latanoprostene bunod ophthalmic solution	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2017 (part2) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

16	Letermovir	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
17	Macimorelin acetate	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
18	Meropenem and vaborbactam	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
19	Neratinib maleate	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
20	Netarsudil	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
21	Ozenoxacin	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 11.0.0, to assess utilization and uptake of the 2017 (part2) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

22	Secnidazole	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
23	Semaglutide	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
24	Sofosbuvir, velpatasvir and voxilaprevir	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
25	Vestronidase alfa-vjbk	First valid index date during query period	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

N/A: Not Applicable

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), Healthcare Common Procedure Coding System (HCPCS), and Current Procedural Terminology (CPT) codes are provided by Optum360.

National Drug codes (NDC) codes are checked against First Data Bank's FDB MedKnowledge®.

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristics

Baseline Characteristics	Care setting/ Principal diagnosis ¹	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensing	Number of instances the covariate should be found in evaluation period	Forced supply to attach to dispensing
<i>Chronic Conditions Data Warehouse</i>						
Acute Myocardial Infarction	IPP, IPS	-183	-1	n/a	1	N/A
Alzheimer's Disease and related conditions	Any	-183	-1	n/a	1	N/A
Atrial Fibrillation	IPP, IPS or	-183	-1	n/a	1	N/A
	AV*, ED*, OA*	-183	-1	n/a	2	N/A
Diabetes	IP*, IS*	-183	-1	n/a	1	N/A
	AV*, ED*, OA*	-183	-1	n/a	2	N/A
Heart Failure	IP*, AV*, ED*	-183	-1	n/a	1	N/A
Hyperlipidemia	IP*, IS*	-183	-1	n/a	1	N/A
	AV*, ED*, OA*	-183	-1	n/a	2	N/A
Hypertension	IP*, IS*	-183	-1	n/a	1	N/A
	AV*, ED*, OA*	-183	-1	n/a	2	N/A
Depression	Any	-183	-1	n/a	1	N/A
Ischemic Heart Disease	Any	-183	-1	n/a	1	N/A
Rheumatoid Arthritis/Osteoarthritis	Any	-183	-1	n/a	2	N/A
Stroke/TIA	IP*	-183	-1	n/a	1	N/A
	AV*, ED*, OA*	-183	-1	n/a	2	N/A
Breast Cancer	IP*, IS* or	-183	-1	n/a	1	N/A
	AV*, ED* OA*	-183	-1	n/a	2	N/A
Colorectal Cancer	IP*, IS* or	-183	-1	n/a	1	N/A
	AV*, ED* OA*	-183	-1	n/a	2	N/A
Prostate Cancer	IP*, IS* or	-183	-1	n/a	1	N/A
	AV*, ED* OA*	-183	-1	n/a	2	N/A
Lung Cancer	IP*, IS* or	-183	-1	n/a	1	N/A
	AV*, ED* OA*	-183	-1	n/a	2	N/A
Endometrial Cancer	IP*, IS* or	-183	-1	n/a	1	N/A
	AV*, ED* OA*	-183	-1	n/a	2	N/A
Acquired Hypothyroidism	IP*, IS*, or	-183	-1	n/a	1	N/A
	AV*, ED* OA*	-183	-1	n/a	2	N/A
Anemia	Any	-183	-1	n/a	1	N/A
Asthma	IP*, IS*, or	-183	-1	n/a	1	N/A
	AV*, ED* OA*	-183	-1	n/a	2	N/A
Benign Prostatic Hyperplasia	IP*, IS*, or	-183	-1	n/a	1	N/A
	AV*, ED* OA*	-183	-1	n/a	2	N/A
Chronic Kidney Disease	IP*, IS*, or	-183	-1	n/a	1	N/A
	AV*, ED* OA*	-183	-1	n/a	2	N/A
COPD and Bronchiectasis	IP*, IS*, or	-183	-1	n/a	1	N/A
	AV*, ED* OA*	-183	-1	n/a	2	N/A
Glaucoma	AV*, ED*, OA*	-183	-1	n/a	2	N/A
Osteoporosis	IP*, IS*, or	-183	-1	n/a	1	N/A
	AV*, ED* OA*	-183	-1	n/a	2	N/A

Baseline Characteristics

<i>Other</i>						
Obesity	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Overweight	Any	-183	-1	n/a	1	N/A
Smoking	Any	-183	-1	Evaluation period should search for evidence of days supply	1	N/A
Alcohol Abuse or Dependence	Any	-183	-1	n/a	1	N/A
Drug Abuse or Dependence	Any	-183	-1	n/a	1	N/A
History of Cardiac Arrest	Any	-183	-1	n/a	1	N/A
History of Coronary Angioplasty or Bypass	Any	-183	-1	n/a	1	N/A

*These codes must be within 365 days of the index date, not each other as in version 1.

N/A: Not Applicable

¹Caresetting/ Principal Diagnosis

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.


Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Appendix H. Design Diagram of Cohort Entry Requirements and Index Exposure



¹ Includes all valid exposure episodes during the query period; only the first valid episode's incidence is assessed using the washout period.

² 25 scenarios defined based on initiation of NMEs approved in 2017 Part 2 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME

³ Baseline characteristics:

Window I: Age, sex, year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking

⁴ Censoring: earliest of death, disenrollment, data partner data end date, query end date